{"questions": [{"id": "5a6f960fb750ff445500005c", "body": "Centor criteria are used for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23613571", "http://www.ncbi.nlm.nih.gov/pubmed/15231926", "http://www.ncbi.nlm.nih.gov/pubmed/22432746"], "snippets": [{"offsetInBeginSection": 274, "offsetInEndSection": 441, "text": "We wanted to evaluate the correlation between Centor criteria and presence of GABHS in children with sore throat admitted to our paediatric emergency department (PED).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 1008, "offsetInEndSection": 1063, "text": "Only records with a full disease history were selected.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 1747, "offsetInEndSection": 1897, "text": "CONCLUSIONS: Our results confirm the ineffectiveness of Centor criteria as a predicting factor for finding GABHS in a throat swab culture in children.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 160, "offsetInEndSection": 259, "text": "Among adults, the sensitivity of this test varies on the basis of disease severity (spectrum bias).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926"}, {"offsetInBeginSection": 797, "offsetInEndSection": 1012, "text": "Patients were stratified according to the number of clinical features present by using modified Centor criteria, ie, history of fever, absence of cough, presence of pharyngeal exudates, and cervical lymphadenopathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926"}, {"offsetInBeginSection": 1479, "offsetInEndSection": 1670, "text": "The prevalence of GABHS pharyngitis was 18% among patients with 0 Centor criteria, 16% among those with 1 criterion, 32% among those with 2 criteria, and 50% among those with 3 or 4 criteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926"}, {"offsetInBeginSection": 1924, "offsetInEndSection": 2044, "text": "CONCLUSIONS: The sensitivity of RADT for GABHS pharyngitis is not a fixed value but varies with the severity of disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926"}, {"offsetInBeginSection": 2045, "offsetInEndSection": 2253, "text": "However, even among pediatric patients with > or =3 Centor criteria for GABHS pharyngitis, the sensitivity of RADT is still too low to support the use of RADT without culture confirmation of negative results.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926"}, {"offsetInBeginSection": 200, "offsetInEndSection": 310, "text": "In diagnosis, Centor clinical scoring system or rapid antigen test can be helpful in targeting antibiotic use.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22432746"}, {"offsetInBeginSection": 503, "offsetInEndSection": 584, "text": "3-4 Centor criteria) physicians can consider the use of rapid antigen test (RAT).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22432746"}]}, {"id": "5a86ebf2faa1ab7d2e000038", "body": "Which are the main transcriptional activators of circadian oscillations?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11517254", "http://www.ncbi.nlm.nih.gov/pubmed/19917250", "http://www.ncbi.nlm.nih.gov/pubmed/20967239", "http://www.ncbi.nlm.nih.gov/pubmed/18177499", "http://www.ncbi.nlm.nih.gov/pubmed/22217096", "http://www.ncbi.nlm.nih.gov/pubmed/9115195"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Modeling circadian oscillations with interlocking positive and negative feedback loops.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Both positive and negative feedback loops of transcriptional regulation have been proposed to be important for the generation of circadian rhythms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 148, "offsetInEndSection": 340, "text": "To test the sufficiency of the proposed mechanisms, two differential equation-based models were constructed to describe the Neurospora crassa and Drosophila melanogaster circadian oscillators.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 341, "offsetInEndSection": 522, "text": "In the model of the Neurospora oscillator, FRQ suppresses frq transcription by binding to a complex of the transcriptional activators WC-1 and WC-2, thus yielding negative feedback.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 979, "offsetInEndSection": 1128, "text": "Both models displayed circadian oscillations that were robust to parameter variations and to noise and that entrained to simulated light/dark cycles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 1129, "offsetInEndSection": 1283, "text": "Circadian oscillations were only obtained if time delays were included to represent processes not modeled in detail (e.g., transcription and translation).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Rhythmic PER abundance defines a critical nodal point for negative feedback within the circadian clock mechanism.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19917250"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1007, "text": "CLOCK:BMAL1 to drive the circadian negative feedback loop.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19917250"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Emergence of noise-induced oscillations in the central circadian pacemaker.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20967239"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Bmal1 is an essential transcriptional activator within the mammalian circadian clock.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20967239"}]}, {"id": "5a67c8c4b750ff4455000013", "body": "What is the link between TADs and GRBs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28874668", "http://www.ncbi.nlm.nih.gov/pubmed/26150425", "http://www.ncbi.nlm.nih.gov/pubmed/28060840", "http://www.ncbi.nlm.nih.gov/pubmed/24727717", "http://www.ncbi.nlm.nih.gov/pubmed/26518482", "http://www.ncbi.nlm.nih.gov/pubmed/27167421", "http://www.ncbi.nlm.nih.gov/pubmed/27919068", "http://www.ncbi.nlm.nih.gov/pubmed/1448082", "http://www.ncbi.nlm.nih.gov/pubmed/16943830"], "snippets": [{"offsetInBeginSection": 235, "offsetInEndSection": 404, "text": "Clusters of CNEs define the span of regulatory inputs for many important developmental regulators and have been described previously as genomic regulatory blocks (GRBs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668"}, {"offsetInBeginSection": 544, "offsetInEndSection": 735, "text": "Here, we show that clusters of CNEs strongly coincide with topological organisation, predicting the boundaries of hundreds of topologically associating domains (TADs) in human and Drosophila.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668"}, {"offsetInBeginSection": 736, "offsetInEndSection": 901, "text": "The set of TADs that are associated with high levels of noncoding conservation exhibit distinct properties compared to TADs devoid of extreme noncoding conservation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1165, "text": "The close correspondence between extreme noncoding conservation and TADs suggests that these TADs are ancient, revealing a regulatory architecture conserved over hundreds of millions of years.Metazoan genomes contain many clusters of conserved noncoding elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668"}, {"offsetInBeginSection": 194, "offsetInEndSection": 390, "text": "However, there is currently no parameter to quantitatively measure the structural characteristics of TADs, thus obscuring our understanding on the structural and functional differences among TADs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150425"}, {"offsetInBeginSection": 391, "offsetInEndSection": 629, "text": "Based on our finding that there exist intrinsic chromatin interaction patterns in TADs, we define a theoretical parameter, called aggregation preference (AP), to characterize TAD structures by capturing the interaction aggregation degree.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150425"}, {"offsetInBeginSection": 630, "offsetInEndSection": 942, "text": "Applying this defined parameter to 11 Hi-C data sets generated by both traditional and in situ Hi-C experimental pipelines, our analyses reveal that heterogeneous structures exist among TADs, and this structural heterogeneity is significantly correlated to DNA sequences, epigenomic signals and gene expressions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150425"}, {"offsetInBeginSection": 943, "offsetInEndSection": 1149, "text": "Although TADs can be stable in genomic positions across cell lines, structural comparisons show that a considerable number of stable TADs undergo significantly structural rearrangements during cell changes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150425"}, {"offsetInBeginSection": 1246, "offsetInEndSection": 1522, "text": "Altogether, the theoretical parameter defined in this work provides a quantitative method to link structural characteristics and biological functions of TADs, and this linkage implies that chromatin interaction pattern has the potential to mark transcription activity in TADs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150425"}, {"offsetInBeginSection": 178, "offsetInEndSection": 378, "text": "This result prompted us to compare maps of the Topologically Associating Domains (TADs) and of the Lamina Associated Domains (LADs) with the corresponding isochore maps of mouse and human chromosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28060840"}]}, {"id": "5a7600b983b0d9ea6600000c", "body": "Which clinical trials for psoriasis involved tofacitinib? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28829236", "http://www.ncbi.nlm.nih.gov/pubmed/27267933", "http://www.ncbi.nlm.nih.gov/pubmed/26267722", "http://www.ncbi.nlm.nih.gov/pubmed/29134822", "http://www.ncbi.nlm.nih.gov/pubmed/28441904", "http://www.ncbi.nlm.nih.gov/pubmed/27692733", "http://www.ncbi.nlm.nih.gov/pubmed/24883332", "http://www.ncbi.nlm.nih.gov/pubmed/26889727", "http://www.ncbi.nlm.nih.gov/pubmed/27716172", "http://www.ncbi.nlm.nih.gov/pubmed/26889081"], "snippets": [{"offsetInBeginSection": 351, "offsetInEndSection": 501, "text": "Phase 2, 3 and 4 clinical trials have investigated the efficacy and safety of tofacitinib given either as monotherapy or in combination with csDMARDs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236"}, {"offsetInBeginSection": 766, "offsetInEndSection": 950, "text": "One critical clinical question is whether tofacitinib monotherapy has similar efficacy as tofacitinib in combination with methotrexate (MTX); this question has recently been addressed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236"}, {"offsetInBeginSection": 951, "offsetInEndSection": 1056, "text": "A literature search on tofacitinib monotherapy was carried out using the PubMed database up to July 2017.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236"}, {"offsetInBeginSection": 774, "offsetInEndSection": 909, "text": "The authors present an overview of Phases I - III clinical trials of tofacitinib for psoriasis based on peer-reviewed literature.EXPERT", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267933"}, {"offsetInBeginSection": 910, "offsetInEndSection": 1095, "text": "OPINION: In clinical practice, it is important to assess the response of psoriasis to tofacitinib and identify possible clinical, genetic, and immune biomarkers to predict the response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267933"}, {"offsetInBeginSection": 1096, "offsetInEndSection": 1254, "text": "Comorbidities associated with psoriasis, in particular metabolic syndrome and obesity, are also an important aspect of using tofacitinib in clinical practice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267933"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722"}, {"offsetInBeginSection": 256, "offsetInEndSection": 439, "text": "Two new oral medications, apremilast and tofacitinib, have been developed for their immunomodulatory properties, and their potential efficacy in treating psoriasis is being evaluated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722"}, {"offsetInBeginSection": 439, "offsetInEndSection": 592, "text": "METHODS: We reviewed phase III randomized, placebo-controlled clinical trial results for apremilast and tofacitinib for efficacy and safety in psoriasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722"}, {"offsetInBeginSection": 1036, "offsetInEndSection": 1147, "text": "CONCLUSION: Both new oral medications, apremilast and tofacitinib, appear to be effective in treating psoriasis", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722"}]}, {"id": "5a551a8fb750ff4455000002", "body": "What is a potential side effect for Tymlos?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17650055", "http://www.ncbi.nlm.nih.gov/pubmed/16370982", "http://www.ncbi.nlm.nih.gov/pubmed/27924737", "http://www.ncbi.nlm.nih.gov/pubmed/21385029", "http://www.ncbi.nlm.nih.gov/pubmed/25119580", "http://www.ncbi.nlm.nih.gov/pubmed/6131489", "http://www.ncbi.nlm.nih.gov/pubmed/2183167", "http://www.ncbi.nlm.nih.gov/pubmed/27836000", "http://www.ncbi.nlm.nih.gov/pubmed/24261314", "http://www.ncbi.nlm.nih.gov/pubmed/7021123"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "One of the great challenges of long-term treatment of schizophrenia and related disorders is minimizing the medical or psychological burden from persistent side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650055"}, {"offsetInBeginSection": 429, "offsetInEndSection": 608, "text": "The authors review changing from one antipsychotic to another (\"switching\") as a potential treatment strategy for reducing the overall side effect burden of antipsychotic therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650055"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Interviews with elderly patients about side effects.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16370982"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Fifty older persons were interviewed about their medicines, side effects, and their responses to statements describing side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16370982"}, {"offsetInBeginSection": 244, "offsetInEndSection": 358, "text": "Participants knew much less about the potential side effects and almost nothing about potential drug interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16370982"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "[The intra-articular glucocorticoid injection; short-term success with potential side effects].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924737"}, {"offsetInBeginSection": 65, "offsetInEndSection": 395, "text": "However, there is increasing awareness of potential side effects associated with the intra- and peri-articular use of both glucocorticoids and topical analgesics.- In this review we will discuss the effects and side effects of intra-articular glucocorticoid injections in the context of non-rheumatic knee and shoulder conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924737"}, {"offsetInBeginSection": 598, "offsetInEndSection": 837, "text": "Long-term therapeutic effects do not exist.- Side effects range from local skin problems to adrenocortical suppression which can persist for weeks.- Glucocorticoid injections may be indicated in daily practice but have no long-term effect.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924737"}, {"offsetInBeginSection": 838, "offsetInEndSection": 945, "text": "In view of the potential (harmful) side effects, it is advisable to use the lowest possible effective dose.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924737"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "One of the critical stages in drug development is the identification of potential side effects for promising drug leads.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21385029"}]}, {"id": "5a87f44061bb38fb2400000f", "body": "Which disorder has been approved for treatment with Alk inhibitors?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23201355", "http://www.ncbi.nlm.nih.gov/pubmed/28182271", "http://www.ncbi.nlm.nih.gov/pubmed/28979145", "http://www.ncbi.nlm.nih.gov/pubmed/26294238", "http://www.ncbi.nlm.nih.gov/pubmed/24166094", "http://www.ncbi.nlm.nih.gov/pubmed/27468827", "http://www.ncbi.nlm.nih.gov/pubmed/26992917", "http://www.ncbi.nlm.nih.gov/pubmed/28536155", "http://www.ncbi.nlm.nih.gov/pubmed/28065466", "http://www.ncbi.nlm.nih.gov/pubmed/27122312"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 515, "offsetInEndSection": 808, "text": "Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 809, "offsetInEndSection": 958, "text": "The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 959, "offsetInEndSection": 1148, "text": "The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 1149, "offsetInEndSection": 1292, "text": "Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 1293, "offsetInEndSection": 1438, "text": "Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 1439, "offsetInEndSection": 1592, "text": "The occurrence of oncogenic ALK, particularly in non-small cell lung cancer, has generated considerable interest and effort in developing ALK inhibitors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 1593, "offsetInEndSection": 1833, "text": "Currently, crizotinib has been approved by the US Food and Drug Administration for the treatment of ALK-positive non-small cell lung cancer along with an approved fluorescence in situ hybridization kit used for the diagnosis of the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 2089, "offsetInEndSection": 2349, "text": "About 28% of the cases of crizotinib resistance are related to nearly a dozen different mutations of ALK in the EML4-ALK fusion protein; the other cases of resistance are related to the upregulation of alternative signaling pathways or to undefined mechanisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}]}, {"id": "5a723edd2dc08e987e00000c", "body": "Is Tofacitinib effective for Ulcerative Colitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28467869", "http://www.ncbi.nlm.nih.gov/pubmed/22894574"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "BACKGROUND: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 260, "offsetInEndSection": 406, "text": "METHODS: We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 407, "offsetInEndSection": 741, "text": "In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, respectively, who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib (10 mg twice daily) or placebo for 8 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 1300, "offsetInEndSection": 1462, "text": "PCONCLUSIONS: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "BACKGROUND: Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574"}, {"offsetInBeginSection": 525, "offsetInEndSection": 697, "text": "METHODS: In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574"}, {"offsetInBeginSection": 832, "offsetInEndSection": 1294, "text": "The primary outcome was a clinical response at 8 weeks, defined as an absolute decrease from baseline in the score on the Mayo scoring system for assessment of ulcerative colitis activity (possible score, 0 to 12, with higher scores indicating more severe disease) of 3 or more and a relative decrease from baseline of 30% or more with an accompanying decrease in the rectal bleeding subscore of 1 point or more or an absolute rectal bleeding subscore of 0 or 1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574"}, {"offsetInBeginSection": 1631, "offsetInEndSection": 1819, "text": "PCONCLUSIONS: Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574"}]}, {"id": "5a85a0f1faa1ab7d2e000032", "body": "What is the definition of General Regulatory Factors (GRFs)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12200417", "http://www.ncbi.nlm.nih.gov/pubmed/28448767", "http://www.ncbi.nlm.nih.gov/pubmed/28158860", "http://www.ncbi.nlm.nih.gov/pubmed/17158163", "http://www.ncbi.nlm.nih.gov/pubmed/27014338", "http://www.ncbi.nlm.nih.gov/pubmed/27540088", "http://www.ncbi.nlm.nih.gov/pubmed/25620770", "http://www.ncbi.nlm.nih.gov/pubmed/21914852", "http://www.ncbi.nlm.nih.gov/pubmed/25215414", "http://www.ncbi.nlm.nih.gov/pubmed/20371324"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "General regulatory factors (GRFs) as genome partitioners.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417"}, {"offsetInBeginSection": 658, "offsetInEndSection": 879, "text": "Together with Reb1p and Tbf1p, previously involved in the activity of Saccharomyces cerevisiae subtelomeric insulators, insulating potential emerges as a supplementary common property of General Regulatory Factors (GRFs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417"}, {"offsetInBeginSection": 880, "offsetInEndSection": 1088, "text": "Thus GRFs, which bind to sites scattered throughout the genome within promoters, would not only play a key role in regulating gene expression but also partition the genome in functionally independent domains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Transcriptional control of yeast ribosome biogenesis: A multifaceted role for general regulatory factors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28448767"}, {"offsetInBeginSection": 122, "offsetInEndSection": 419, "text": "This regulon has recently been shown to rely on a small set of transcriptional regulators (mainly Abf1, but also Reb1, Tbf1 and Rap1) previously referred to as general regulatory factors (GRFs) because of their widespread binding and action at many promoters and other specialized genomic regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28448767"}, {"offsetInBeginSection": 420, "offsetInEndSection": 542, "text": "Intriguingly, Abf1 binding to Ribi genes is differentially modulated in response to distinct nutrition signaling pathways.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28448767"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Abf1 and other general regulatory factors control ribosome biogenesis gene expression in budding yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158860"}, {"offsetInBeginSection": 304, "offsetInEndSection": 519, "text": "Here, we show that most Ribi gene promoters also contain binding sites for one or more General Regulatory Factors (GRFs), most frequently Abf1 and Reb1, and that these factors are enriched in vivo at Ribi promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158860"}, {"offsetInBeginSection": 1159, "offsetInEndSection": 1305, "text": "Our observations point to GRFs as new multifaceted players in Ribi gene regulation both during exponential growth and under repressive conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158860"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "Abf1 and Rap1 are general regulatory factors (GRFs) that contribute to transcriptional activation of a large number of genes, as well as to replication, silencing and telomere structure in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17158163"}]}, {"id": "5a68a463b750ff4455000014", "body": "Do chromatin features predict genes associated with eQTLs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23275551"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Transcription factor and chromatin features predict genes associated with eQTLs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 138, "offsetInEndSection": 381, "text": "Mapping studies for expression quantitative trait loci (eQTLs), transcription factors (TFs) and chromatin markers have become widely used tools for identifying gene regulatory elements, but prediction of target genes remains a major challenge.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 382, "offsetInEndSection": 529, "text": "Here, we integrate genome-wide data on TF-binding sites, chromatin markers and functional annotations to predict genes associated with human eQTLs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 530, "offsetInEndSection": 702, "text": "Using the random forest classifier, we found that genomic proximity plus five TF and chromatin features are able to predict >90% of target genes within 1 megabase of eQTLs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 703, "offsetInEndSection": 956, "text": "Despite being regularly used to map target genes, proximity is not a good indicator of eQTL targets for genes   150 kilobases away, but insulators, TF co-occurrence, open chromatin and functional similarities between TFs and genes are better indicators.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 1137, "offsetInEndSection": 1332, "text": "We hope this study will not only provide validation of eQTL-mapping studies, but also provide insight into the molecular mechanisms explaining how genetic variation can influence gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Cell type-specific gene expression in humans involves complex interactions between regulatory factors and DNA at enhancers and promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 957, "offsetInEndSection": 1136, "text": "Using all six features in the classifier achieved an area under the specificity and sensitivity curve of 0.91, much better compared with at most 0.75 for using any single feature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}]}, {"id": "5a760a4183b0d9ea66000016", "body": "What is filgotinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27988142", "http://www.ncbi.nlm.nih.gov/pubmed/25681059", "http://www.ncbi.nlm.nih.gov/pubmed/27993829", "http://www.ncbi.nlm.nih.gov/pubmed/27993828", "http://www.ncbi.nlm.nih.gov/pubmed/28838249", "http://www.ncbi.nlm.nih.gov/pubmed/26693854", "http://www.ncbi.nlm.nih.gov/pubmed/28645489", "http://www.ncbi.nlm.nih.gov/pubmed/24818516", "http://www.ncbi.nlm.nih.gov/pubmed/28622463", "http://www.ncbi.nlm.nih.gov/pubmed/28765121"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "BACKGROUND: Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142"}, {"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25681059"}, {"offsetInBeginSection": 15, "offsetInEndSection": 186, "text": "OBJECTIVES: Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25681059"}, {"offsetInBeginSection": 847, "offsetInEndSection": 968, "text": "Non-compartmental analysis was used to determine individual pharmacokinetic parameters for filgotinib and its metabolite.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25681059"}, {"offsetInBeginSection": 1596, "offsetInEndSection": 1726, "text": "Simulation of biomarker response supports that the maximum pharmacodynamic effect is reached at a daily dose of 200\u00a0mg filgotinib.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25681059"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26693854"}, {"offsetInBeginSection": 0, "offsetInEndSection": 283, "text": "OBJECTIVE: The selective Janus kinase 1 inhibitor filgotinib (GLPG0634), which is currently in clinical development for the treatment of rheumatoid arthritis (RA) and Crohn's disease, demonstrated encouraging safety and efficacy profiles in RA patients after 4 weeks of daily dosing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26693854"}, {"offsetInBeginSection": 284, "offsetInEndSection": 512, "text": "As RA patients might be treated with multiple medications simultaneously, possible drug-drug interactions of filgotinib with cytochrome P450 enzymes and with key drug transporters were evaluated in vitro and in clinical studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26693854"}, {"offsetInBeginSection": 779, "offsetInEndSection": 1001, "text": "Furthermore, filgotinib's interaction potential with CYP3A4 was examined in an open-label study in healthy volunteers, which evaluated the impact of filgotinib co-administration on the CYP3A4-sensitive substrate midazolam.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26693854"}]}, {"id": "5a74d9980384be9551000008", "body": "What is LHON, also known as Lebers syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27843288", "http://www.ncbi.nlm.nih.gov/pubmed/9147893", "http://www.ncbi.nlm.nih.gov/pubmed/25566062", "http://www.ncbi.nlm.nih.gov/pubmed/9309689", "http://www.ncbi.nlm.nih.gov/pubmed/11329546", "http://www.ncbi.nlm.nih.gov/pubmed/16523300", "http://www.ncbi.nlm.nih.gov/pubmed/7916404", "http://www.ncbi.nlm.nih.gov/pubmed/10993496", "http://www.ncbi.nlm.nih.gov/pubmed/27756254", "http://www.ncbi.nlm.nih.gov/pubmed/8240101"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 309, "text": "Leber's hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disorder with bilateral loss of central vision primarily due to mitochondrial DNA (mtDNA) mutations in subunits of complex I in the respiratory chain (primary LHON mutations), while other mtDNA mutations can also be causative.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288"}, {"offsetInBeginSection": 310, "offsetInEndSection": 575, "text": "Since the first description, it is known that LHON is not restricted to the eyes but is a multisystem disorder additionally involving the central nervous system, ears, endocrinological organs, heart, bone marrow, arteries, kidneys, or the peripheral nervous system.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288"}, {"offsetInBeginSection": 658, "offsetInEndSection": 824, "text": "Involvement of organs other than the eyes may be subclinical depending on age, ethnicity, and possibly the heteroplasmy rate of the responsible primary LHON mutation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288"}, {"offsetInBeginSection": 825, "offsetInEndSection": 980, "text": "Primary LHON mutations may rarely manifest without ocular compromise but with arterial hypertension, various neurodegenerative diseases, or Leigh syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288"}, {"offsetInBeginSection": 981, "offsetInEndSection": 1099, "text": "Patients with LHON need to be closely followed up to detect at which point organs other than the eyes become affected.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288"}, {"offsetInBeginSection": 1100, "offsetInEndSection": 1209, "text": "Multiorgan disease in LHON often responds more favorably to symptomatic treatment than the ocular compromise.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Cardiac conduction abnormalities have been reported in families with Leber's hereditary optic neuropathy (LHON).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9147893"}, {"offsetInBeginSection": 113, "offsetInEndSection": 331, "text": "The pre-excitation syndrome Wolff-Parkinson-White syndrome or Lown-Ganong-Levine syndrome, is reportedly common in Finns with LHON, being seen in 14 (9%) of the 163 individuals with mitochondrial DNA (mtDNA) mutations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9147893"}, {"offsetInBeginSection": 332, "offsetInEndSection": 588, "text": "While this syndrome is thought to be rare in other ethnic groups with LHON, the present study of 35 Japanese LHON families confirmed that it is also relatively common among Japanese families, being seen in 5 (8%) of the 63 individuals with mtDNA mutations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9147893"}, {"offsetInBeginSection": 589, "offsetInEndSection": 834, "text": "It remains to be determined whether the high incidence of the pre-excitation syndrome in Finnish and Japanese LHON families is due to a particular genetic composition of ethnic groups such as in Finland and in Japan, or only to a reporting bias.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9147893"}]}, {"id": "5a8842a261bb38fb24000015", "body": "List proteins that are targeted by \"immune checkpoints inhibitors\".", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26282545", "http://www.ncbi.nlm.nih.gov/pubmed/27770382", "http://www.ncbi.nlm.nih.gov/pubmed/27683114", "http://www.ncbi.nlm.nih.gov/pubmed/26183909", "http://www.ncbi.nlm.nih.gov/pubmed/26765776", "http://www.ncbi.nlm.nih.gov/pubmed/27068940", "http://www.ncbi.nlm.nih.gov/pubmed/26680224", "http://www.ncbi.nlm.nih.gov/pubmed/23691926", "http://www.ncbi.nlm.nih.gov/pubmed/27664133", "http://www.ncbi.nlm.nih.gov/pubmed/26860624"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282545"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "A major breakthrough in cancer immunotherapy was the discovery of immune checkpoint proteins, which function to effectively inhibit the immune system through various mechanisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282545"}, {"offsetInBeginSection": 676, "offsetInEndSection": 786, "text": "Following the success of ipilimumab, other immune checkpoints were studied as possible targets for inhibition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282545"}, {"offsetInBeginSection": 1108, "offsetInEndSection": 1276, "text": "Nevertheless, the exciting field of immune checkpoint inhibitors offers a potential curative option for many cancer patients who previously had a more dismal prognosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282545"}, {"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Immune checkpoint inhibitors for cancer treatment.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27770382"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "During immune responses antigen-specific T cells are regulated by several mechanisms, including through inhibitory receptors and regulatory T cells, to avoid excessive or persistent immune responses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27770382"}, {"offsetInBeginSection": 200, "offsetInEndSection": 460, "text": "These regulatory mechanisms, which are called 'immune checkpoints', suppress T cell responses, particularly in patients with chronic viral infections and cancer where viral antigens or tumor antigens persist for a long time and contribute to T cell exhaustion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27770382"}, {"offsetInBeginSection": 668, "offsetInEndSection": 819, "text": "As a result, anti-CTLA-4 and anti-PD-1 (or anti-PD-L1) antibodies were recently developed as immune checkpoint inhibitors for use in cancer treatments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27770382"}, {"offsetInBeginSection": 820, "offsetInEndSection": 956, "text": "In this review we describe several receptors that function as immunological checkpoints as well as the pharmaceuticals that target them.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27770382"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27683114"}]}, {"id": "5a736efc3b9d13c708000006", "body": "Which chromosomes are implicated in the Emanuel syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19606488", "http://www.ncbi.nlm.nih.gov/pubmed/22434056", "http://www.ncbi.nlm.nih.gov/pubmed/22876593", "http://www.ncbi.nlm.nih.gov/pubmed/27973931", "http://www.ncbi.nlm.nih.gov/pubmed/18286821", "http://www.ncbi.nlm.nih.gov/pubmed/24171835", "http://www.ncbi.nlm.nih.gov/pubmed/28981939", "http://www.ncbi.nlm.nih.gov/pubmed/27785401", "http://www.ncbi.nlm.nih.gov/pubmed/27617132"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Phenotypic delineation of Emanuel syndrome (supernumerary derivative 22 syndrome): Clinical features of 63 individuals.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Emanuel syndrome is characterized by multiple congenital anomalies and developmental disability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 408, "offsetInEndSection": 538, "text": "Little has been published on the clinical features of this syndrome since the 1980s and information on natural history is limited.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 833, "offsetInEndSection": 939, "text": "We received information on 63 individuals with Emanuel syndrome, ranging in age from newborn to adulthood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 1111, "offsetInEndSection": 1273, "text": "Our data suggest that vision and hearing impairment, seizures, failure to thrive and recurrent infections, particularly otitis media, are common in this syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 1477, "offsetInEndSection": 1635, "text": "This study provides new information on the clinical spectrum and natural history of Emanuel syndrome for families and physicians caring for these individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Prenatal screening characteristics in Emanuel syndrome: a case series and review of the literature.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22434056"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "PURPOSE: Emanuel syndrome is a rare chromosomal disorder characterized by severe mental retardation and multiple anomalies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22434056"}, {"offsetInBeginSection": 124, "offsetInEndSection": 220, "text": "The syndrome is caused by chromosomal imbalance due to a supernumerary derivative chromosome 22.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22434056"}, {"offsetInBeginSection": 221, "offsetInEndSection": 347, "text": "Little is known regarding the characteristics of prenatal biochemical screening, or ultrasonographic markers in this syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22434056"}]}, {"id": "5a86c938faa1ab7d2e000034", "body": "Which genes belong to the AUX/IAA family of transcription repressors in plants?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28111153", "http://www.ncbi.nlm.nih.gov/pubmed/27247276", "http://www.ncbi.nlm.nih.gov/pubmed/17077182", "http://www.ncbi.nlm.nih.gov/pubmed/17919906", "http://www.ncbi.nlm.nih.gov/pubmed/22368074", "http://www.ncbi.nlm.nih.gov/pubmed/27049520", "http://www.ncbi.nlm.nih.gov/pubmed/16478940", "http://www.ncbi.nlm.nih.gov/pubmed/22409484", "http://www.ncbi.nlm.nih.gov/pubmed/16284307", "http://www.ncbi.nlm.nih.gov/pubmed/17430601"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Plant Stress Tolerance Requires Auxin-Sensitive Aux/IAA Transcriptional Repressors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "The Aux/IAA proteins are auxin-sensitive repressors that mediate diverse physiological and developmental processes in plants [1, 2].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 133, "offsetInEndSection": 248, "text": "There are 29 Aux/IAA genes in Arabidopsis that exhibit unique but partially overlapping patterns of expression [3].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 249, "offsetInEndSection": 443, "text": "Although some studies have suggested that individual Aux/IAA genes have specialized function, genetic analyses of the family\u00a0have been limited by the scarcity of loss-of-function phenotypes [4].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 444, "offsetInEndSection": 560, "text": "Furthermore, with a few exceptions, our knowledge of the factors that regulate Aux/IAA expression is limited [1, 5].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 561, "offsetInEndSection": 760, "text": "We\u00a0hypothesize that transcriptional control of Aux/IAA genes plays a central role in the establishment of the auxin-signaling pathways that regulate organogenesis, growth, and environmental response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 761, "offsetInEndSection": 852, "text": "Here, we describe a screen for\u00a0transcription factors (TFs) that regulate the Aux/IAA genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 853, "offsetInEndSection": 931, "text": "We identify TFs from 38 families, including 26 members of the DREB/CBF family.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 1043, "offsetInEndSection": 1183, "text": "Recessive mutations in these IAA\u00a0genes result in decreased tolerance to stress conditions, demonstrating a role for auxin in abiotic stress.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 1184, "offsetInEndSection": 1326, "text": "Our results demonstrate that stress\u00a0pathways interact with the auxin gene regulatory network (GRN) through transcription of\u00a0the Aux/IAA genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}]}, {"id": "5a6a2bbcb750ff4455000022", "body": "What is Cellbase?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22693220", "http://www.ncbi.nlm.nih.gov/pubmed/28535294"], "snippets": [{"offsetInBeginSection": 1200, "offsetInEndSection": 1285, "text": "CellBase documentation can be found at http://docs.bioinfo.cipf.es/projects/cellbase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 771, "offsetInEndSection": 935, "text": "HGVA calculates population frequencies for these projects and enriches their data with variant annotation provided by CellBase, a rich and fast annotation solution.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28535294"}, {"offsetInBeginSection": 193, "offsetInEndSection": 342, "text": "Today, there is more biological information than ever but, unfortunately, the current status of many of these repositories is far from being optimal.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 1136, "offsetInEndSection": 1199, "text": "The database is hosted in our servers and is regularly updated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 601, "offsetInEndSection": 703, "text": "In addition, data size is increasingly becoming an obstacle when accessing or storing biological data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "CellBase, a comprehensive collection of RESTful web services for retrieving relevant biological information from heterogeneous sources.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 343, "offsetInEndSection": 600, "text": "Some of the most common problems are that the information is spread out in many small databases; frequently there are different standards among repositories and some databases are no longer supported or they contain too specific and unconnected information.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 888, "offsetInEndSection": 997, "text": "CellBase provides a solution to the growing necessity of integration by easing the access to biological data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 998, "offsetInEndSection": 1135, "text": "CellBase implements a set of RESTful web services that query a centralized database containing the most relevant biological data sources.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 388, "offsetInEndSection": 561, "text": "The Human Genome Variation Archive (HGVA) tackles these challenges and facilitates access to genomic data for key reference projects in a clean, fast and integrated fashion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28535294"}]}, {"id": "5a76155c83b0d9ea6600001e", "body": "Which phase III clinical trials for rheumatoid arthritis involve baricitinib? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27910962", "http://www.ncbi.nlm.nih.gov/pubmed/28255337", "http://www.ncbi.nlm.nih.gov/pubmed/27799159", "http://www.ncbi.nlm.nih.gov/pubmed/28923098", "http://www.ncbi.nlm.nih.gov/pubmed/27689735", "http://www.ncbi.nlm.nih.gov/pubmed/28290136", "http://www.ncbi.nlm.nih.gov/pubmed/28405473", "http://www.ncbi.nlm.nih.gov/pubmed/27577235"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Baricitinib: JAK inhibition for rheumatoid arthritis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962"}, {"offsetInBeginSection": 828, "offsetInEndSection": 865, "text": "in pivotal phase III clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962"}, {"offsetInBeginSection": 1040, "offsetInEndSection": 1143, "text": "A phase III study aimed at assessing long-term (4 years) safety and efficacy of baricitinib is ongoing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255337"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Biologics have changed expectation and outcomes for rheumatoid arthritis (RA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255337"}, {"offsetInBeginSection": 569, "offsetInEndSection": 935, "text": "Baricitinib has now been evaluated in four phase III clinical trials, and although safety concerns cannot fully be answered until the drug is studied over longer periods of time, the data to date suggest that this drug with its once daily dosing, rapid onset of action and efficacy as monotherapy represents an important addition to the RA therapeutic armamentarium.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255337"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799159"}, {"offsetInBeginSection": 0, "offsetInEndSection": 300, "text": "OBJECTIVES: To assess baricitinib on patient-reported outcomes (PROs) in patients with moderately to severely active rheumatoid arthritis, who had insufficient response or intolerance to \u22651 tumour necrosis factor inhibitors (TNFis) or other biological disease-modifying antirheumatic drugs (bDMARDs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799159"}, {"offsetInBeginSection": 300, "offsetInEndSection": 432, "text": "METHODS: In this double-blind phase III study, patients were randomised to once-daily placebo or baricitinib 2 or 4\u2005mg for 24\u2005weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799159"}, {"offsetInBeginSection": 1638, "offsetInEndSection": 1720, "text": "PRO results aligned with clinical efficacy data for baricitinib.TRIAL REGISTRATION", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27799159"}]}, {"id": "5a87124561bb38fb24000001", "body": "What is cebocephaly", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23072180", "http://www.ncbi.nlm.nih.gov/pubmed/19673365", "http://www.ncbi.nlm.nih.gov/pubmed/16061113", "http://www.ncbi.nlm.nih.gov/pubmed/957381", "http://www.ncbi.nlm.nih.gov/pubmed/9132501", "http://www.ncbi.nlm.nih.gov/pubmed/2255999", "http://www.ncbi.nlm.nih.gov/pubmed/828460", "http://www.ncbi.nlm.nih.gov/pubmed/411936", "http://www.ncbi.nlm.nih.gov/pubmed/23599105", "http://www.ncbi.nlm.nih.gov/pubmed/115387"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Severe semilobar holoprosencephaly and lissencephaly associated with cebocephaly in a newborn.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Holoprosencephaly is frequently accompanied by midline facial abnormalities such as hypotelorism, cyclopia, etmocephaly and cebocephaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180"}, {"offsetInBeginSection": 137, "offsetInEndSection": 226, "text": "Cebocephaly is a very rare congenital anomaly combining with semilobar holoprosencephaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180"}, {"offsetInBeginSection": 274, "offsetInEndSection": 382, "text": "Lissencephaly and holoprosencephaly are rare associations, that have not been reported yet with cebocephaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180"}, {"offsetInBeginSection": 383, "offsetInEndSection": 489, "text": "Herein we present the first case of cebocephaly with severe semilobar holoprosencephaly and lissencephaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Alobar holoprosencephaly associated with cebocephaly and craniosynostosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673365"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Cebocephaly is a very rare congenital midline facial anomaly characterized by a blind-ended single nostril and ocular hypotelorism, and is usually combined with alobar holoprosencephaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673365"}, {"offsetInBeginSection": 187, "offsetInEndSection": 275, "text": "We report here a case of alobar holoprosencephaly with cebocephaly and craniosynostosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673365"}, {"offsetInBeginSection": 641, "offsetInEndSection": 763, "text": "Early detection by the prenatal ultrasound examination is important because of poor prognosis of alobar holoprosencephaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673365"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "A case of holoprosencephaly and cebocephaly associated to torch infection.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16061113"}]}, {"id": "5a8881118cb19eca6b000006", "body": "Has the proteome of mice hippocampus been analysed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18283665", "http://www.ncbi.nlm.nih.gov/pubmed/15863242", "http://www.ncbi.nlm.nih.gov/pubmed/27062398", "http://www.ncbi.nlm.nih.gov/pubmed/17663576", "http://www.ncbi.nlm.nih.gov/pubmed/28449397"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Interlocking transcriptomics, proteomics and toponomics technologies for brain tissue analysis in murine hippocampus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665"}, {"offsetInBeginSection": 218, "offsetInEndSection": 469, "text": "We find that transcriptome and proteome levels of function as well as the topological organization of synaptic protein clusters, detected by toponomics at physiological sites of hippocampus CA3 region, are all largely conserved between different mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665"}, {"offsetInBeginSection": 719, "offsetInEndSection": 877, "text": "The findings provide insight in the systems biology of gene expression on transcriptome, proteome and toponome levels of function in the same brain subregion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Proteome analysis in hippocampus of mice overexpressing human Cu/Zn-superoxide dismutase 1.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15863242"}, {"offsetInBeginSection": 1132, "offsetInEndSection": 1341, "text": "For example, several members of the Septin family of cytoskeletal proteins were up-regulated only in the hippocampus, while Septin-9 was down-regulated in the hippocampus, the frontal cortex, and the striatum.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27062398"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "14-3-3 expression in denervated hippocampus after entorhinal cortex lesion assessed by culture-derived isotope tags in quantitative proteomics.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17663576"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Differential proteome profiling in the hippocampus of amnesic mice.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449397"}, {"offsetInBeginSection": 253, "offsetInEndSection": 389, "text": "This study of proteome profiling in the hippocampus could provide conceptual insights into the molecular mechanisms involved in amnesia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449397"}, {"offsetInBeginSection": 529, "offsetInEndSection": 702, "text": "Using two-dimensional gel electrophoresis coupled with MALDI-MS/MS, we have analyzed the hippocampal proteome and identified 18 proteins which were differentially expressed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449397"}, {"offsetInBeginSection": 1420, "offsetInEndSection": 1587, "text": "Therefore, we silenced Vdac1 in the hippocampus of normal young mice and found similar impairment in recognition memory of Vdac1 silenced and scopolamine-treated mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449397"}]}, {"id": "5a742d620384be9551000002", "body": "Which disease risk can be estimated with the Stop-Bang questionnaire?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27610133", "http://www.ncbi.nlm.nih.gov/pubmed/27898430", "http://www.ncbi.nlm.nih.gov/pubmed/25837173", "http://www.ncbi.nlm.nih.gov/pubmed/22270686", "http://www.ncbi.nlm.nih.gov/pubmed/25758298", "http://www.ncbi.nlm.nih.gov/pubmed/25010615", "http://www.ncbi.nlm.nih.gov/pubmed/26961117", "http://www.ncbi.nlm.nih.gov/pubmed/26378880", "http://www.ncbi.nlm.nih.gov/pubmed/27938922", "http://www.ncbi.nlm.nih.gov/pubmed/26557740"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Length of Stay in Ambulatory Surgical Oncology Patients at High Risk for Sleep Apnea as Predicted by STOP-BANG Questionnaire.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27610133"}, {"offsetInBeginSection": 12, "offsetInEndSection": 197, "text": "The STOP-BANG questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (OSA) by classifying patients as low risk (LR) if STOP-BANG score", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27610133"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "An update on the various practical applications of the STOP-Bang questionnaire in anesthesia, surgery, and perioperative medicine.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 11, "offsetInEndSection": 190, "text": "REVIEW: The present review aims to provide an update on the various practical applications of the STOP-Bang questionnaire in anesthesia, surgery, and perioperative medicine.RECENT", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 191, "offsetInEndSection": 358, "text": "FINDINGS: The STOP-Bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (OSA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 359, "offsetInEndSection": 482, "text": "A recent meta-analysis confirmed that STOP-Bang is validated for use in the sleep clinic, surgical, and general population.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 483, "offsetInEndSection": 580, "text": "Patients with a STOP-Bang score of 0--2 can be classified as low-risk for moderate-to-severe OSA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 581, "offsetInEndSection": 666, "text": "Those with a score of 5--8 can be classified as high-risk for moderate-to-severe OSA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 921, "offsetInEndSection": 1068, "text": "Further, patients with a STOP-Bang score at least 3 can be classified as high risk for moderate-to-severe OSA if the serum HCO3 at least 28\u200ammol/l.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 1069, "offsetInEndSection": 1240, "text": "STOP-Bang can be used as a novel tool for perioperative risk stratification because it easily identifies patients who are at increased risk of perioperative complications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}]}, {"id": "5a86ea05faa1ab7d2e000037", "body": "How is CTCF activated post-translationally?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21465478", "http://www.ncbi.nlm.nih.gov/pubmed/19170077", "http://www.ncbi.nlm.nih.gov/pubmed/21912613", "http://www.ncbi.nlm.nih.gov/pubmed/15361875", "http://www.ncbi.nlm.nih.gov/pubmed/24362533", "http://www.ncbi.nlm.nih.gov/pubmed/25183525", "http://www.ncbi.nlm.nih.gov/pubmed/20110362", "http://www.ncbi.nlm.nih.gov/pubmed/23843455", "http://www.ncbi.nlm.nih.gov/pubmed/29077515", "http://www.ncbi.nlm.nih.gov/pubmed/26657029"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 34, "text": "The tumor suppressor role of CTCF.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465478"}, {"offsetInBeginSection": 120, "offsetInEndSection": 310, "text": "Ectopic expression of CTCF in various normal and tumoral human cell lines inhibits cell division and clonogenicity, with the consequence to consider CTCF a potential tumor-suppressor factor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465478"}, {"offsetInBeginSection": 311, "offsetInEndSection": 569, "text": "In this review article, we focused on the molecular mechanisms engaged by CTCF to modulate the expression of several key-regulators of differentiation, cellular senescence, cell cycle control and progression, whose expression is frequently altered in tumors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465478"}, {"offsetInBeginSection": 570, "offsetInEndSection": 768, "text": "Moreover, we discussed common features of CTCF at each tumor-related DNA-binding sequence, such as protein-partners, post-translational modifications, and distinctive epigenetic marks establishment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465478"}, {"offsetInBeginSection": 769, "offsetInEndSection": 928, "text": "The investigation of the molecular mechanisms engaged by CTCF to modulate tumor-related genes emphasizes the cell-type dependency of its tumor suppressor role.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465478"}, {"offsetInBeginSection": 929, "offsetInEndSection": 1105, "text": "Indeed, the ability of CTCF to bind their promoters strictly depends by cell-type features as DNA methylation, BORIS-binding and post-translational modifications as PARYlation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465478"}, {"offsetInBeginSection": 0, "offsetInEndSection": 238, "text": "CCCTC-binding factor (CTCF) is a ubiquitous Zn-finger-containing protein with numerous recognized functions, including, but not limited to, gene activation and repression, enhancer-blocking, X-chromosome inactivation, and gene imprinting.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19170077"}, {"offsetInBeginSection": 363, "offsetInEndSection": 466, "text": "In addition, CTCF undergoes several post-translational modifications, including poly(ADP-ribosyl)ation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19170077"}, {"offsetInBeginSection": 106, "offsetInEndSection": 249, "text": "Previous studies found in corneal epithelial cells that CTCF is regulated by epidermal growth factor (EGF) through activation of NF-\u03baB p65/p50.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21912613"}, {"offsetInBeginSection": 250, "offsetInEndSection": 348, "text": "It also found that CTCF is suppressed in ultraviolet (UV) stress-induced corneal epithelial cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21912613"}]}, {"id": "5a6a2f88b750ff4455000024", "body": "What is Target Explorer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12824372"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Target Explorer: An automated tool for the identification of new target genes for a specified set of transcription factors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372"}, {"offsetInBeginSection": 417, "offsetInEndSection": 664, "text": "Target Explorer automates the entire process from the creation of a customized library of binding sites for known transcription factors through the prediction and annotation of putative target genes that are potentially regulated by these factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372"}, {"offsetInBeginSection": 820, "offsetInEndSection": 901, "text": "Target Explorer is available at http://trantor.bioc.columbia.edu/Target_Explorer/", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372"}, {"offsetInBeginSection": 665, "offsetInEndSection": 819, "text": "It was specifically designed for the well-annotated Drosophila melanogaster genome, but most options can be used for sequences from other genomes as well.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372"}, {"offsetInBeginSection": 0, "offsetInEndSection": 174, "text": "With the increasing number of eukaryotic genomes available, high-throughput automated tools for identification of regulatory DNA sequences are becoming increasingly feasible.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372"}, {"offsetInBeginSection": 275, "offsetInEndSection": 416, "text": "Here we combine the prediction of clusters of binding sites for transcription factors with context information taken from genome annotations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372"}, {"offsetInBeginSection": 175, "offsetInEndSection": 274, "text": "Several computational approaches for the prediction of regulatory elements were recently developed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372"}]}, {"id": "5a772e9dfaa1ab7d2e000001", "body": "Was saracatinib being considered as a treatment for Alzheimer's disease in November 2017?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26062928", "http://www.ncbi.nlm.nih.gov/pubmed/25874001", "http://www.ncbi.nlm.nih.gov/pubmed/29112196", "http://www.ncbi.nlm.nih.gov/pubmed/11802333", "http://www.ncbi.nlm.nih.gov/pubmed/26271177", "http://www.ncbi.nlm.nih.gov/pubmed/28828744", "http://www.ncbi.nlm.nih.gov/pubmed/11763163", "http://www.ncbi.nlm.nih.gov/pubmed/28817221", "http://www.ncbi.nlm.nih.gov/pubmed/22299278", "http://www.ncbi.nlm.nih.gov/pubmed/21977379"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928"}, {"offsetInBeginSection": 918, "offsetInEndSection": 998, "text": "RESULTS: A total of 10 patients were enrolled between January and November 2007.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928"}, {"offsetInBeginSection": 1386, "offsetInEndSection": 1641, "text": "CONCLUSION: Saracatinib is a novel oral Src kinase inhibitor that was well tolerated but failed to meet its primary endpoint of improvement in 4 month progression-free survival as a single agent in previously treated metastatic colorectal cancer patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "INTRODUCTION: Despite significant progress, a disease-modifying therapy for Alzheimer's disease (AD) has not yet been developed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1714, "text": "Secondary endpoints included changes in clinical efficacy measures (Alzheimer's Disease Assessment Scale - cognitive subscale, MMSE, Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory, Neuropsychiatric Inventory, and Clinical Dementia Rating Scale - Sum of Boxes) and regional cerebral glucose metabolism measured by fluorodeoxyglucose positron emission tomography.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 2710, "offsetInEndSection": 2734, "text": "Registered 12 June 2014.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29112196"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Many models of disease progression in Alzheimer's disease (AD) have been proposed to help guide experimental design and aid the interpretation of results.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29112196"}, {"offsetInBeginSection": 1474, "offsetInEndSection": 1716, "text": "A more flexible theoretical framework capable of accommodating the complexity of the APP proteolytic system is required to integrate available evidence.Molecular Psychiatry advance online publication, 7 November 2017; doi:10.1038/mp.2017.218.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29112196"}]}, {"id": "5a897729fcd1d6a10c000009", "body": "What is the asosciation between the  eustachian tube and the uvula?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/6586052", "http://www.ncbi.nlm.nih.gov/pubmed/18695625", "http://www.ncbi.nlm.nih.gov/pubmed/17049625", "http://www.ncbi.nlm.nih.gov/pubmed/19644792", "http://www.ncbi.nlm.nih.gov/pubmed/21112097", "http://www.ncbi.nlm.nih.gov/pubmed/7401840"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "Otitis media and eustachian tube caliber.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "Clinical data supported the hypothesis that most otitis media requiring surgery is part of a life-long bilateral process that correlates with small mastoid air system, and with a bougie-assessable large eustachian tube.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 220, "offsetInEndSection": 334, "text": "Cleft palate, even in the microform of cleft uvula, was an indicator of large eustachian tube (p less than 0.001).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 335, "offsetInEndSection": 486, "text": "The 1.48 mm mean eustachian tube caliber of the otitis patients was larger (p less than 0.001) than the 0.73 mm mean of the reference eustachian tubes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 546, "offsetInEndSection": 755, "text": "Comparatively small caliber eustachian tubes were associated with trauma-caused tympanic membrane perforation (p less than 0.01), and middle ear effusion in allergic airway disease patients (p less than 0.05).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 756, "offsetInEndSection": 872, "text": "Large eustachian tube caliber seemed a reliable correlate of the spectrum of manifestations of chronic otitis media.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "The patulous eustachian tube complicated with amyotrophic lateral sclerosis: a video clip demonstration.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18695625"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "We report a 60-year-old case diagnosed as the amyotrophic lateral sclerosis with patulous eustachian tube (ET).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18695625"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Floating the uvula: an intraoperative method for detecting bifidity.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17049625"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "A bifid uvula, midline diastasis of the palatal muscles, and notching of the posterior hard palate have classically formed a triad diagnosing submucosal clefts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17049625"}]}, {"id": "5a888b56d543831129000002", "body": "What induces Arabidopsis ROF1 expression?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19366428", "http://www.ncbi.nlm.nih.gov/pubmed/17080288"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Arabidopsis ROF1 (FKBP62) modulates thermotolerance by interacting with HSP90.1 and affecting the accumulation of HsfA2-regulated sHSPs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Arabidopsis ROF1 (AtFKBP62) is a peptidyl prolyl cis/trans isomerase and a member of the FKBP (FK506 binding protein) family.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 126, "offsetInEndSection": 198, "text": "ROF1 expression is induced by heat stress and developmentally regulated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 199, "offsetInEndSection": 362, "text": "In this study, we show that ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain, and localizes in the cytoplasm under normal conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 363, "offsetInEndSection": 564, "text": "Exposure to heat stress induces nuclear localization of the ROF1-HSP90.1 complex, which is dependent upon the presence of the transcription factor HsfA2, which interacts with HSP90.1 but not with ROF1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 565, "offsetInEndSection": 661, "text": "Nuclear localization of ROF1 was not detected in Arabidopsis HSP90.1 and HsfA2 knockout mutants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 662, "offsetInEndSection": 913, "text": "The rof1 knockout plants exhibited collapse when 24-48 h passed between acclimation at 37 degrees C and exposure to 45 degrees C. Transgenic ROF1 over-expressors showed better survival in response to exposure to 45 degrees C than wild-type plants did.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 914, "offsetInEndSection": 1125, "text": "In rof1 knockout mutants, the level of expression of small HSPs regulated by HsfA2 was dramatically reduced after exposure to 37 degrees C and recovery for 24-48 h, and correlates well with the mutant phenotype.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 1126, "offsetInEndSection": 1280, "text": "We suggest a role for ROF1 in prolongation of thermotolerance by sustaining the levels of small HSPs that are essential for survival at high temperatures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Arabidopsis immunophilins ROF1 (AtFKBP62) and ROF2 (AtFKBP65) exhibit tissue specificity, are heat-stress induced, and bind HSP90.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17080288"}]}, {"id": "5a67a207b750ff4455000008", "body": "List indications for palivizumab for treatment of RSV-induced bronchiolitis. ", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21077358", "http://www.ncbi.nlm.nih.gov/pubmed/12171262", "http://www.ncbi.nlm.nih.gov/pubmed/28807039", "http://www.ncbi.nlm.nih.gov/pubmed/20705882", "http://www.ncbi.nlm.nih.gov/pubmed/20695756", "http://www.ncbi.nlm.nih.gov/pubmed/28987219", "http://www.ncbi.nlm.nih.gov/pubmed/26636747", "http://www.ncbi.nlm.nih.gov/pubmed/19811111", "http://www.ncbi.nlm.nih.gov/pubmed/20457017", "http://www.ncbi.nlm.nih.gov/pubmed/16236360"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "[Two cases of symptomatic West syndrome suffering from severe respiratory syncytial virus-induced bronchiolitis].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "We report two cases of symptomatic West syndrome with severe respiratory syncytial virus (RSV)-induced bronchiolitis: one was a 9-month-old boy who was hospitalized for shock, and the other was a 15-month-old boy in pre-shock condition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358"}, {"offsetInBeginSection": 532, "offsetInEndSection": 722, "text": "According to a one-year epidemiological survey of RSV infection conducted in 2004-2005 in Nagano prefecture, 7 of 238 hospitalized RSV cases were found to have basic neuromuscular disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358"}, {"offsetInBeginSection": 899, "offsetInEndSection": 994, "text": "Neuromuscular disorders may thus be an important risk factor for severe forms of RSV infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358"}, {"offsetInBeginSection": 995, "offsetInEndSection": 1187, "text": "Although children with such disorders should be protected from RSV, they are currently excluded from the indication for palivizumab administration as passive immunization against RSV in Japan.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "To establish current practice for hospital-based treatment of uncomplicated respiratory syncytial virus (RSV) infection in the Republic of Ireland.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171262"}, {"offsetInBeginSection": 347, "offsetInEndSection": 469, "text": "The scenario was of a 3-month-old infant with uncomplicated but moderately severe RSV infection requiring hospitalization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171262"}, {"offsetInBeginSection": 1049, "offsetInEndSection": 1172, "text": "The routine use of RSV monoclonal antibody, palivizumab, for RSV prophylaxis was reported by 49% (31/63) of paediatricians.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171262"}, {"offsetInBeginSection": 1348, "offsetInEndSection": 1455, "text": "The management of infants with RSV bronchiolitis varies greatly among consultant paediatricians in Ireland.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171262"}, {"offsetInBeginSection": 0, "offsetInEndSection": 118, "text": "The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28807039"}]}, {"id": "5a86f074faa1ab7d2e00003a", "body": "With which cancers has the loss of SMARCB1 been associated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26941181", "http://www.ncbi.nlm.nih.gov/pubmed/23432645", "http://www.ncbi.nlm.nih.gov/pubmed/24853101", "http://www.ncbi.nlm.nih.gov/pubmed/28974397", "http://www.ncbi.nlm.nih.gov/pubmed/22797305", "http://www.ncbi.nlm.nih.gov/pubmed/23060122", "http://www.ncbi.nlm.nih.gov/pubmed/26743474", "http://www.ncbi.nlm.nih.gov/pubmed/23851500", "http://www.ncbi.nlm.nih.gov/pubmed/25490678", "http://www.ncbi.nlm.nih.gov/pubmed/23174932"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 27, "text": "Gene of the month: SMARCB1.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26941181"}, {"offsetInBeginSection": 158, "offsetInEndSection": 335, "text": "Since discovering genetic alterations of the SMARCB1 gene in malignant rhabdoid tumours, the family of tumours harbouring loss of SMARCB1 expression has been steadily expanding.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26941181"}, {"offsetInBeginSection": 336, "offsetInEndSection": 522, "text": "In this review, we give a general overview of SMARCB1, its role in various cancers including germline mutations, association with genetic syndromes and role in future targeted therapies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26941181"}, {"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "The discovery of biallelic, inactivating SMARCB1 mutations in rhabdoid tumors (RTs) over a decade ago represented the first recognized link between chromatin remodeling and tumor suppression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23432645"}, {"offsetInBeginSection": 656, "offsetInEndSection": 796, "text": "Indeed, the mutation rate in RTs is among the lowest of all cancers sequenced, with loss of SMARCB1 as essentially the sole recurrent event.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23432645"}, {"offsetInBeginSection": 797, "offsetInEndSection": 1134, "text": "Given the genetic simplicity of this disease, understanding the chromatin dysregulation caused by SMARCB1 loss may provide more general insight into how epigenetic alterations can contribute to oncogenic transformation and may reveal opportunities for targeted therapy not only of RT but also the variety of other SWI/SNF mutant cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23432645"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853101"}, {"offsetInBeginSection": 247, "offsetInEndSection": 400, "text": "Mouse models validated Smarcb1 as a bona fide tumor suppressor, as Smarcb1 inactivation in mice results in 100% of the animals rapidly developing cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853101"}, {"offsetInBeginSection": 479, "offsetInEndSection": 601, "text": "More recently, at least seven other genes encoding SWI/SNF subunits have been identified as recurrently mutated in cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853101"}, {"offsetInBeginSection": 669, "offsetInEndSection": 867, "text": "Consequently, investigation of the mechanisms by which SMARCB1 mutation causes cancer has relevance not only for rhabdoid tumors, but also potentially for the wide variety of SWI/SNF mutant cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853101"}]}, {"id": "5a6d022ab750ff445500002a", "body": "Is there any linear-time and linear-space algorithm for the computation of avoided words in biological sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28293277"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "On avoided words, absent words, and their application to biological sequence analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277"}, {"offsetInBeginSection": 62, "offsetInEndSection": 225, "text": "RESULTS: In this article, we propose an [Formula: see text]-time and [Formula: see text]-space algorithm to compute all [Formula: see text]-avoided words of length", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277"}, {"offsetInBeginSection": 226, "offsetInEndSection": 335, "text": "CONCLUSIONS: The systematic search for avoided words is particularly useful for biological sequence analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277"}, {"offsetInBeginSection": 336, "offsetInEndSection": 434, "text": "We present a linear-time and linear-space algorithm for the computation of avoided words of length", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277"}, {"offsetInBeginSection": 0, "offsetInEndSection": 61, "text": "BACKGROUND: The deviation of the observed frequency of a word", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277"}]}, {"id": "5a735b383b9d13c708000002", "body": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28893208", "http://www.ncbi.nlm.nih.gov/pubmed/27033334", "http://www.ncbi.nlm.nih.gov/pubmed/25003808", "http://www.ncbi.nlm.nih.gov/pubmed/23432579", "http://www.ncbi.nlm.nih.gov/pubmed/10137064", "http://www.ncbi.nlm.nih.gov/pubmed/10137850", "http://www.ncbi.nlm.nih.gov/pubmed/28389707"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "BACKGROUND: Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}, {"offsetInBeginSection": 240, "offsetInEndSection": 485, "text": "METHODS: Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}, {"offsetInBeginSection": 0, "offsetInEndSection": 85, "text": "Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 115, "offsetInEndSection": 246, "text": "RNA interference (RNAi) is a clinically validated technology that may be a promising approach to the treatment of ATTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 566, "offsetInEndSection": 676, "text": "To test this hypothesis, TTR-targeting siRNAs were evaluated in a murine model of hereditary ATTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 1098, "offsetInEndSection": 1286, "text": "Together, the data presented herein support the therapeutic hypothesis behind TTR lowering and highlight the potential of RNAi in the treatment of patients afflicted with ATTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25003808"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "INTRODUCTION: Transthyretin (TTR)-related hereditary amyloidosis is an adult-onset, dominantly inherited, systemic neurodegenerative disease endemic in some populations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25003808"}, {"offsetInBeginSection": 828, "offsetInEndSection": 976, "text": "But there are also reports on clinical trials in asthma, hypercholesterolemia and genetic diseases such as inherited skin disorders and amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23432579"}]}, {"id": "5a67b48cb750ff4455000010", "body": "SGOT is an abbreviation for an enzyme other wise known as alanine amino transferase, yes or no?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21375200", "http://www.ncbi.nlm.nih.gov/pubmed/1678364", "http://www.ncbi.nlm.nih.gov/pubmed/589307", "http://www.ncbi.nlm.nih.gov/pubmed/1681419", "http://www.ncbi.nlm.nih.gov/pubmed/17880731", "http://www.ncbi.nlm.nih.gov/pubmed/5349302", "http://www.ncbi.nlm.nih.gov/pubmed/17904308", "http://www.ncbi.nlm.nih.gov/pubmed/1355593", "http://www.ncbi.nlm.nih.gov/pubmed/5470040", "http://www.ncbi.nlm.nih.gov/pubmed/16877991"], "snippets": [{"offsetInBeginSection": 252, "offsetInEndSection": 377, "text": "Subjects were measured for waist/hip ratio, BMI and serum levels of ALT, AST, Alk phosphatase and glutamyl transferase (GGT).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21375200"}, {"offsetInBeginSection": 378, "offsetInEndSection": 626, "text": "The study excluded by screening for AntiHCV, HBsAg and patients with aspartate amino transferase (SGOT), alanine amino transferase (SGPT), GGT levels more than three times the normal and subject with a total leukocyte count more than 10,000/microl.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21375200"}, {"offsetInBeginSection": 419, "offsetInEndSection": 584, "text": "DEC inhibited activities of monoamine oxidase, aspartate amino transferase and alanine amino transferase and enhanced those of cathepsin and glutamate dehydrogenase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1678364"}, {"offsetInBeginSection": 156, "offsetInEndSection": 550, "text": "Mean values of glutamate dehydrogenase (GDH), serum aspartate and alanine transferase (SGOT and SGPT), ornithine carbamoyltransferase (OCT), and gamma-glutamyltranspeptidase (gamma-GTP) tended to rise with increasing liver cell necrosis, though values of SGOT, SGPT, OCT, and gamma-GTP showed considerable overlap between the 32 patients with histologically proved hepatitis and the 68 without.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/589307"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Effect of glucagon and some other alpha and beta adrenergic agonists and antagonists on alanine amino transferase of perfused rat liver.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1681419"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Glucagon increased alanine amino transferase (AAT) activity in perfused rat liver by about 90% over control.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1681419"}, {"offsetInBeginSection": 292, "offsetInEndSection": 487, "text": "Complete blood picture, differential leukocyte count, and serum levels of Estrogen, Alanine amino transferase (SGPT), Aspartate amino transferase (SGOT), total protein and albumin were estimated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17880731"}, {"offsetInBeginSection": 118, "offsetInEndSection": 228, "text": "When synthetic oestrogens were given, raised values of serum aspartate and alanine amino-transferase (S.G.O.T.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/5349302"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "Effect of adrenergic agonists and antagonists on alanine amino transferase, fructose-1:6-bisphosphatase and glucose production in hepatocytes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1355593"}, {"offsetInBeginSection": 0, "offsetInEndSection": 203, "text": "Using rat hepatocytes we confirmed our previous results that glucagon and beta-adrenergic agonists increased the enzyme activity of alanine aminotransferase (AAT) and propranolol abolished their effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1355593"}]}, {"id": "5a893da7bc7bade53a000001", "body": "Is CREB a key memory protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16266283", "http://www.ncbi.nlm.nih.gov/pubmed/9530494", "http://www.ncbi.nlm.nih.gov/pubmed/22267118", "http://www.ncbi.nlm.nih.gov/pubmed/21712073", "http://www.ncbi.nlm.nih.gov/pubmed/23504989", "http://www.ncbi.nlm.nih.gov/pubmed/12006982", "http://www.ncbi.nlm.nih.gov/pubmed/15988467", "http://www.ncbi.nlm.nih.gov/pubmed/28017136", "http://www.ncbi.nlm.nih.gov/pubmed/19110430", "http://www.ncbi.nlm.nih.gov/pubmed/21734652"], "snippets": [{"offsetInBeginSection": 233, "offsetInEndSection": 423, "text": "The cAMP responsive element binding protein (CREB) is a nuclear transcription factor that modulates transcription of genes containing cAMP responsive elements (CRE sites) in their promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 530, "offsetInEndSection": 635, "text": "Numerous studies on invertebrates and vertebrates demonstrate that CREB is critical for long-term memory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 636, "offsetInEndSection": 834, "text": "Here, we review the key features of CREB-dependent transcription and critically evaluate the data examining the roles of CREB in different forms of plasticity, including long-term memory in mammals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 835, "offsetInEndSection": 1069, "text": "Because learning and memory have been linked to specific types of synaptic plasticity in several species, we also review studies on the role of CREB in long-term facilitation in Aplysia and in hippocampal long-term potentiation (LTP).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 1070, "offsetInEndSection": 1170, "text": "Several human cognitive disorders have been linked to alterations of CREB-regulated gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 0, "offsetInEndSection": 16, "text": "CREB and memory.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9530494"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "The cAMP responsive element binding protein (CREB) is a nuclear protein that modulates the transcription of genes with cAMP responsive elements in their promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9530494"}, {"offsetInBeginSection": 164, "offsetInEndSection": 276, "text": "Increases in the concentration of either calcium or cAMP can trigger the phosphorylation and activation of CREB.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9530494"}, {"offsetInBeginSection": 277, "offsetInEndSection": 457, "text": "This transcription factor is a component of intracellular signaling events that regulate a wide range of biological functions, from spermatogenesis to circadian rhythms and memory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9530494"}, {"offsetInBeginSection": 458, "offsetInEndSection": 578, "text": "Here we review the key features of CREB-dependent transcription, as well as the involvement of CREB in memory formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9530494"}]}, {"id": "5a67ade5b750ff445500000c", "body": "Does erythromycin increase risk of hypertrophic pyloric stenosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12693559", "http://www.ncbi.nlm.nih.gov/pubmed/12090829", "http://www.ncbi.nlm.nih.gov/pubmed/10609814", "http://www.ncbi.nlm.nih.gov/pubmed/11562617", "http://www.ncbi.nlm.nih.gov/pubmed/27655365", "http://www.ncbi.nlm.nih.gov/pubmed/12100810", "http://www.ncbi.nlm.nih.gov/pubmed/25687145", "http://www.ncbi.nlm.nih.gov/pubmed/18358279", "http://www.ncbi.nlm.nih.gov/pubmed/12381214"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "A case report has suggested that exposure to erythromycin through breast milk might cause infantile hypertrophic pyloric stenosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559"}, {"offsetInBeginSection": 131, "offsetInEndSection": 283, "text": "This study therefore examined whether macrolides, transmitted via breast milk, increase the risk of infantile hypertrophic pyloric stenosis in neonates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559"}, {"offsetInBeginSection": 614, "offsetInEndSection": 894, "text": "The odds ratios for infantile hypertrophic pyloric stenosis varied between 2.3 and 3.0 according to different periods of postnatal exposure, and after stratification for gender they were 10.3 [95% confidence interval (95% CI) 1.2-92.3] for girls and 2.0 (95% CI 0.5-8.4) for boys.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559"}, {"offsetInBeginSection": 895, "offsetInEndSection": 1001, "text": "The use of macrolides during breast-feeding increases the risk of infantile hypertrophic pyloric stenosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090829"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "OBJECTIVE: To assess the link between very early erythromycin exposure and pyloric stenosis in young infants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090829"}, {"offsetInBeginSection": 301, "offsetInEndSection": 426, "text": "Cases of infants with a hospital discharge diagnosis of pyloric stenosis and an associated surgical procedure code were used.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090829"}, {"offsetInBeginSection": 562, "offsetInEndSection": 664, "text": "MEASURES: Hospital discharge diagnosis of pyloric stenosis, and an associated surgical procedure code.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090829"}, {"offsetInBeginSection": 764, "offsetInEndSection": 846, "text": "Among these infants, 804 (2.6/1000 infants) met the criteria for pyloric stenosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090829"}]}, {"id": "5a870b7bfaa1ab7d2e00003d", "body": "What is the function of STAR elements in yeast telomeres?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10228166", "http://www.ncbi.nlm.nih.gov/pubmed/21351687", "http://www.ncbi.nlm.nih.gov/pubmed/21949764", "http://www.ncbi.nlm.nih.gov/pubmed/8720065", "http://www.ncbi.nlm.nih.gov/pubmed/16228207", "http://www.ncbi.nlm.nih.gov/pubmed/16132818", "http://www.ncbi.nlm.nih.gov/pubmed/10517334", "http://www.ncbi.nlm.nih.gov/pubmed/12498682", "http://www.ncbi.nlm.nih.gov/pubmed/7991584", "http://www.ncbi.nlm.nih.gov/pubmed/9188726"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Cohabitation of insulators and silencing elements in yeast subtelomeric regions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "In budding yeast, the telomeric DNA is flanked by a combination of two subtelomeric repetitive sequences, the X and Y' elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166"}, {"offsetInBeginSection": 331, "offsetInEndSection": 404, "text": "These elements were named STARs, for subtelomeric anti-silencing regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166"}, {"offsetInBeginSection": 1098, "offsetInEndSection": 1259, "text": "Overall, our results suggest that the silencing emanating from telomeres can be propagated in a discontinuous manner via a series of subtelomeric relay elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "DNA fragments isolated from the left end of chromosome III in yeast are repaired to generate functional telomeres.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "DNA fragments isolated from the left end of chromosome III in the yeast Saccharomyces cerevisiae are recognized as telomeres in yeast, since plasmids constructed with such fragments are replicated as linear molecules in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687"}, {"offsetInBeginSection": 227, "offsetInEndSection": 402, "text": "The fragments have a 1.18-kb region homologous with the type X regions at yeast telomeres that contain ARS elements that allow the autonomous replication of plasmids in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687"}, {"offsetInBeginSection": 542, "offsetInEndSection": 721, "text": "Distal to the type X region, the fragments have a region of tandemly repeated DNA sequence defined by the formula 5\u2032-C(1\u20133)A-3\u2032, and designated as the T region at yeast telomeres.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687"}, {"offsetInBeginSection": 722, "offsetInEndSection": 938, "text": "Although the terminus of the chromosome was removed in the procedure used to molecularly isolate the left end of chromosome III, the fragments containing the X and T region are recognized as chromosome ends in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687"}, {"offsetInBeginSection": 939, "offsetInEndSection": 1159, "text": "Plasmids with inverted repeats of the chromosome III end fragments are resolved in yeast to produce linear plasmids with telomeres that are similar in length and heterogeneity with the natural left end on chromosome III.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687"}]}, {"id": "5a6d13fbb750ff445500002f", "body": "What is MINDY (motif interacting with Ub-containing novel DUB family)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27292798"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Deubiquitinating enzymes (DUBs) remove ubiquitin (Ub) from Ub-conjugated substrates to regulate the\u00a0functional outcome of ubiquitylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 138, "offsetInEndSection": 274, "text": "Here we report the discovery of a new family of DUBs, which we have named MINDY (motif interacting with Ub-containing novel DUB family).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 275, "offsetInEndSection": 417, "text": "Found in all eukaryotes, MINDY-family DUBs are highly selective at cleaving K48-linked polyUb, a signal that targets proteins for degradation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 418, "offsetInEndSection": 612, "text": "We identify the catalytic activity to be encoded within a previously unannotated domain, the crystal structure of which reveals a distinct protein fold with no homology to any of the known DUBs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 613, "offsetInEndSection": 776, "text": "The crystal structure of MINDY-1 (also known as FAM63A) in complex with propargylated Ub reveals conformational changes that realign the active site for catalysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 871, "offsetInEndSection": 984, "text": "Collectively, our results reveal a new family of DUBs that may have specialized roles in regulating proteostasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 777, "offsetInEndSection": 870, "text": "MINDY-1 prefers cleaving long polyUb chains and\u00a0works by trimming chains from the distal end.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}]}, {"id": "5a735c143b9d13c708000003", "body": "Is patisiran currently (November 2017) in clinical phase II trials?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26338094", "http://www.ncbi.nlm.nih.gov/pubmed/28893208"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 146, "offsetInEndSection": 419, "text": "This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of patisiran (ALN-TTR02), a small interfering RNA encapsulated within lipid nanoparticles, in patients with transthyretin-mediated familial amyloid polyneuropathy (FAP).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 419, "offsetInEndSection": 682, "text": "METHODS: In this phase II study, patients with FAP were administered 2 intravenous infusions of patisiran at one of the following doses: 0.01 (n\u2009=\u20094), 0.05 (n\u2009=\u20093), 0.15 (n\u2009=\u20093), or 0.3 (n\u2009=\u20097) mg/kg every 4\u00a0weeks (Q4W), or 0.3\u00a0mg/kg (n\u2009=\u200912) every 3\u00a0weeks (Q3W).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 1638, "offsetInEndSection": 1718, "text": "Patisiran 0.3\u00a0mg/kg Q3W is currently in phase III development.TRIAL REGISTRATION", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}, {"offsetInBeginSection": 1626, "offsetInEndSection": 1812, "text": "DISCUSSION: APOLLO represents the largest randomized, Phase 3 study to date in patients with hATTR amyloidosis, with endpoints that capture the multisystemic nature of this disease.TRIAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}, {"offsetInBeginSection": 1813, "offsetInEndSection": 1907, "text": "REGISTRATION: This trial is registered at clinicaltrials.gov ( NCT01960348 ); October 9, 2013.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}, {"offsetInBeginSection": 680, "offsetInEndSection": 788, "text": "Patients are randomized 2:1 to receive either intravenous patisiran 0.3\u00a0mg/kg or placebo once every 3\u00a0weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}, {"offsetInBeginSection": 240, "offsetInEndSection": 485, "text": "METHODS: Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}, {"offsetInBeginSection": 1568, "offsetInEndSection": 1626, "text": "Safety of patisiran will be assessed throughout the study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}]}, {"id": "5a787544faa1ab7d2e00000b", "body": "Is Kummell\u2019s disease an avascular necrosis of the vertebral body?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9280031", "http://www.ncbi.nlm.nih.gov/pubmed/27446290", "http://www.ncbi.nlm.nih.gov/pubmed/19321060", "http://www.ncbi.nlm.nih.gov/pubmed/12865850", "http://www.ncbi.nlm.nih.gov/pubmed/19214087", "http://www.ncbi.nlm.nih.gov/pubmed/19124637", "http://www.ncbi.nlm.nih.gov/pubmed/22220246", "http://www.ncbi.nlm.nih.gov/pubmed/23814399"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Idiopathic avascular necrosis of a vertebral body.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 48, "offsetInEndSection": 157, "text": "OBJECTIVES: To review the English literature pertaining to idiopathic avascular necrosis of a vertebral body.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 158, "offsetInEndSection": 293, "text": "As an illustrative example, the case of a 60-year-old woman with idiopathic avascular necrosis of L4 is presented.SUMMARY OF BACKGROUND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 294, "offsetInEndSection": 361, "text": "DATA: Avascular necrosis of a vertebral body is an uncommon entity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 531, "offsetInEndSection": 662, "text": "The intravertebral vacuum cleft phenomenon seen on plain films has been strongly associated with vertebral body avascular necrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 716, "offsetInEndSection": 822, "text": "Vertebral body avascular necrosis was initially identified with imaging studies and confirmed with biopsy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 823, "offsetInEndSection": 919, "text": "A comprehensive preoperative evaluation did not identify a specific cause of avascular necrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 920, "offsetInEndSection": 996, "text": "The patient underwent vertebral body resection with fibula allograft struts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 996, "offsetInEndSection": 1225, "text": "CONCLUSIONS: Although vertebral body collapse in an osteoporotic individual is relatively common, a case is reported of vertebral body collapse and subsequent necrosis without evidence of underlying disease at 48-month follow-up.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 1226, "offsetInEndSection": 1308, "text": "The current findings support the diagnosis of idiopathic avascular necrosis of L4.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}]}, {"id": "5a895a96fcd1d6a10c000003", "body": "Can a circRNA be translated into protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28344080", "http://www.ncbi.nlm.nih.gov/pubmed/28344082", "http://www.ncbi.nlm.nih.gov/pubmed/25449546", "http://www.ncbi.nlm.nih.gov/pubmed/28634583", "http://www.ncbi.nlm.nih.gov/pubmed/28223408", "http://www.ncbi.nlm.nih.gov/pubmed/29116363", "http://www.ncbi.nlm.nih.gov/pubmed/28705773", "http://www.ncbi.nlm.nih.gov/pubmed/29028266", "http://www.ncbi.nlm.nih.gov/pubmed/27612318", "http://www.ncbi.nlm.nih.gov/pubmed/29036403"], "snippets": [{"offsetInBeginSection": 101, "offsetInEndSection": 163, "text": "Here, we show that a subset of circRNAs is translated in\u00a0vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28344080"}, {"offsetInBeginSection": 465, "offsetInEndSection": 618, "text": "In addition, we found that a circRNA generated from the muscleblind locus encodes a protein, which we detected in fly head extracts by mass spectrometry.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28344080"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28344082"}, {"offsetInBeginSection": 907, "offsetInEndSection": 1106, "text": "Circ-ZNF609 is associated with heavy polysomes, and it is translated into a protein in a splicing-dependent and cap-independent manner, providing an example of a protein-coding circRNA in eukaryotes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28344082"}, {"offsetInBeginSection": 305, "offsetInEndSection": 483, "text": "Here we constructed a single exon minigene containing split GFP, and found that the pre-mRNA indeed produces circRNA through efficient backsplicing in human and Drosophila cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25449546"}, {"offsetInBeginSection": 792, "offsetInEndSection": 864, "text": "The resulting circRNA can be translated to generate functional proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25449546"}, {"offsetInBeginSection": 723, "offsetInEndSection": 921, "text": "These features confer numerous potential functions to circRNAs, such as acting as miRNA sponges, or binding to RNA-associated proteins to form RNA-protein complexes that regulate gene transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634583"}, {"offsetInBeginSection": 922, "offsetInEndSection": 1161, "text": "It has been proposed that circRNA regulate gene expression at the transcriptional or post-transcriptional level by interacting with miRNAs and that circRNAs may have a role in regulating miRNA function in cancer initiation and progression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634583"}, {"offsetInBeginSection": 1677, "offsetInEndSection": 1842, "text": "In addition, though originally thought to be non-coding, there is now increasing evidence to suggest that select circRNAs can be translated into functional proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634583"}, {"offsetInBeginSection": 271, "offsetInEndSection": 434, "text": "Here we describe a switch for inducing back-splicing of an engineered circRNA that relies on the CRISPR endoribonuclease, Csy4, as an activator of circularization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28223408"}]}, {"id": "5a67afb7b750ff445500000d", "body": "List main clinical features of the POEMS syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2227242", "http://www.ncbi.nlm.nih.gov/pubmed/10378364", "http://www.ncbi.nlm.nih.gov/pubmed/27208909", "http://www.ncbi.nlm.nih.gov/pubmed/25984208", "http://www.ncbi.nlm.nih.gov/pubmed/8699962", "http://www.ncbi.nlm.nih.gov/pubmed/22453306"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "[Unusual cause of ascites: the POEMS syndrome].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2227242"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "A 39-year-old woman presented with polyneuropathy, hepatomegaly, splenomegaly, endocrinopathy, monoclonal protein and skin changes, several of the many clinical features of the recently described POEMS syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2227242"}, {"offsetInBeginSection": 297, "offsetInEndSection": 348, "text": "In this case ascites was a main presenting feature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2227242"}, {"offsetInBeginSection": 349, "offsetInEndSection": 426, "text": "Thus, the POEMS syndrome must be added to the list of rare causes of ascites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2227242"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The POEMS syndrome is a rare multisystemic disorder with polyneuropathy, organomegaly, endocrinopathy of various forms, production of monoclonal (M) component, and skin changes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364"}, {"offsetInBeginSection": 541, "offsetInEndSection": 701, "text": "The patient had many clinical features of the described POEMS syndrome including sclerotic bone lesions, a persistent lambda-paraprotein and refractory ascites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364"}, {"offsetInBeginSection": 702, "offsetInEndSection": 753, "text": "In this case ascites was a main presenting feature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364"}, {"offsetInBeginSection": 754, "offsetInEndSection": 842, "text": "Thus, the POEMS syndrome must be added to the list of rare causes of refractory ascites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364"}, {"offsetInBeginSection": 0, "offsetInEndSection": 42, "text": "Glomeruloid hemangioma and POEMS syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27208909"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "POEMS syndrome is a paraneoplastic manifestation associated with hematopoietic disorders such as multiple myeloma and Castleman disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27208909"}]}, {"id": "5a89528dfcd1d6a10c000001", "body": "Where do centromeres locate according to the Rabl orientation of eukaryotic nuclei?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9886774", "http://www.ncbi.nlm.nih.gov/pubmed/21674259", "http://www.ncbi.nlm.nih.gov/pubmed/11559751", "http://www.ncbi.nlm.nih.gov/pubmed/20501974", "http://www.ncbi.nlm.nih.gov/pubmed/26208647", "http://www.ncbi.nlm.nih.gov/pubmed/15102067"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Non-Rabl patterns of centromere and telomere distribution in the interphase nuclei of plant cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 136, "offsetInEndSection": 267, "text": "Such a polarized orientation of centromeres and telomeres is believed to be preserved in the interphase and is known as Rabl model.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 268, "offsetInEndSection": 375, "text": "We analyzed the distributions of centromeres and telomeres in interphase nuclei from several plant species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 376, "offsetInEndSection": 505, "text": "Although Rabl polarity was observed in wheat, rye, barley and oats, non-Rabl patterns were discovered in sorghum, rice and maize.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 506, "offsetInEndSection": 658, "text": "In the non-Rabl patterns, both centromeres and telomeres were dispersed throughout the interphase nucleus, except in the area occupied by the nucleolus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 659, "offsetInEndSection": 866, "text": "Both Rabl and non-Rabl distribution patterns of centromeres and telomeres were consistent in interphase nuclei derived from meristematic root tip cells, microspore mother cells and differentiated leaf cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 867, "offsetInEndSection": 1021, "text": "Our study demonstrated that there is a diversity of interphase chromatin organization and that the classical Rabl model is not universal in plant species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Similar rye A and B chromosome organization in meristematic and differentiated interphase nuclei.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21674259"}, {"offsetInBeginSection": 122, "offsetInEndSection": 258, "text": "These special features inspired us to analyse whether there are differences between A and B chromatin organization in interphase nuclei.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21674259"}, {"offsetInBeginSection": 259, "offsetInEndSection": 451, "text": "Applying fluorescence in situ hybridization, we found that both rye A and B chromosomes added to hexaploid wheat showed in meristematic nuclei a string-like shape and a clear Rabl orientation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21674259"}]}, {"id": "5a6e18d8b750ff4455000038", "body": "Are Conserved Nonexonic Elements (CNEEs) important in phylogenomics research?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28637293"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Conserved Nonexonic Elements: A Novel Class of Marker for Phylogenomics.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 187, "offsetInEndSection": 289, "text": "Thus far, ultraconserved elements (UCEs) and introns have been the most widely used noncoding markers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 290, "offsetInEndSection": 536, "text": "Here we analyze and study the evolutionary properties of a new type of noncoding marker, conserved nonexonic elements (CNEEs), which consists of noncoding elements that are estimated to evolve slower than the neutral rate across a set of species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 537, "offsetInEndSection": 746, "text": "Although they often include UCEs, CNEEs are distinct from UCEs because they are not ultraconserved, and, most importantly, the core region alone is analyzed, rather than both the core and its flanking regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 1310, "offsetInEndSection": 1554, "text": "Comparison of phylogenetic results across the three marker types indicated that one branch, the sister group to the passerine + falcon clade, was resolved differently and with moderate (>70%) bootstrap support between CNEEs and UCEs or introns.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Noncoding markers have a particular appeal as tools for phylogenomic analysis because, at least in vertebrates, they appear less subject to strong variation in GC content among lineages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 1555, "offsetInEndSection": 1865, "text": "Overall, CNEEs appear to be promising as phylogenomic markers, yielding phylogenetic resolution as high as for UCEs and introns but with fewer gaps, less ambiguity in alignments and with patterns of nucleotide substitution more consistent with the assumptions of commonly used methods of phylogenetic analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 747, "offsetInEndSection": 1158, "text": "Using a data set of 16 birds plus an alligator outgroup, and \u223c3600-\u223c3800 loci per marker type, we found that although CNEEs were less variable than bioinformatically derived UCEs or introns and in some cases exhibited a slower approach to branch resolution as determined by phylogenomic subsampling, the quality of CNEE alignments was superior to those of the other markers, with fewer gaps and missing species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 1159, "offsetInEndSection": 1309, "text": "Phylogenetic resolution using coalescent approaches was comparable among the three marker types, with most nodes being fully and congruently resolved.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}]}, {"id": "5a7361d83b9d13c708000005", "body": "What is miravirsen?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25385103", "http://www.ncbi.nlm.nih.gov/pubmed/24068553", "http://www.ncbi.nlm.nih.gov/pubmed/24354366", "http://www.ncbi.nlm.nih.gov/pubmed/27805315", "http://www.ncbi.nlm.nih.gov/pubmed/23534542", "http://www.ncbi.nlm.nih.gov/pubmed/26503793", "http://www.ncbi.nlm.nih.gov/pubmed/25218783", "http://www.ncbi.nlm.nih.gov/pubmed/23109665", "http://www.ncbi.nlm.nih.gov/pubmed/22545703", "http://www.ncbi.nlm.nih.gov/pubmed/24385319"], "snippets": [{"offsetInBeginSection": 456, "offsetInEndSection": 675, "text": "Combination studies of miravirsen with interferon \u03b12b, ribavirin, and nonnucleoside (VX-222) and nucleoside (2'-methylcytidine) inhibitors of NS5B, NS5A (BMS-790052), or NS3 (telaprevir) indicated additive interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103"}, {"offsetInBeginSection": 1304, "offsetInEndSection": 1393, "text": "An HCV variant constructed to contain the A4C change was fully susceptible to miravirsen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103"}, {"offsetInBeginSection": 1394, "offsetInEndSection": 1538, "text": "A C3U HCV variant demonstrated overall reductions in susceptibility to miravirsen but was fully susceptible to all other anti-HCV agents tested.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103"}, {"offsetInBeginSection": 288, "offsetInEndSection": 390, "text": "MiR-122 is a liver-specific miRNA with an important role in the life cycle of hepatitis C virus (HCV).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068553"}, {"offsetInBeginSection": 391, "offsetInEndSection": 521, "text": "It is the target of miravirsen (SPC3649), an antimiR drug candidate currently in clinical testing for treatment of HCV infections.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068553"}, {"offsetInBeginSection": 798, "offsetInEndSection": 977, "text": "While miravirsen is thought to work mainly by hybridizing to mature miR-122 and blocking its interaction with HCV RNA, its target sequence is also present in pri- and pre-miR-122.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068553"}, {"offsetInBeginSection": 990, "offsetInEndSection": 1118, "text": "However, there is certainly the need for future investigations to better determine whether miR-122 is really specific for liver.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24354366"}, {"offsetInBeginSection": 1119, "offsetInEndSection": 1269, "text": "It is also important to elucidate whether miR-122 is actually specific for HCV genome and further investigate the therapeutic potential of miravirsen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24354366"}, {"offsetInBeginSection": 307, "offsetInEndSection": 440, "text": "The aim of this study was to assess the efficacy of delivering miravirsen during NEVLP to inhibit miR-122 function in a pig LT model.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27805315"}, {"offsetInBeginSection": 441, "offsetInEndSection": 515, "text": "Pig livers were treated with miravirsen during NEVLP or cold storage (CS).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27805315"}]}, {"id": "5a7a44b4faa1ab7d2e000010", "body": "Is Loss of function one of the cardinal signs of inflammation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29135930", "http://www.ncbi.nlm.nih.gov/pubmed/28282278", "http://www.ncbi.nlm.nih.gov/pubmed/23583354"], "snippets": [{"offsetInBeginSection": 60, "offsetInEndSection": 255, "text": "As early as 2000 years ago, the Roman encyclopaedist Aulus Cornelius Celsus recognised four cardinal signs of this response-redness, heat, swelling and pain; a fifth sign is loss of function.[...", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Tumor, calor, rubor, and dolor describe four cardinal signs of inflammation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278"}, {"offsetInBeginSection": 77, "offsetInEndSection": 244, "text": "The fifth-functio laesa, or loss of function-was promulgated by Rudolf Virchow, who, in the 19th century, also noted an intricate link between inflammation and cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278"}, {"offsetInBeginSection": 245, "offsetInEndSection": 522, "text": "However, the role of cancer inflammation in driving loss of therapeutic efficacy has only recently been fully appreciated, as a result of molecular and immunohistochemical approaches applied in clinical medicine and the availability of novel agents for modulating inflammation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278"}, {"offsetInBeginSection": 709, "offsetInEndSection": 911, "text": "Understanding the multifaceted relationship between inflammation and patient outcomes has the potential to advance prognostic tools and uncover therapeutic opportunities for improving clinical outcomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Resolution of inflammation: mechanisms and opportunity for drug development.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354"}, {"offsetInBeginSection": 246, "offsetInEndSection": 440, "text": "The cardinal signs of inflammation dolor, calor, tumor and rubor are intrinsically associated with events including vasodilatation, edema and leukocyte trafficking into the site of inflammation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354"}, {"offsetInBeginSection": 441, "offsetInEndSection": 627, "text": "If uncontrolled or unresolved, inflammation itself can lead to further tissue damage and give rise to chronic inflammatory diseases and autoimmunity with eventual loss of organ function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354"}, {"offsetInBeginSection": 628, "offsetInEndSection": 763, "text": "It is now evident that the resolution of inflammation is an active continuous process that occurs during an acute inflammatory episode.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354"}, {"offsetInBeginSection": 1362, "offsetInEndSection": 1602, "text": "Such strategies have proved beneficial in several pre-clinical models of inflammatory diseases, suggesting that pharmacological modulation of the resolution process may be useful for the treatment of chronic inflammatory diseases in humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354"}]}, {"id": "5a89a20ffcd1d6a10c00000e", "body": "List factors that promote lymphangiogenesis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16557570", "http://www.ncbi.nlm.nih.gov/pubmed/28804221", "http://www.ncbi.nlm.nih.gov/pubmed/25142796", "http://www.ncbi.nlm.nih.gov/pubmed/26968383", "http://www.ncbi.nlm.nih.gov/pubmed/22967508", "http://www.ncbi.nlm.nih.gov/pubmed/18519975", "http://www.ncbi.nlm.nih.gov/pubmed/19958632", "http://www.ncbi.nlm.nih.gov/pubmed/16611067", "http://www.ncbi.nlm.nih.gov/pubmed/26706909", "http://www.ncbi.nlm.nih.gov/pubmed/16793912"], "snippets": [{"offsetInBeginSection": 144, "offsetInEndSection": 347, "text": "Studies of tumor models in animals and clinicopathological data have indicated that growth of lymphatic vessels (lymphangiogenesis) in the vicinity of solid tumors may contribute to lymphatic metastasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570"}, {"offsetInBeginSection": 348, "offsetInEndSection": 533, "text": "Research over the past 5 years has identified a range of lymphangiogenic growth factors that could conceivably play a role in promoting tumor lymphangiogenesis and lymphatic metastasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570"}, {"offsetInBeginSection": 534, "offsetInEndSection": 805, "text": "The most extensively studied signaling system that promotes lymphangiogenesis in tumors involves the secreted lymphangiogenic proteins vascular endothelial growth factor-C (VEGF-C) and VEGF-D, and their cognate receptor on lymphatic endothelium VEGF receptor-3 (VEGFR-3).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570"}, {"offsetInBeginSection": 806, "offsetInEndSection": 1103, "text": "More recent studies have identified other signaling molecules that can also promote lymphangiogenesis in vivo, including hepatocyte growth factor and members of the fibroblast growth factor, angiopoietin, platelet-derived growth factor and insulin-like growth factor families of secreted proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "SIX1 promotes tumor lymphangiogenesis by coordinating TGF\u03b2 signals that increase expression of VEGF-C.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796"}, {"offsetInBeginSection": 85, "offsetInEndSection": 209, "text": "Malignant tumors release growth factors such as VEGF-C to induce lymphangiogenesis, thereby promoting lymph node metastasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796"}, {"offsetInBeginSection": 210, "offsetInEndSection": 555, "text": "Here, we report that sine oculis homeobox homolog 1 (SIX1), expressed in tumor cells, can promote tumor lymphangiogenesis and lymph node metastasis by coordinating with TGF\u03b2 to increase the expression of VEGF-C. Lymphangiogenesis and lymph node metastasis in cervical cancer were closely correlated with higher expression of SIX1 in tumor cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796"}, {"offsetInBeginSection": 556, "offsetInEndSection": 770, "text": "By enhancing VEGF-C expression in tumor cells, SIX1 could augment the promoting effect of tumor cells on the migration and tube formation of lymphatic endothelial cells (LEC) in vitro and lymphangiogenesis in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796"}, {"offsetInBeginSection": 994, "offsetInEndSection": 1128, "text": "Despite its effect in promoting VEGF-C expression, TGF\u03b2 could inhibit lymphangiogenesis by directly inhibiting tube formation by LECs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796"}, {"offsetInBeginSection": 1294, "offsetInEndSection": 1486, "text": "That is, tumor cells that expressed high levels of SIX1 could promote lymphangiogenesis and counteract the negative effects of TGF\u03b2 on lymphangiogenesis by increasing the expression of VEGF-C.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796"}]}, {"id": "5a68f448b750ff4455000018", "body": "Which bacteria causes erythrasma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21393451", "http://www.ncbi.nlm.nih.gov/pubmed/7969634", "http://www.ncbi.nlm.nih.gov/pubmed/25477907", "http://www.ncbi.nlm.nih.gov/pubmed/6859802", "http://www.ncbi.nlm.nih.gov/pubmed/12010076", "http://www.ncbi.nlm.nih.gov/pubmed/27294050", "http://www.ncbi.nlm.nih.gov/pubmed/3965026", "http://www.ncbi.nlm.nih.gov/pubmed/9614412", "http://www.ncbi.nlm.nih.gov/pubmed/8469500", "http://www.ncbi.nlm.nih.gov/pubmed/15189194"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Exogenous coproporphyrin III production by Corynebacterium aurimucosum and Microbacterium oxydans in erythrasma lesions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21393451"}, {"offsetInBeginSection": 90, "offsetInEndSection": 216, "text": "Coral-red fluorescence under Wood's light, strongly suggestive of erythrasma, can be attributed to the presence of porphyrins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21393451"}, {"offsetInBeginSection": 217, "offsetInEndSection": 293, "text": "Fractionated porphyrin analysis in erythrasma lesions is yet to be reported.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21393451"}, {"offsetInBeginSection": 294, "offsetInEndSection": 449, "text": "We attempted to investigate erythrasma lesions by isolating the responsible bacteria and determining their exogenous porphyrin production by HPLC analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21393451"}, {"offsetInBeginSection": 450, "offsetInEndSection": 599, "text": "We observed a 78-year-old woman with erythrasma who had a well-demarcated slightly scaling patch on her left foot, between the fourth and fifth toes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21393451"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "[Swimmer's eczema: intertrigo, erythrasma or a yeast or fungus infection?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969634"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "OBJECTIVE: To determine the proportional contributions of tinea pedis, intertrigo, erythrasma and Candida to 'swimmer's eczema.'", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969634"}, {"offsetInBeginSection": 511, "offsetInEndSection": 644, "text": "In 56% of the patients with swimmer's eczema dermatophytes were recognised, 10% showed erythrasma and in 30% no cause could be found.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969634"}, {"offsetInBeginSection": 886, "offsetInEndSection": 982, "text": "Microscopy is the most sensitive method in regard to demonstrating dermatophytes and erythrasma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969634"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Interdigital foot infections are mostly caused initially by dermatophytes, yeasts and less frequently by bacteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25477907"}]}, {"id": "5a89537cfcd1d6a10c000002", "body": "Are mouse chromosomes acrocentric?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/6538846", "http://www.ncbi.nlm.nih.gov/pubmed/7606923", "http://www.ncbi.nlm.nih.gov/pubmed/8528584", "http://www.ncbi.nlm.nih.gov/pubmed/23030344", "http://www.ncbi.nlm.nih.gov/pubmed/2767161", "http://www.ncbi.nlm.nih.gov/pubmed/11387219", "http://www.ncbi.nlm.nih.gov/pubmed/6177004", "http://www.ncbi.nlm.nih.gov/pubmed/2832136", "http://www.ncbi.nlm.nih.gov/pubmed/100785", "http://www.ncbi.nlm.nih.gov/pubmed/1733676"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Flow cytometry isolation and improved visualization of sorted mouse chromosomes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 81, "offsetInEndSection": 170, "text": "Purification of chromosomes X and ISO-1 from cell lines with Robertsonian translocations.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "While analysis and sorting of human chromosomes by flow cytometry has been widely used, isolation of a pure mouse chromosome remains very difficult, since most murine chromosomes are quite similar in size.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 206, "offsetInEndSection": 326, "text": "To overcome this problem, we have analysed mouse cell lines having either Robertsonian translocations or isochromosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 327, "offsetInEndSection": 452, "text": "The resulting metacentric chromosomes are very different in size and in morphology from normal mouse acrocentric chromosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 905, "offsetInEndSection": 1131, "text": "The technical modifications made, coupled with the existence of a great diversity of metacentric chromosomes resulting from Robertsonian translocations, should allow the purification of a number of different mouse chromosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Establishment of permanent wild-mouse cell lines with readily identifiable marker chromosomes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7606923"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Physical gene mapping by in situ hybridization is a difficult task in an all-acrocentric mouse karyotype, because all of the chromosomes are morphologically very similar.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7606923"}, {"offsetInBeginSection": 171, "offsetInEndSection": 313, "text": "These difficulties can be overcome by using the many different metacentric Robertsonian translocation (Rb) chromosomes derived from wild mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7606923"}, {"offsetInBeginSection": 484, "offsetInEndSection": 573, "text": "These mice carry nine pairs of metacentric Rb chromosomes containing chromosomes 1 to 18.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7606923"}]}, {"id": "5a6e1db0b750ff4455000039", "body": "What is Q-nexus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27814676"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 379, "offsetInEndSection": 563, "text": "To date, only a very limited number of software packages are available for the analysis of ChIP-exo data, which have not yet been systematically tested and compared on ChIP-nexus data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 741, "offsetInEndSection": 916, "text": "Furthermore, we developed bespoke methods to estimate the width of the protected region resulting from protein-DNA binding and to infer binding positions from ChIP-nexus data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 917, "offsetInEndSection": 1042, "text": "Finally, we applied our peak calling method as well as the two other methods MACE and MACS2 to the available ChIP-nexus data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 1042, "offsetInEndSection": 1105, "text": "CONCLUSIONS: The Q-nexus software is efficient and easy to use.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 1547, "offsetInEndSection": 1621, "text": "An implementation of Q-nexus is available at http://charite.github.io/Q/ .", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 563, "offsetInEndSection": 740, "text": "RESULTS: Here, we present a comprehensive software package for ChIP-nexus data that exploits the random barcodes for selective removal of PCR duplicates and for quality control.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "BACKGROUND: ChIP-nexus, an extension of the ChIP-exo protocol, can be used to map the borders of protein-bound DNA sequences at nucleotide resolution, requires less input DNA and enables selective PCR duplicate removal using random barcodes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 1106, "offsetInEndSection": 1198, "text": "Novel statistics about duplication rates in consideration of random barcodes are calculated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 242, "offsetInEndSection": 378, "text": "However, the use of random barcodes requires additional preprocessing of the mapping data, which complicates the computational analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}]}, {"id": "5a74a8a70384be9551000005", "body": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27147553", "http://www.ncbi.nlm.nih.gov/pubmed/24432033", "http://www.ncbi.nlm.nih.gov/pubmed/19853645", "http://www.ncbi.nlm.nih.gov/pubmed/26930249", "http://www.ncbi.nlm.nih.gov/pubmed/26000366", "http://www.ncbi.nlm.nih.gov/pubmed/27316377", "http://www.ncbi.nlm.nih.gov/pubmed/28423924", "http://www.ncbi.nlm.nih.gov/pubmed/21744502", "http://www.ncbi.nlm.nih.gov/pubmed/28085753", "http://www.ncbi.nlm.nih.gov/pubmed/21330062"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27147553"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Conventional chemotherapy treatments for pancreatic cancer are mainly palliative.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27147553"}, {"offsetInBeginSection": 82, "offsetInEndSection": 169, "text": "RNA interference (RNAi)-based drugs present the potential for a new targeted treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27147553"}, {"offsetInBeginSection": 370, "offsetInEndSection": 435, "text": "siG12D-LODER has successfully passed a phase 1/2a clinical trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27147553"}, {"offsetInBeginSection": 1163, "offsetInEndSection": 1349, "text": "These findings provide valuable information for future preclinical studies with siRNA-bearing biodegradable polymers and for the safety aspects of RNAi-based drugs as a targeted therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27147553"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Novel therapeutic modalities and drug delivery in pancreatic cancer - an ongoing search for improved efficacy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Pancreatic cancer is an incredibly challenging disease due to its high rates of resistance to traditional chemotherapy and radiotherapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033"}, {"offsetInBeginSection": 137, "offsetInEndSection": 308, "text": "There has been little improvement in the prognosis of pancreatic cancer cases in the past decades, highlighting the crucial need for more effective therapeutic approaches.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033"}, {"offsetInBeginSection": 309, "offsetInEndSection": 581, "text": "Erlotinib, an EGFR inhibitor, and gemcitabine, a nucleoside analog, are currently used in combination for chemotherapy treatment, but new developments in drug delivery systems using liposomes and nanoparticles may be promising new modalities for management of the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033"}, {"offsetInBeginSection": 1019, "offsetInEndSection": 1153, "text": "Despite significant preclinical data, there are currently very few clinical trials involving pancreatic cancer targeted drug delivery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033"}]}, {"id": "5a678d63b750ff4455000003", "body": "What are the 4 cardinal signs of inflammation according to Celsus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12799851", "http://www.ncbi.nlm.nih.gov/pubmed/29135930", "http://www.ncbi.nlm.nih.gov/pubmed/15041917", "http://www.ncbi.nlm.nih.gov/pubmed/7734328"], "snippets": [{"offsetInBeginSection": 804, "offsetInEndSection": 1007, "text": "Aristotle (4th century B. C.), Celsus (1st century A. D.), and the famous experimental physiologist Galen (2nd century A. D.) agreed that pain was a sign of evil which should be fought without exception.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12799851"}, {"offsetInBeginSection": 1008, "offsetInEndSection": 1195, "text": "It was Galen who added the disturbance of function (functio laesa) as the fifth cardinal sign of inflammation to the four well-known cardinal signs of Celsus (rubor, calor, tumor, dolor).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12799851"}, {"offsetInBeginSection": 1270, "offsetInEndSection": 1400, "text": "In algotherapy, Galen used a complex pharmacological system which was based upon the four cardinal qualities of humoral pathology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12799851"}, {"offsetInBeginSection": 60, "offsetInEndSection": 255, "text": "As early as 2000 years ago, the Roman encyclopaedist Aulus Cornelius Celsus recognised four cardinal signs of this response-redness, heat, swelling and pain; a fifth sign is loss of function.[...", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "[The role of neuromodulators (substance P and calcitonin gene-related peptide) in the development of neurogenic inflammation in the oral mucosa].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15041917"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Vatous observations carried out in the course of the years have shown that certain neuropeptides have a possible role to play as inflammation mediators.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15041917"}, {"offsetInBeginSection": 936, "offsetInEndSection": 1482, "text": "In fact it has been understood that behind the typical signs of inflammation (the famous four cardinal signs of Celsus: pain, redness, swelling, heat) no abstract entities or strange alchemies are concealed, but a series of well-known, classified substance, the so-called \"inflammation mediators\", namely a variety of substances of cellular or plasmatic origin united by the fact that exist, in stationary state conditions, in the form of inactive precursors, or sequestered in intracellular sites where they are unable to carry out their action.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15041917"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Inflammation: John Hunter's \"A treatise on the blood, inflammation and gun-shot wounds\".", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7734328"}, {"offsetInBeginSection": 223, "offsetInEndSection": 395, "text": "After a section on the nature of blood and the circulatory system, in which he describes the vascular supply in detail, he passes on to an extensive survey of inflammation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7734328"}, {"offsetInBeginSection": 575, "offsetInEndSection": 673, "text": "He bases his observations on the four cardinal signs of Celsus (redness, heat, swelling and pain).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7734328"}]}, {"id": "5a8a9abdfcd1d6a10c000019", "body": "List polyubiquitin binding proteins involved in NF-kappaB signaling.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19285159"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Identification of polyubiquitin binding proteins involved in NF-kappaB signaling using protein arrays.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 122, "offsetInEndSection": 250, "text": "In the NF-kappaB pathway, binding of NEMO to polyubiquitinated substrates initiates the pathway in response to cellular stimuli.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 251, "offsetInEndSection": 357, "text": "Other polyubiquitin binding proteins can antagonize this pathway by competing with NEMO for polyubiquitin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 358, "offsetInEndSection": 462, "text": "We have used protein arrays to identify polyubiquitin binding proteins that regulate NF-kappaB activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 559, "offsetInEndSection": 793, "text": "Novel polyubiquitin binders AWP1, CALCOCO2, N4BP1, RIO3, TEX27, TTC3, UBFD1 and ZNF313 were identified using this approach, while known NF-kappaB regulators including NEMO, A20, ABIN-1, ABIN-2, optineurin and p62 were also identified.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 794, "offsetInEndSection": 962, "text": "Overexpressed AWP1 and RIO3 repressed NF-kappaB activity in a manner similar to optineurin, while siRNAs directed against AWP1 and RIO3 also reduced NF-kappaB activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 963, "offsetInEndSection": 1135, "text": "TNFalpha-dependent degradation of IkappaBalpha was also suppressed by overexpression of AWP1 and RIO3, possibly due to the polyubiquitin binding activity of these proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 1136, "offsetInEndSection": 1317, "text": "Protein array screening using polyubiquitin enabled rapid identification of many known and novel polyubiquitin binding proteins and the identification of novel NF-kappaB regulators.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 463, "offsetInEndSection": 558, "text": "Using polyubiquitin as bait, protein arrays were screened and polyubiquitin binders identified.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Attachment of ubiquitin to proteins represents a central mechanism for the regulation of protein metabolism and function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}]}, {"id": "5a690487b750ff445500001f", "body": "Which virus can be diagnosed with the monospot test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26275628", "http://www.ncbi.nlm.nih.gov/pubmed/28130396", "http://www.ncbi.nlm.nih.gov/pubmed/20086647", "http://www.ncbi.nlm.nih.gov/pubmed/24650116", "http://www.ncbi.nlm.nih.gov/pubmed/19772007", "http://www.ncbi.nlm.nih.gov/pubmed/23918629", "http://www.ncbi.nlm.nih.gov/pubmed/17217023", "http://www.ncbi.nlm.nih.gov/pubmed/11369969", "http://www.ncbi.nlm.nih.gov/pubmed/21108750", "http://www.ncbi.nlm.nih.gov/pubmed/11298158"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "False positivity of monospot test in an immunocompetent elderly woman with acute cytomegalovirus infection.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628"}, {"offsetInBeginSection": 103, "offsetInEndSection": 237, "text": "Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628"}, {"offsetInBeginSection": 697, "offsetInEndSection": 804, "text": "This case conveys that monospot test can yield false-positive result in the setting of acute CMV infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "How to use \u2026 the Monospot and other heterophile antibody tests.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "Epstein-Barr virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396"}, {"offsetInBeginSection": 199, "offsetInEndSection": 419, "text": "Heterophile antibody tests, including the Monospot test, are red cell or latex agglutination assays, which detect antired cell antibodies produced as part of a polyclonal antibody response occurring during EBV infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396"}, {"offsetInBeginSection": 420, "offsetInEndSection": 560, "text": "Heterophile antibody tests are rapid, cheap and specific tests that can be performed from the onset of symptoms of infectious mononucleosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1112, "text": "Virus-specific serology is required in children under the age of 4 or if an older child is heterophile negative.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396"}, {"offsetInBeginSection": 1113, "offsetInEndSection": 1248, "text": "Virus-specific serology allows diagnosis and the pattern of positivity and negativity enables the clinician to stage the EBV infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396"}, {"offsetInBeginSection": 143, "offsetInEndSection": 343, "text": "Subsequent clinical, laboratory, and serologic evaluation revealed that he, in fact, had a latent infection with Epstein-Barr virus (EBV), a current viral syndrome, and a false-positive Monospot test.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20086647"}]}, {"id": "5a896a06fcd1d6a10c000006", "body": "What is the phenomenon of gene kissing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23099887", "http://www.ncbi.nlm.nih.gov/pubmed/17933509", "http://www.ncbi.nlm.nih.gov/pubmed/27785578", "http://www.ncbi.nlm.nih.gov/pubmed/26063576", "http://www.ncbi.nlm.nih.gov/pubmed/21059491", "http://www.ncbi.nlm.nih.gov/pubmed/25918627", "http://www.ncbi.nlm.nih.gov/pubmed/27403349", "http://www.ncbi.nlm.nih.gov/pubmed/26370077", "http://www.ncbi.nlm.nih.gov/pubmed/27721082", "http://www.ncbi.nlm.nih.gov/pubmed/9534425"], "snippets": [{"offsetInBeginSection": 135, "offsetInEndSection": 274, "text": "This positioning can also result in the clustering of genes with similar expression patterns, a phenomenon sometimes called \"gene kissing.\"", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099887"}, {"offsetInBeginSection": 884, "offsetInEndSection": 1049, "text": "We speculate that our findings might provide insight into other types of gene kissing, some of which also require cis-acting DNA sequences and trans-acting proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099887"}, {"offsetInBeginSection": 0, "offsetInEndSection": 19, "text": "Chromosome kissing.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509"}, {"offsetInBeginSection": 133, "offsetInEndSection": 260, "text": "Nevertheless, several contacts between different chromosomal loci have been documented, a phenomenon called chromosome kissing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509"}, {"offsetInBeginSection": 456, "offsetInEndSection": 742, "text": "Recent approaches that allow to detect chromosome kissing events in an unbiased manner suggest that chromatin folding is such that cis contacts with neighboring elements are most frequent, but contacts with remote parts of the same chromosome or with different chromosomes are possible.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509"}, {"offsetInBeginSection": 743, "offsetInEndSection": 889, "text": "These contacts are modulated by specific chromatin features of each locus, and they may play important roles in the regulation of gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509"}, {"offsetInBeginSection": 890, "offsetInEndSection": 972, "text": "Chromosome kissing events may also be at the origin of chromosomal rearrangements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509"}, {"offsetInBeginSection": 324, "offsetInEndSection": 511, "text": "We then searched the electronic database PubMed on September 21, 2016 using the following search terms in the English language: \"ictal\" OR \"seizure\" OR \"epilepsy\" AND \"kiss\" OR \"kissing\".", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27785578"}, {"offsetInBeginSection": 643, "offsetInEndSection": 707, "text": "One patient (0.02%) had one episode of documented ictal kissing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27785578"}, {"offsetInBeginSection": 1007, "offsetInEndSection": 1115, "text": "We add to the literature on ictal kissing by providing additional information on its frequency and etiology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27785578"}]}, {"id": "5a6e24a5b750ff445500003c", "body": "Which workflow in Bioconductor has been developed for accessing human RNA-seq samples?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29043067"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "recount workflow: Accessing over 70,000 human RNA-seq samples with Bioconductor.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "The recount2 resource is composed of over 70,000 uniformly processed human RNA-seq samples spanning TCGA and SRA, including GTEx.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067"}, {"offsetInBeginSection": 130, "offsetInEndSection": 197, "text": "The processed data can be accessed via the recount2 website and the", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067"}]}, {"id": "5a74b1730384be9551000007", "body": "Which retinal dystrophy related gene is targeted by the AAV2-hRPE65v2 drug?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27375040", "http://www.ncbi.nlm.nih.gov/pubmed/29097191", "http://www.ncbi.nlm.nih.gov/pubmed/22323828"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040"}, {"offsetInBeginSection": 0, "offsetInEndSection": 296, "text": "BACKGROUND: Safety and efficacy have been shown in a phase 1 dose-escalation study involving a unilateral subretinal injection of a recombinant adeno-associated virus (AAV) vector containing the RPE65 gene (AAV2-hRPE65v2) in individuals with inherited retinal dystrophy caused by RPE65 mutations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040"}, {"offsetInBeginSection": 297, "offsetInEndSection": 527, "text": "This finding, along with the bilateral nature of the disease and intended use in treatment, prompted us to determine the safety of administration of AAV2-hRPE65v2 to the contralateral eye in patients enrolled in the phase 1 study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040"}, {"offsetInBeginSection": 527, "offsetInEndSection": 916, "text": "METHODS: In this follow-on phase 1 trial, one dose of AAV2-hRPE65v2 (1.5\u2008\u00d7\u200810(11) vector genomes) in a total volume of 300 \u03bcL was subretinally injected into the contralateral, previously uninjected, eyes of 11 children and adults (aged 11-46 years at second administration) with inherited retinal dystrophy caused by RPE65 mutations, 1.71-4.58 years after the initial subretinal injection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040"}, {"offsetInBeginSection": 1103, "offsetInEndSection": 1172, "text": "This study is registered with ClinicalTrials.gov, number NCT01208389.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040"}, {"offsetInBeginSection": 1811, "offsetInEndSection": 1934, "text": "INTERPRETATION: To our knowledge, AAV2-hRPE65v2 is the first successful gene therapy administered to the contralateral eye.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040"}, {"offsetInBeginSection": 242, "offsetInEndSection": 400, "text": "In addition to more than 3000 genetic mutations from about 70 genes, a wide genetic overlap with other types of retinal dystrophies has been reported with RP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191"}, {"offsetInBeginSection": 738, "offsetInEndSection": 862, "text": "Current therapies for RP in ongoing or completed clinical trials include gene therapy, cell therapy, and retinal prostheses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191"}, {"offsetInBeginSection": 1047, "offsetInEndSection": 1327, "text": "Among many clinical trials of gene therapy for hereditary retinal diseases, a phase 3 clinical trial of voretigene neparvovec (AAV2-hRPE65v2, Luxturna) recently showed significant efficacy for RPE65-mediated inherited retinal dystrophy including Leber congenital amaurosis and RP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "AAV2 gene therapy readministration in three adults with congenital blindness.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22323828"}]}, {"id": "5a679875b750ff4455000004", "body": "Do bacteria from the genus Morexella cause respiratory infections?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8007629", "http://www.ncbi.nlm.nih.gov/pubmed/28063019", "http://www.ncbi.nlm.nih.gov/pubmed/28369241", "http://www.ncbi.nlm.nih.gov/pubmed/24786571", "http://www.ncbi.nlm.nih.gov/pubmed/25362808", "http://www.ncbi.nlm.nih.gov/pubmed/18619696", "http://www.ncbi.nlm.nih.gov/pubmed/28059171"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Clinical studies of oral quinolone once daily in the treatment of lower respiratory tract infections.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "The efficacy and safety of oral ofloxacin, 400 mg once daily, for the treatment of patients with lower respiratory tract infections were studied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629"}, {"offsetInBeginSection": 693, "offsetInEndSection": 801, "text": "It is concluded that ofloxacin, 400 mg once daily, is useful for patients with respiratory tract infections.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "The genus Raoultella belongs to the family of Enterobacteriaceae.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019"}, {"offsetInBeginSection": 127, "offsetInEndSection": 257, "text": "This genus can be distinguished from the genus Klebsiella, in that genus use histamine as the only source of carbon in the medium.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019"}, {"offsetInBeginSection": 415, "offsetInEndSection": 501, "text": "The reservoir of Raoultella is the gastrointestinal tract and upper respiratory tract.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019"}, {"offsetInBeginSection": 518, "offsetInEndSection": 671, "text": "are opportunistic bacteria, which usually cause infections of the biliary tract, pneumonia and bacteraemia in oncologic and with lower immunity patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019"}, {"offsetInBeginSection": 672, "offsetInEndSection": 804, "text": "Raoultella planticola and Raoultella ornithinolytica are the most frequently encountered human pathogens among the genus Raoultella.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Neisseria models of infection and persistence in the upper respiratory tract.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369241"}, {"offsetInBeginSection": 0, "offsetInEndSection": 168, "text": "The Gram-negative bacteria genus Neisseria includes both pathogenic and commensal species that are found primarily in the upper respiratory tract of humans and animals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369241"}]}, {"id": "5a8aa253fcd1d6a10c00001b", "body": "Which is the specificity of deubiquitinase USP25?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28327663", "http://www.ncbi.nlm.nih.gov/pubmed/23754700", "http://www.ncbi.nlm.nih.gov/pubmed/28538147", "http://www.ncbi.nlm.nih.gov/pubmed/26305951"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "Tandem UIMs confer Lys48 ubiquitin chain substrate preference to deubiquitinase USP25.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28327663"}, {"offsetInBeginSection": 415, "offsetInEndSection": 530, "text": "Purified USP25 exhibited higher ubiquitin isopeptidase activity to Lys48-, than to Lys63-, linked ubiquitin chains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28327663"}, {"offsetInBeginSection": 531, "offsetInEndSection": 749, "text": "Mutations that disrupted the ubiquitin-binding ability of the tandem UIMs resulted in a reduced ubiquitin isopeptidase activity of USP25, suggesting a role for the UIMs in exerting the full catalytic activity of USP25.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28327663"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "\u00b9H, \u00b9\u00b3C and \u00b9\u2075N backbone and side-chain resonance assignments of the N-terminal ubiquitin-binding domains of USP25.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754700"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Ubiquitin Specific Protease 25 (USP25), a member of the deubiquitinase family, is involved in several disease-related signal pathways including myogenesis, immunity and protein degradation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754700"}, {"offsetInBeginSection": 472, "offsetInEndSection": 615, "text": "Besides, it has been shown that the catalysis activity of USP25 is either impaired by sumoylation or enhanced by ubiquitination within its UIM.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754700"}, {"offsetInBeginSection": 616, "offsetInEndSection": 828, "text": "To elucidate the structural basis of the cross-regulation of USP25 function by non-covalent binding and covalent modifications of ubiquitin and SUMO2/3, a systematic structural biology study of USP25 is required.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754700"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Structural and Functional Investigations of the N-Terminal Ubiquitin Binding Region of Usp25.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28538147"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Ubiquitin-specific protease 25 (Usp25) is a deubiquitinase that is involved in multiple biological processes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28538147"}, {"offsetInBeginSection": 110, "offsetInEndSection": 303, "text": "The N-terminal ubiquitin-binding region (UBR) of Usp25 contains one ubiquitin-associated domain, one small ubiquitin-like modifier (SUMO)-interacting motif and two ubiquitin-interacting motifs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28538147"}]}, {"id": "5a70dbe599e2c3af26000004", "body": "Which two genes are implicated in Juvenile polyposis syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16152648", "http://www.ncbi.nlm.nih.gov/pubmed/9491322", "http://www.ncbi.nlm.nih.gov/pubmed/27326320", "http://www.ncbi.nlm.nih.gov/pubmed/21834858", "http://www.ncbi.nlm.nih.gov/pubmed/21465659", "http://www.ncbi.nlm.nih.gov/pubmed/25841492", "http://www.ncbi.nlm.nih.gov/pubmed/22171123", "http://www.ncbi.nlm.nih.gov/pubmed/17573831", "http://www.ncbi.nlm.nih.gov/pubmed/26837502", "http://www.ncbi.nlm.nih.gov/pubmed/26159157"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Vessels' morphology in SMAD4 and BMPR1A-related juvenile polyposis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16152648"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Juvenile polyposis syndrome is a hamartomatous intestinal polyposis associated with malignant changes in 20% of patients at an early age.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16152648"}, {"offsetInBeginSection": 413, "offsetInEndSection": 595, "text": "Forty-two unrelated patients affected by juvenile polyposis syndrome were analyzed for germline alterations in the BMPR1A and SMAD4 genes, and for clinical and histological features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16152648"}, {"offsetInBeginSection": 1007, "offsetInEndSection": 1126, "text": "SMAD4 germline mutations are responsible for a more aggressive digestive phenotype in patients with juvenile polyposis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16152648"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Deletion 10q23.2-q23.33 in a patient with gastrointestinal juvenile polyposis and other features of a Cowden-like syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9491322"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "A cytogenetically visible interstitial deletion of chromosome band 10q23 was found in a 6-year-old boy with mental retardation, dysmorphic features, and juvenile polyposis coli.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9491322"}, {"offsetInBeginSection": 658, "offsetInEndSection": 757, "text": "Furthermore, the deletion is near and possibly overlaps a locus associated with juvenile polyposis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9491322"}, {"offsetInBeginSection": 758, "offsetInEndSection": 1070, "text": "The findings in this patient with a constitutional 10q23 deletion raise the issue of whether there are separate genes in this region that are involved in Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, juvenile polyposis, and tumor progression, or whether all of these entities could be due to a single gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9491322"}, {"offsetInBeginSection": 256, "offsetInEndSection": 358, "text": "Certain genetic polyposis syndromes and familial diseases are associated with increased risks for SBA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27326320"}, {"offsetInBeginSection": 359, "offsetInEndSection": 526, "text": "These include familial adenomatous polyposis (FAP), Lynch syndromes (LS), Juvenile polyposis syndrome, Peutz-Jeghers syndrome, Crohn's disease (CD) and celiac disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27326320"}]}, {"id": "5a86bf2efaa1ab7d2e000033", "body": "What is the mechanism of the auxin-inducible degron system?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23836714", "http://www.ncbi.nlm.nih.gov/pubmed/19915560", "http://www.ncbi.nlm.nih.gov/pubmed/24236031", "http://www.ncbi.nlm.nih.gov/pubmed/28680098", "http://www.ncbi.nlm.nih.gov/pubmed/26519318", "http://www.ncbi.nlm.nih.gov/pubmed/26081484", "http://www.ncbi.nlm.nih.gov/pubmed/27010248", "http://www.ncbi.nlm.nih.gov/pubmed/25181302"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "An expanded tool kit for the auxin-inducible degron system in budding yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Fusion of inducible degradation signals, so-called degrons, to cellular proteins is an elegant method of controlling protein levels in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714"}, {"offsetInBeginSection": 141, "offsetInEndSection": 259, "text": "Recently, a degron system relying on the plant hormone auxin has been described for use in yeast and vertebrate cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714"}, {"offsetInBeginSection": 260, "offsetInEndSection": 429, "text": "We now report the construction of a series of vectors that significantly enhance the versatility of this auxin-inducible degron (AID) system in Saccharomyces cerevisiae.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714"}, {"offsetInBeginSection": 593, "offsetInEndSection": 753, "text": "The vectors are compatible with PCR-based genomic tagging strategies, allow for C- or N-terminal fusion of the degron, and provide a range of selection markers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714"}, {"offsetInBeginSection": 754, "offsetInEndSection": 895, "text": "Application to a series of yeast proteins, including essential replication factors, provides evidence for a general usefulness of the system.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "An auxin-based degron system for the rapid depletion of proteins in nonplant cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915560"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Plants have evolved a unique system in which the plant hormone auxin directly induces rapid degradation of the AUX/IAA family of transcription repressors by a specific form of the SCF E3 ubiquitin ligase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915560"}, {"offsetInBeginSection": 205, "offsetInEndSection": 439, "text": "Other eukaryotes lack the auxin response but share the SCF degradation pathway, allowing us to transplant the auxin-inducible degron (AID) system into nonplant cells and use a small molecule to conditionally control protein stability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915560"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "2A and the auxin-based degron system facilitate control of protein levels in Plasmodium falciparum.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24236031"}]}, {"id": "5a6e3155b750ff445500003f", "body": "Which R/Bioconductor package has been developed for cancer subtype identification?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28605519", "http://www.ncbi.nlm.nih.gov/pubmed/26607490"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "CancerSubtypes: an R/Bioconductor package for molecular cancer subtype identification, validation and visualization.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Summary: Identifying molecular cancer subtypes from multi-omics data is an important step in the personalized medicine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519"}, {"offsetInBeginSection": 120, "offsetInEndSection": 287, "text": "We introduce CancerSubtypes, an R package for identifying cancer subtypes using multi-omics data, including gene expression, miRNA expression and DNA methylation data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519"}, {"offsetInBeginSection": 288, "offsetInEndSection": 582, "text": "CancerSubtypes integrates four main computational methods which are highly cited for cancer subtype identification and provides a standardized framework for data pre-processing, feature selection, and result follow-up analyses, including results computing, biology validation and visualization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519"}, {"offsetInBeginSection": 724, "offsetInEndSection": 1308, "text": "The package is useful for inferring cancer subtypes from an input genomic dataset, comparing the predictions from different well-known methods and testing new subtype discovery methods, as shown with different application scenarios in the Supplementary Material.Availability and implementation: The package is implemented in R and available under GPL-2 license from the Bioconductor website (http://bioconductor.org/packages/CancerSubtypes/).Contact: thuc.le@unisa.edu.au or jiuyong.li@unisa.edu.au.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490"}, {"offsetInBeginSection": 75, "offsetInEndSection": 288, "text": "Extensive studies into the molecular heterogeneity of breast cancer have produced a plethora of molecular subtype classification and prognosis prediction algorithms, as well as numerous gene expression signatures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490"}, {"offsetInBeginSection": 477, "offsetInEndSection": 681, "text": "Here, we present the genefu R/Bioconductor package, a multi-tiered compendium of bioinformatics algorithms and gene signatures for molecular subtyping and prognostication in breast cancer.AVAILABILITY AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490"}, {"offsetInBeginSection": 682, "offsetInEndSection": 748, "text": "IMPLEMENTATION: The genefu package is available from Bioconductor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490"}, {"offsetInBeginSection": 749, "offsetInEndSection": 886, "text": "http://www.bioconductor.org/packages/devel/bioc/html/genefu.html Source code is also available on Github https://github.com/bhklab/genefu", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490"}]}, {"id": "5a75fbf383b0d9ea6600000a", "body": "Name the phase 3 clinical trials for tofacitinib in colitis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28467869", "http://www.ncbi.nlm.nih.gov/pubmed/26376350", "http://www.ncbi.nlm.nih.gov/pubmed/27177233", "http://www.ncbi.nlm.nih.gov/pubmed/22894574", "http://www.ncbi.nlm.nih.gov/pubmed/25651782", "http://www.ncbi.nlm.nih.gov/pubmed/29051788", "http://www.ncbi.nlm.nih.gov/pubmed/26669566", "http://www.ncbi.nlm.nih.gov/pubmed/28829236", "http://www.ncbi.nlm.nih.gov/pubmed/25110261", "http://www.ncbi.nlm.nih.gov/pubmed/25047498"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "BACKGROUND: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 174, "offsetInEndSection": 260, "text": "We further evaluated the efficacy of tofacitinib as induction and maintenance therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 260, "offsetInEndSection": 406, "text": "METHODS: We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 407, "offsetInEndSection": 741, "text": "In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, respectively, who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib (10 mg twice daily) or placebo for 8 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 790, "offsetInEndSection": 1011, "text": "In the OCTAVE Sustain trial, 593 patients who had a clinical response to induction therapy were randomly assigned to receive maintenance therapy with tofacitinib (either 5 mg or 10 mg twice daily) or placebo for 52 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 1300, "offsetInEndSection": 1462, "text": "PCONCLUSIONS: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376350"}, {"offsetInBeginSection": 13, "offsetInEndSection": 120, "text": "AIMS: Accurate biomarkers of disease activity and therapeutic response can be valuable for clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376350"}, {"offsetInBeginSection": 121, "offsetInEndSection": 378, "text": "We performed a post hoc analysis of data from a phase 2\u00a0trial to assess the relationship between the concentration of fecal calprotectin (FCP) and clinical and endoscopic outcomes of patients with moderate to severe ulcerative colitis receiving tofacitinib.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376350"}]}, {"id": "5a679be1b750ff4455000005", "body": "Are organisms in the genus Morexella associated with sepsis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24669633", "http://www.ncbi.nlm.nih.gov/pubmed/9587088", "http://www.ncbi.nlm.nih.gov/pubmed/24786571", "http://www.ncbi.nlm.nih.gov/pubmed/6954635", "http://www.ncbi.nlm.nih.gov/pubmed/3071072", "http://www.ncbi.nlm.nih.gov/pubmed/10403734", "http://www.ncbi.nlm.nih.gov/pubmed/18696148", "http://www.ncbi.nlm.nih.gov/pubmed/8909835"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "Causative bacteria and antibiotic resistance in neonatal sepsis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "BACKGROUND: Neonatal sepsis is characterised by bacteraemia and clinical symptoms caused by microorganisms and their toxic products.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 133, "offsetInEndSection": 200, "text": "Gram negative bacteria are the commonest causes of neonatal Sepsis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 408, "offsetInEndSection": 573, "text": "We have carried out this study to find out various bacteria causing neonatal sepsis and their susceptibility to antibiotics for better management of neonatal sepsis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 573, "offsetInEndSection": 687, "text": "METHODS: A total of 130 neonates with sepsis who were found to be blood culture positive were taken in this study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 880, "offsetInEndSection": 1042, "text": "RESULTS: Out of 130 culture proven cases of neonatal sepsis, gram negative bacteria were found in 71 (54.6%) cases and gram positive bacteria in 59 (45.4%) cases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 1170, "offsetInEndSection": 1389, "text": "Acinetobacter species, Staphylococcus epidermidis, Klebseila, Streptococci, Enterobacter cloacae and Morexella species were found in 17 (13.1%), 17 (13.1%), 13 (10%), 7 (5.4%), 6 (4.6%), and 5 (3.8%) cases respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 1928, "offsetInEndSection": 2093, "text": "CONCLUSION: Staphylococcus aureus are the most common gram positive bacteria and Escherichia coli are the most common gram negative bacteria causing neonatal sepsis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "The genus Citrobacter includes three species of organisms that are uncommonly associated with human infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9587088"}, {"offsetInBeginSection": 111, "offsetInEndSection": 276, "text": "When they are pathogenic, there are usually one or more associated respiratory, urinary, skin-soft tissue, and central nervous system infections and neonatal sepsis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9587088"}]}, {"id": "5a70e1d999e2c3af26000007", "body": "Is Solanezumab effective for Alzheimer's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22288451", "http://www.ncbi.nlm.nih.gov/pubmed/25459121", "http://www.ncbi.nlm.nih.gov/pubmed/21504387", "http://www.ncbi.nlm.nih.gov/pubmed/27239538", "http://www.ncbi.nlm.nih.gov/pubmed/26238576", "http://www.ncbi.nlm.nih.gov/pubmed/27025080", "http://www.ncbi.nlm.nih.gov/pubmed/26271177", "http://www.ncbi.nlm.nih.gov/pubmed/23574434", "http://www.ncbi.nlm.nih.gov/pubmed/24450890", "http://www.ncbi.nlm.nih.gov/pubmed/22339463"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the central region of \u03b2-amyloid, a peptide believed to play a key role in the pathogenesis of Alzheimer's disease (AD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451"}, {"offsetInBeginSection": 193, "offsetInEndSection": 305, "text": "Eli Lilly & Co is developing an intravenous formulation of solanezumab for the treatment of mild-to-moderate AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451"}, {"offsetInBeginSection": 306, "offsetInEndSection": 592, "text": "Acute and subchronic treatment with solanezumab of transgenic mice attenuated or reversed memory deficits with no effects on incidence or severity of cerebral amyloid angiopathy-associated microhemorrhages, a severe side effect associated with bapineuzumab, another monoclonal antibody.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451"}, {"offsetInBeginSection": 789, "offsetInEndSection": 1031, "text": "While there is a strong hope that solanezumab may represent the first effective passive vaccine for AD treatment, skepticism still exists on the ability of the drug to slow the rate of deterioration in patients with fully established disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Amyloid beta peptide immunotherapy in Alzheimer disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Recent advances in the understanding of Alzheimer's disease pathogenesis have led to the development of numerous compounds that might modify the disease process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121"}, {"offsetInBeginSection": 162, "offsetInEndSection": 261, "text": "Amyloid \u03b2 peptide represents an important molecular target for intervention in Alzheimer's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121"}, {"offsetInBeginSection": 262, "offsetInEndSection": 366, "text": "The main purpose of this work is to review immunotherapy studies in relation to the Alzheimer's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121"}, {"offsetInBeginSection": 367, "offsetInEndSection": 574, "text": "Several types of amyloid \u03b2 peptide immunotherapy for Alzheimer's disease are under investigation, active immunization and passive administration with monoclonal antibodies directed against amyloid \u03b2 peptide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121"}]}, {"id": "5a86ecc7faa1ab7d2e000039", "body": "What is the function of the H19 (ICR) locus in the human genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24023912", "http://www.ncbi.nlm.nih.gov/pubmed/19546235", "http://www.ncbi.nlm.nih.gov/pubmed/16006531", "http://www.ncbi.nlm.nih.gov/pubmed/20427289", "http://www.ncbi.nlm.nih.gov/pubmed/21991322", "http://www.ncbi.nlm.nih.gov/pubmed/20047949", "http://www.ncbi.nlm.nih.gov/pubmed/26328763", "http://www.ncbi.nlm.nih.gov/pubmed/17948025", "http://www.ncbi.nlm.nih.gov/pubmed/21600199", "http://www.ncbi.nlm.nih.gov/pubmed/16815976"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "The chicken HS4 insulator element does not protect the H19 ICR from differential DNA methylation in yeast artificial chromosome transgenic mouse.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Mono-allelic expression at the mouse IGF2/H19 locus is controlled by differential allelic DNA methylation of the imprinting control region (ICR).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 146, "offsetInEndSection": 529, "text": "Because a randomly integrated H19 ICR fragment, when incorporated into the genome of transgenic mice (TgM), was allele-specifically methylated in somatic, but not in germ cells, it was suggested that allele-discriminating epigenetic signature, set within or somewhere outside of the Tg H19 ICR fragment in germ cells, was later translated into a differential DNA methylation pattern.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 530, "offsetInEndSection": 820, "text": "To test if the chicken \u03b2-globin HS4 (cHS4) chromatin insulator might interfere with methylation imprinting establishment at the H19 ICR, we inserted the H19 ICR fragment, flanked by a set of floxed cHS4 core sequences, into a human \u03b2-globin locus YAC and generated TgM (insulated ICR' TgM).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 821, "offsetInEndSection": 988, "text": "As controls, the cHS4 sequences were removed from one side (5'HS4-deleted ICR') or both sides (pseudo-WT ICR') of the insulated ICR' by in vivo cre-loxP recombination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 989, "offsetInEndSection": 1218, "text": "The data show that while maternally inherited transgenic H19 ICR was not methylated in insulated ICR' TgM, it was significantly methylated upon paternal transmission, though the level was lower than in the pseudo-WT ICR' control.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 1443, "offsetInEndSection": 1678, "text": "Collectively, although we cannot rule out the possibility that cHS4 is incapable of blocking an allele-discriminating signal from outside of the transgene, the epigenetic signature appears to be marked intrinsically within the H19 ICR.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 0, "offsetInEndSection": 261, "text": "The imprinted expression of the mouse Igf2/H19 locus is governed by the differential methylation of the imprinting control region (ICR), which is established initially in germ cells and subsequently maintained in somatic cells, depending on its parental origin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19546235"}, {"offsetInBeginSection": 262, "offsetInEndSection": 708, "text": "By grafting a 2.9-kbp H19 ICR fragment into a human beta-globin yeast artificial chromosome in transgenic mice, we previously showed that the ICR could recapitulate imprinted methylation and expression at a heterologous locus, suggesting that the H19 ICR in the beta-globin locus contained sufficient information to maintain the methylation mark (K. Tanimoto, M. Shimotsuma, H. Matsuzaki, A. Omori, J. Bungert, J. D. Engel, and A. Fukamizu, Proc.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19546235"}, {"offsetInBeginSection": 754, "offsetInEndSection": 884, "text": "Curiously, however, the transgenic H19 ICR was not methylated in sperm, which was distinct from that seen in the endogenous locus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19546235"}]}, {"id": "5a6e354fb750ff4455000042", "body": "Which R/bioconductor package has been developed to aid in epigenomic analysis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28334349", "http://www.ncbi.nlm.nih.gov/pubmed/26704973", "http://www.ncbi.nlm.nih.gov/pubmed/26415965", "http://www.ncbi.nlm.nih.gov/pubmed/26424858"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "DeepBlueR: large-scale epigenomic analysis in R.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334349"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Motivation: While large amounts of epigenomic data are publicly available, their retrieval in a form suitable for downstream analysis is a bottleneck in current research.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334349"}, {"offsetInBeginSection": 171, "offsetInEndSection": 908, "text": "The DeepBlue Epigenomic Data Server provides a powerful interface and API for filtering, transforming, aggregating and downloading data from several epigenomic consortia.Results: To make public epigenomic data conveniently available for analysis in R, we developed an R/Bioconductor package that connects to the DeepBlue Epigenomic Data Server, enabling users to quickly gather and transform epigenomic data from selected experiments for analysis in the Bioconductor ecosystem.Availability and Implementation: http://deepblue.mpi-inf.mpg.de/R .Requirements: R 3.3, Bioconductor 3.4.Contact: felipe.albrecht@mpi-inf.mpg.de or markus.list@mpi-inf.mpg.de.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334349"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704973"}, {"offsetInBeginSection": 188, "offsetInEndSection": 331, "text": "Using this cohort, TCGA has published over 20 marker papers detailing the genomic and epigenomic alterations associated with these tumor types.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704973"}, {"offsetInBeginSection": 728, "offsetInEndSection": 957, "text": "We developed an R/Bioconductor package called TCGAbiolinks to address these challenges and offer bioinformatics solutions by using a guided workflow to allow users to query, download and perform integrative analyses of TCGA data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704973"}, {"offsetInBeginSection": 1128, "offsetInEndSection": 1396, "text": "Using four different TCGA tumor types (Kidney, Brain, Breast and Colon) as examples, we provide case studies to illustrate examples of reproducibility, integrative analysis and utilization of different Bioconductor packages to advance and accelerate novel discoveries.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704973"}, {"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "methylPipe and compEpiTools: a suite of R packages for the integrative analysis of epigenomics data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415965"}, {"offsetInBeginSection": 335, "offsetInEndSection": 531, "text": "Despite the numerous computational tools covering specific steps in the analysis of large-scale epigenomics data, comprehensive software solutions for their integrative analysis are still missing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415965"}, {"offsetInBeginSection": 778, "offsetInEndSection": 916, "text": "RESULTS: To overcome the burden of integrating various data types with multiple tools, we developed two companion R/Bioconductor packages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415965"}]}, {"id": "5a76dd749e632bc066000008", "body": "What does VBP15 do to skeletal muscle?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24014378"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Absence of dystrophin makes skeletal muscle more susceptible to injury, resulting in breaches of the plasma membrane and chronic inflammation in Duchenne muscular dystrophy (DMD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}, {"offsetInBeginSection": 617, "offsetInEndSection": 744, "text": "We find VBP15 protects and promotes efficient repair of skeletal muscle cells upon laser injury, in opposition to prednisolone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}, {"offsetInBeginSection": 1107, "offsetInEndSection": 1338, "text": "These data demonstrate successful improvement of dystrophy independent of hormonal, growth, or immunosuppressive effects, indicating VBP15 merits clinical investigation for DMD and would benefit other chronic inflammatory diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}, {"offsetInBeginSection": 931, "offsetInEndSection": 1106, "text": "The translation of these drug mechanisms into DMD model mice improves muscle strength, live-imaging and pathology through both preventive and post-onset intervention regimens.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}, {"offsetInBeginSection": 745, "offsetInEndSection": 930, "text": "Potent inhibition of NF-\u03baB is mediated through protein interactions of the glucocorticoid receptor, however VBP15 shows significantly reduced hormonal receptor transcriptional activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}, {"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}, {"offsetInBeginSection": 423, "offsetInEndSection": 616, "text": "Here, we discover an oral drug with mechanisms that provide efficacy through anti-inflammatory signaling and membrane-stabilizing pathways, independent of hormonal or immunosuppressive effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}, {"offsetInBeginSection": 180, "offsetInEndSection": 272, "text": "Current management by glucocorticoids has unclear molecular benefits and harsh side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}, {"offsetInBeginSection": 273, "offsetInEndSection": 422, "text": "It is uncertain whether therapies that avoid hormonal stunting of growth and development, and/or immunosuppression, would be more or less beneficial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}]}, {"id": "5a6a02a3b750ff4455000021", "body": "What protein is the most common cause of hereditary  renal amyloidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29142973", "http://www.ncbi.nlm.nih.gov/pubmed/25331409", "http://www.ncbi.nlm.nih.gov/pubmed/26299174", "http://www.ncbi.nlm.nih.gov/pubmed/22540225", "http://www.ncbi.nlm.nih.gov/pubmed/22967253", "http://www.ncbi.nlm.nih.gov/pubmed/19073821", "http://www.ncbi.nlm.nih.gov/pubmed/28153807", "http://www.ncbi.nlm.nih.gov/pubmed/16468976", "http://www.ncbi.nlm.nih.gov/pubmed/8560604", "http://www.ncbi.nlm.nih.gov/pubmed/19013120"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Renal Amyloidosis Associated With 5 Novel\u00a0Variants in the Fibrinogen A Alpha Chain Protein.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29142973"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Mutations in the fibrinogen A\u03b1-chain genes are the most common cause of hereditary renal amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25331409"}, {"offsetInBeginSection": 421, "offsetInEndSection": 553, "text": "Here, we described a patient with hereditary fibrinogen amyloidosis, who presented with proteinuria, hypertension and renal failure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25331409"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Hereditary apolipoprotein AI-associated renal amyloidosis: A diagnostic challenge.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Hereditary renal amyloidosis is an autosomal dominant condition with considerable overlap with other amyloidosis types.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174"}, {"offsetInBeginSection": 204, "offsetInEndSection": 321, "text": "We describe a patient with nephrotic syndrome and progressive renal failure, who had a mother with renal amiloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174"}, {"offsetInBeginSection": 322, "offsetInEndSection": 426, "text": "Renal biopsy revealed amyloid deposits in glomerular space, with absence of light chains and protein AA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174"}, {"offsetInBeginSection": 427, "offsetInEndSection": 605, "text": "We suspected amyloidosis with fibrinogen A alpha chain deposits, which is the most frequent cause of hereditary amyloidosis in Europe, with a glomerular preferential affectation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174"}, {"offsetInBeginSection": 679, "offsetInEndSection": 872, "text": "On reviewing the biopsy of the patient's mother similar glomerular deposits were found, but there were significant deposits in the renal medulla as well, which is typical in APO AI amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174"}, {"offsetInBeginSection": 926, "offsetInEndSection": 1083, "text": "Apo AI amyloidosis is characterized by slowly progressive renal disease and end-stage renal disease occurs aproximately 3 to 15 years from initial diagnosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174"}]}, {"id": "5a7234352dc08e987e000007", "body": "What is the most common histological diagnosis of \"butterfly glioma\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1656290", "http://www.ncbi.nlm.nih.gov/pubmed/28361164"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "A 45 year-old male with a butterfly glioma received stereotactic biopsy for histologic confirmation of the clinical diagnosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290"}, {"offsetInBeginSection": 127, "offsetInEndSection": 303, "text": "Microscopically, the results were controversial since some biopsy specimens showed distinct inflammatory changes, while others displayed typical features of a malignant glioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290"}, {"offsetInBeginSection": 416, "offsetInEndSection": 686, "text": "In addition to a large butterfly glioblastoma originating from the frontal part of the corpus callosum, neuropathologic examination revealed a mycotic encephalitis with formation of numerous fungi-containing inflammatory foci in all parts of the brain and in the glioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290"}, {"offsetInBeginSection": 779, "offsetInEndSection": 997, "text": "A previous steroid medication over several weeks for treatment of increased intracranial pressure may be considered as an important factor in the origin of the pulmonary aspergillosis complicating the butterfly glioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290"}, {"offsetInBeginSection": 37, "offsetInEndSection": 101, "text": "Corpus callosum glioblastoma multiforme (GBM): butterfly glioma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164"}, {"offsetInBeginSection": 134, "offsetInEndSection": 281, "text": "The diagnosis of butterfly glioma (glioblastoma multiforme) was made based on imaging characteristics and was further confirmed by biopsy findings.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164"}, {"offsetInBeginSection": 448, "offsetInEndSection": 616, "text": "Other neoplastic and non-neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma, as well as associated imaging features, are discussed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164"}, {"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "[Aspergillosis of the central nervous system in glioblastoma multiforme].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290"}, {"offsetInBeginSection": 282, "offsetInEndSection": 447, "text": "As the corpus callosum is usually resistant to infiltration by tumours, a mass that involves and crosses the corpus callosum is suggestive of an aggressive neoplasm.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164"}, {"offsetInBeginSection": 687, "offsetInEndSection": 778, "text": "General autopsy disclosed pulmonary aspergillosis as the source of the inflammatory spread.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290"}]}, {"id": "5a86fd5bfaa1ab7d2e00003b", "body": "Is a CpG island methylator phenotype involved in ependymomas?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24553142", "http://www.ncbi.nlm.nih.gov/pubmed/22109108", "http://www.ncbi.nlm.nih.gov/pubmed/28548123", "http://www.ncbi.nlm.nih.gov/pubmed/25182241", "http://www.ncbi.nlm.nih.gov/pubmed/23619990", "http://www.ncbi.nlm.nih.gov/pubmed/24674026", "http://www.ncbi.nlm.nih.gov/pubmed/17096326", "http://www.ncbi.nlm.nih.gov/pubmed/19136926", "http://www.ncbi.nlm.nih.gov/pubmed/10411935", "http://www.ncbi.nlm.nih.gov/pubmed/19571709"], "snippets": [{"offsetInBeginSection": 269, "offsetInEndSection": 443, "text": "Whole-genome and whole-exome sequencing of 47 hindbrain ependymomas reveals an extremely low mutation rate, and zero significant recurrent somatic single nucleotide variants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142"}, {"offsetInBeginSection": 444, "offsetInEndSection": 614, "text": "Although devoid of recurrent single nucleotide variants and focal copy number aberrations, poor-prognosis hindbrain ependymomas exhibit a CpG island methylator phenotype.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142"}, {"offsetInBeginSection": 615, "offsetInEndSection": 821, "text": "Transcriptional silencing driven by CpG methylation converges exclusively on targets of the Polycomb repressive complex 2 which represses expression of differentiation genes through trimethylation of H3K27.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142"}, {"offsetInBeginSection": 822, "offsetInEndSection": 988, "text": "CpG island methylator phenotype-positive hindbrain ependymomas are responsive to clinical drugs that target either DNA or H3K27 methylation both in vitro and in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109108"}, {"offsetInBeginSection": 529, "offsetInEndSection": 739, "text": "Supratentorial and spinal tumors displayed significantly more hypermethylated genes than posterior fossa tumors, similar to the 'CpG island methylator phenotype' (CIMP) identified in glioma and colon carcinoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109108"}, {"offsetInBeginSection": 1287, "offsetInEndSection": 1464, "text": "The data suggests epigenetic silencing of tumor suppressor genes is an important mechanism in the pathogenesis of supratentorial and spinal, but not posterior fossa ependymomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109108"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182241"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Here, we review the recent literature on molecular discoveries in ependymomas and pediatric diffuse gliomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182241"}, {"offsetInBeginSection": 109, "offsetInEndSection": 308, "text": "Ependymomas can now be categorized into three location-related subgroups according to their biological profile: posterior fossa ependymomas, group A (PFA) and B (PFB), and supratentorial ependymomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182241"}]}, {"id": "5a6e4814b750ff445500004a", "body": "Are loop domains preserved upon cohesin loss?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28985562"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "Cohesin Loss Eliminates All Loop Domains.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 142, "offsetInEndSection": 269, "text": "\"Loop domains\" form because of tethering between two loci-almost always bound by CTCF and cohesin-lying on the same chromosome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 361, "offsetInEndSection": 411, "text": "Here, we explore the effects of degrading cohesin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 412, "offsetInEndSection": 508, "text": "All loop domains are eliminated, but neither compartment domains nor histone marks are affected.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 509, "offsetInEndSection": 637, "text": "Loss of loop domains does not lead to widespread ectopic gene activation but does affect a significant minority of active genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 638, "offsetInEndSection": 805, "text": "In particular, cohesin loss causes superenhancers to co-localize, forming hundreds of links within and across chromosomes and affecting the regulation of nearby genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 806, "offsetInEndSection": 872, "text": "We then restore cohesin and monitor the re-formation of each loop.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 873, "offsetInEndSection": 1023, "text": "Although re-formation rates vary greatly, many megabase-sized loops recovered in under an hour, consistent with a model where loop extrusion is rapid.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 0, "offsetInEndSection": 141, "text": "The human genome folds to create thousands of intervals, called \"contact domains,\" that exhibit enhanced contact frequency within themselves.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 270, "offsetInEndSection": 360, "text": "\"Compartment domains\" form when genomic intervals with similar histone marks co-segregate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}]}, {"id": "5a7723b79e632bc06600000b", "body": "What are the prednisone side effects in DMD patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/12548530", "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "http://www.ncbi.nlm.nih.gov/pubmed/25809413", "http://www.ncbi.nlm.nih.gov/pubmed/22655511", "http://www.ncbi.nlm.nih.gov/pubmed/19306039", "http://www.ncbi.nlm.nih.gov/pubmed/16980656", "http://www.ncbi.nlm.nih.gov/pubmed/28450193", "http://www.ncbi.nlm.nih.gov/pubmed/9128400"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 149, "offsetInEndSection": 320, "text": "As mechanisms of improvement and side effect differences remain unknown, we evaluated effects of corticosteroid administration on gene expression in blood of DMD patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 321, "offsetInEndSection": 498, "text": "Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents na\u00efve to corticosteroids (DMD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 499, "offsetInEndSection": 583, "text": "The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 812, "offsetInEndSection": 925, "text": "Deflazacort compared with prednisone yielded 508 regulated probes, including many involved in adipose metabolism.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 926, "offsetInEndSection": 1106, "text": "These genes and pathways help explain mechanisms of efficacy and side effects of corticosteroids, and could provide new treatment targets for DMD and other neuromuscular disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Early prednisone treatment in Duchenne muscular dystrophy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12548530"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "The purpose of this long-term, open parallel-group, double-consent study of alternate-day, low-dose prednisone in 2-4-year-old patients with Duchenne muscular dystrophy (DMD) was to determine whether prednisone produces a beneficial effect when given earlier than usual.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12548530"}, {"offsetInBeginSection": 364, "offsetInEndSection": 567, "text": "After 55 months of treatment, the five patients (mean age 8.3 years) in the prednisone group were still able to get up from the floor, whereas two of the three in the control group had lost this ability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12548530"}, {"offsetInBeginSection": 568, "offsetInEndSection": 718, "text": "Side effects included a decline in growth rate in the prednisone-treated patients and excessive weight gain in one control and three treated patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12548530"}]}, {"id": "5a6e42f1b750ff4455000046", "body": "What gene is mutated in Familial Mediterranean Fever?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12387810", "http://www.ncbi.nlm.nih.gov/pubmed/20437121", "http://www.ncbi.nlm.nih.gov/pubmed/24980720", "http://www.ncbi.nlm.nih.gov/pubmed/12615073", "http://www.ncbi.nlm.nih.gov/pubmed/18347298", "http://www.ncbi.nlm.nih.gov/pubmed/10666224", "http://www.ncbi.nlm.nih.gov/pubmed/18219832", "http://www.ncbi.nlm.nih.gov/pubmed/28690860", "http://www.ncbi.nlm.nih.gov/pubmed/17431422", "http://www.ncbi.nlm.nih.gov/pubmed/20645115"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 66, "text": "Overt and occult rheumatic diseases: the child with chronic fever.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "Identification of the genes involved in hereditary periodic fever syndromes has led to the recognition of a new pathophysiological category, the autoinflammatory disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810"}, {"offsetInBeginSection": 173, "offsetInEndSection": 461, "text": "The main non-hereditary autoinflammatory disease in childhood is systemic juvenile idiopathic arthritis (sJIA), others being the chronic infantile neurological cutaneous arthropathy (CINCA) syndrome and the periodic fever, aphthous stomatitis, pharyngitis and adenopathy (PFAPA) syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810"}, {"offsetInBeginSection": 462, "offsetInEndSection": 543, "text": "Familial Mediterranean fever (FMF) has been traced to mutations in the MEFV gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810"}, {"offsetInBeginSection": 662, "offsetInEndSection": 896, "text": "The tumour necrosis factor(TNF)-receptor-associated periodic syndromes (TRAPS) have been linked to mutations in theTNFRSF1A gene, encoding a TNF-alpha receptor, and the CIAS1 gene is mutated in familial cold autoinflammatory syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "We aimed to investigate the rate of MEFV, the gene mutated in familial Mediterranean fever, mutations in patients with myeloid neoplasm and to determine if known mutations of MEFV cause a tendency for myeloid neoplasms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20437121"}, {"offsetInBeginSection": 370, "offsetInEndSection": 576, "text": "We identified 1 homozygous (E148Q/E148Q), 1 compound heterozygous (M694V/E148Q) and 5 heterozygous MEFV gene mutations; none had their own and/or family history compatible with familial Mediterranean fever.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20437121"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "A novel insertion mutation identified in exon 10 of the MEFV gene associated with Familial Mediterranean Fever.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24980720"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "BACKGROUND: Familial Mediterranean Fever (FMF), characterized by recurrent fever and inflammation of serous membranes, is an autosomal recessive disease caused by mutations in the Mediterranean fever (MEFV) gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24980720"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12615073"}]}, {"id": "5a7242a22dc08e987e00000e", "body": "Describe swirl sign in intracerebral hemorrhage.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23013418", "http://www.ncbi.nlm.nih.gov/pubmed/23517301"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Swirl sign in intracerebral haemorrhage: definition, prevalence, reliability and prognostic value.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "BACKGROUND: Swirl sign has previously been described in epidural hematomas as areas of low attenuation, radiolucency or irregular density.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 139, "offsetInEndSection": 336, "text": "The aims of this study were to describe swirl sign in ICH, study its prevalence, study the reliability of the subjective evaluation on computed tomography (CT), and to explore its prognostic value.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 336, "offsetInEndSection": 436, "text": "METHODS: CTs of 203 patients with ICH were retrospectively evaluated for the presence of swirl sign.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 437, "offsetInEndSection": 530, "text": "Association between swirl sign and different clinical and radiological variables was studied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 530, "offsetInEndSection": 685, "text": "RESULTS: Inter- and intraobserver agreement with regard to the occurrence of swirl sign was substantial (\u041a 0.80) and almost perfect (\u041a 0.87), respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 739, "offsetInEndSection": 842, "text": "61% of patients with swirl sign were dead at one month compared with 21% of those with no swirl sign (p", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 843, "offsetInEndSection": 958, "text": "CONCLUSIONS: As swirl sign showed to be an ominous sign, we recommend identification of this sign in cases of ICHs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Prediction of evolution toward brain death upon admission to ICU in comatose patients with spontaneous intracerebral hemorrhage using simple signs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517301"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "The aim of the study was to identify the predictors of brain death (BD) upon admission to the intensive care unit (ICU) of comatose patients with spontaneous intracerebral hemorrhage (ICH).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517301"}]}, {"id": "5a8718a261bb38fb24000007", "body": "What is the function of yeast TERRA RNAs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19026778", "http://www.ncbi.nlm.nih.gov/pubmed/24698720", "http://www.ncbi.nlm.nih.gov/pubmed/29145644", "http://www.ncbi.nlm.nih.gov/pubmed/20376293", "http://www.ncbi.nlm.nih.gov/pubmed/21525956", "http://www.ncbi.nlm.nih.gov/pubmed/22139922", "http://www.ncbi.nlm.nih.gov/pubmed/28666128", "http://www.ncbi.nlm.nih.gov/pubmed/24550456", "http://www.ncbi.nlm.nih.gov/pubmed/24074956", "http://www.ncbi.nlm.nih.gov/pubmed/20679250"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "The Rat1p 5' to 3' exonuclease degrades telomeric repeat-containing RNA and promotes telomere elongation in Saccharomyces cerevisiae.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Vertebrate telomeres are transcribed into telomeric repeat-containing RNA (TERRA) that associates with telomeres and may be important for telomere function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778"}, {"offsetInBeginSection": 273, "offsetInEndSection": 376, "text": "Yeast TERRA is polyadenylated and stabilized by Pap1p and regulated by the 5' to 3' exonuclease, Rat1p.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778"}, {"offsetInBeginSection": 377, "offsetInEndSection": 503, "text": "rat1-1 mutant cells accumulate TERRA and harbor short telomeres because of defects in telomerase-mediated telomere elongation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778"}, {"offsetInBeginSection": 681, "offsetInEndSection": 807, "text": "Thus, telomeric transcription combined with Rat1p-dependent TERRA degradation is important for regulating telomerase in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778"}, {"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "Breaking new ground: digging into TERRA function.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24698720"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Despite the fact that telomeres carry chromatin marks typically associated with silent heterochromatin, they are actively transcribed into TElomeric Repeat containing RNA (TERRA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24698720"}, {"offsetInBeginSection": 180, "offsetInEndSection": 349, "text": "TERRA transcription is conserved from yeast to man, initiates in the subtelomeric region and proceeds through the telomeric tract of presumably each individual telomere.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24698720"}, {"offsetInBeginSection": 350, "offsetInEndSection": 472, "text": "TERRA levels are increased in yeast survivors and in cancer cells employing ALT as a telomere maintenance mechanism (TMM).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24698720"}, {"offsetInBeginSection": 559, "offsetInEndSection": 740, "text": "Interestingly, several recent publications implicate TERRA in regulatory processes including telomere end protection and the establishment of the heterochromatic state at telomeres.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24698720"}]}, {"id": "5a6e4d22b750ff445500004d", "body": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28623093", "http://www.ncbi.nlm.nih.gov/pubmed/26354575", "http://www.ncbi.nlm.nih.gov/pubmed/27813696", "http://www.ncbi.nlm.nih.gov/pubmed/15523612", "http://www.ncbi.nlm.nih.gov/pubmed/24589093", "http://www.ncbi.nlm.nih.gov/pubmed/23359635", "http://www.ncbi.nlm.nih.gov/pubmed/16648978", "http://www.ncbi.nlm.nih.gov/pubmed/18520775"], "snippets": [{"offsetInBeginSection": 219, "offsetInEndSection": 397, "text": "Mutations in this gene are the cause of Schimke immune-osseous dysplasia (SIOD), an autosomal recessive disorder characterized by T-cell immunodeficiency and growth dysfunctions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28623093"}, {"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Schimke immune-osseous dysplasia: A case report.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26354575"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "Schimke immune-osseous dysplasia (SIOD) is a rare autosomal recessive disorder characterized by spondylo-epiphyseal dysplasia (SED), progressive renal insufficiency beginning as steroid-resistant nephrotic syndrome (SRNS) and defective cellular immunity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26354575"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Chromatin changes in SMARCAL1 deficiency: A hypothesis for the gene expression alterations of Schimke immuno-osseous dysplasia.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813696"}, {"offsetInBeginSection": 0, "offsetInEndSection": 326, "text": "Mutations in SMARCAL1, which encodes a DNA annealing helicase with roles in DNA replication fork restart, DNA repair, and gene expression modulation, cause Schimke immuno-osseous dysplasia (SIOD), an autosomal recessive disease characterized by skeletal dysplasia, renal disease, T-cell immunodeficiency, and arteriosclerosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813696"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Fatal lymphoproliferative disorder in a child with Schimke immuno-osseous dysplasia.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15523612"}, {"offsetInBeginSection": 0, "offsetInEndSection": 181, "text": "Schimke immuno-osseous dysplasia (SIOD) is a rare autosomal recessive disorder characterized by spondyloepiphyseal dysplasia, nephrotic syndrome, and cell-mediated immunodeficiency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15523612"}, {"offsetInBeginSection": 182, "offsetInEndSection": 321, "text": "Mutations in the SMARCAL1 gene (SW1/SNF2-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like1) cause SIOD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15523612"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "A novel SMARCAL1 mutation associated with a mild phenotype of Schimke immuno-osseous dysplasia (SIOD).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24589093"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "BACKGROUND: Schimke immuno-osseous dysplasia (SIOD, OMIM #242900) is an autosomal-recessive pleiotropic disorder characterized by spondyloepiphyseal dysplasia, renal dysfunction and T-cell immunodeficiency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24589093"}]}, {"id": "5a7727f39e632bc06600000d", "body": "What are the side effects of deflazacort in DMD patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11148511", "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "http://www.ncbi.nlm.nih.gov/pubmed/22655511"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "OBJECTIVE: We report the long-term effects on muscle strength and side effects with deflazacort in Duchenne muscular dystrophy (DMD).STUDY", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511"}, {"offsetInBeginSection": 139, "offsetInEndSection": 280, "text": "DESIGN: Boys with DMD between the ages of 7 and 15 years were reviewed retrospectively; 30 had been treated with deflazacort, and 24 had not.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511"}, {"offsetInBeginSection": 281, "offsetInEndSection": 349, "text": "Muscle function, pulmonary function, and side effects were compared.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511"}, {"offsetInBeginSection": 499, "offsetInEndSection": 633, "text": "PCONCLUSIONS: We conclude that deflazacort can preserve gross motor and pulmonary function in boys with DMD with limited side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 149, "offsetInEndSection": 320, "text": "As mechanisms of improvement and side effect differences remain unknown, we evaluated effects of corticosteroid administration on gene expression in blood of DMD patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 321, "offsetInEndSection": 498, "text": "Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents na\u00efve to corticosteroids (DMD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 499, "offsetInEndSection": 583, "text": "The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 926, "offsetInEndSection": 1106, "text": "These genes and pathways help explain mechanisms of efficacy and side effects of corticosteroids, and could provide new treatment targets for DMD and other neuromuscular disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 0, "offsetInEndSection": 143, "text": "Several studies have demonstrated the slowing effect of corticosteroids on the decline of muscle strength in Duchenne muscular dystrophy (DMD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570"}]}, {"id": "5a6e47b1b750ff4455000049", "body": "Is overproduction of transthyretin is associated with amyloidosis associated neuropathy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12762139", "http://www.ncbi.nlm.nih.gov/pubmed/28802308", "http://www.ncbi.nlm.nih.gov/pubmed/28217248", "http://www.ncbi.nlm.nih.gov/pubmed/25819286", "http://www.ncbi.nlm.nih.gov/pubmed/8579098", "http://www.ncbi.nlm.nih.gov/pubmed/24082415", "http://www.ncbi.nlm.nih.gov/pubmed/17554795", "http://www.ncbi.nlm.nih.gov/pubmed/14987380", "http://www.ncbi.nlm.nih.gov/pubmed/10694917", "http://www.ncbi.nlm.nih.gov/pubmed/2847318"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "A transthyretin mutation (Tyr78Phe) associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "BACKGROUND: More than 80 transthyretin (TTR) mutations have been described, most associated with amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139"}, {"offsetInBeginSection": 110, "offsetInEndSection": 340, "text": "Peripheral neuropathy is the most common clinical presentation in TTR amyloidosis although the carpal tunnel syndrome (CTS) may be the first symptom and skin can be involved, as transthyretin amyloidosis is a systemic disease.CASE", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139"}, {"offsetInBeginSection": 1227, "offsetInEndSection": 1354, "text": "CONCLUSION: This TTR mutation (Tyr78Phe) is associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139"}, {"offsetInBeginSection": 1355, "offsetInEndSection": 1408, "text": "It is also associated with late onset of the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Vitreous amyloidosis with autonomic neuropathy of the digestive tract associated with a novel transthyretin p.Gly87Arg variant in a Bangladeshi patient: a case report.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "BACKGROUND: Hereditary transthyretin amyloidosis is an autosomal dominant inherited disorder, first described in families with sensorimotor and autonomic neuropathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308"}, {"offsetInBeginSection": 166, "offsetInEndSection": 475, "text": "Since its first description, more than 120 amyloidogenic transthyretin mutations have been reported with various geographic distributions and associated with a wide range of phenotypes involving the peripheral nerve, the heart, the gastrointestinal tract, the eyes, the central nervous system, or the kidneys.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308"}, {"offsetInBeginSection": 476, "offsetInEndSection": 577, "text": "In some cases of transthyretin amyloidosis, the first clinical manifestation is vitreous opacity.CASE", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308"}, {"offsetInBeginSection": 578, "offsetInEndSection": 857, "text": "PRESENTATION: A 46-year-old Bangladeshi woman presented with vitreous amyloidosis and progressive autonomic neuropathy of the digestive tract as initial clinical manifestations, with no clinical evidence of cardiac, renal, central nervous system, or peripheral nerve dysfunction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308"}]}, {"id": "5a7244aa2dc08e987e00000f", "body": "Which two interleukins are inhibited by Ustekinumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22123062", "http://www.ncbi.nlm.nih.gov/pubmed/19882785", "http://www.ncbi.nlm.nih.gov/pubmed/18486739", "http://www.ncbi.nlm.nih.gov/pubmed/19217154", "http://www.ncbi.nlm.nih.gov/pubmed/19886505", "http://www.ncbi.nlm.nih.gov/pubmed/18703004", "http://www.ncbi.nlm.nih.gov/pubmed/29042094", "http://www.ncbi.nlm.nih.gov/pubmed/21436972", "http://www.ncbi.nlm.nih.gov/pubmed/20421912", "http://www.ncbi.nlm.nih.gov/pubmed/22758911"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 155, "text": "Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062"}, {"offsetInBeginSection": 499, "offsetInEndSection": 738, "text": "A recent example is ustekinumab, a first-in-class therapeutic human immunoglobulin G1 kappa mAb that binds to the interleukins (IL)-12 and IL-23, cytokines that modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062"}, {"offsetInBeginSection": 1176, "offsetInEndSection": 1366, "text": "The clinical characterization of ustekinumab continues to clarify our understanding of human immune pathologies and may offer a novel therapeutic option for certain immune-mediated diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062"}, {"offsetInBeginSection": 0, "offsetInEndSection": 266, "text": "(1) For adults with plaque psoriasis, after failure of topical symptomatic treatments and PUVA therapy, several systemic immunosuppressive agents are acceptable for severe disease: methotrexate, then ciclosporin, and possible a TNF alpha antagonist (etanercept, etc.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785"}, {"offsetInBeginSection": 266, "offsetInEndSection": 390, "text": "); (2) Ustekinumab is an inhibitor of interleukins 12 and 23, which are believed to be implicated in the onset of psoriasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785"}, {"offsetInBeginSection": 913, "offsetInEndSection": 1283, "text": "The results beyond this period have not been reported; (4) Two randomised, double-blind, placebo-controlled trials in a total of 1996 patients showed that at least two-thirds of patients treated with ustekinumab achieved at least a 75% reduction in their PASI score versus fewer than 4% with placebo; (5) In animal studies, interleukin 12 and 23 inhibitors cause cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785"}, {"offsetInBeginSection": 1284, "offsetInEndSection": 1754, "text": "There is therefore a high risk of cancer developing during prolonged treatment with ustekinumab; (6) The main adverse effects identified in clinical trials include infections, injection-site reactions, psychological disorders and development of anti-ustekinumab antibodies; (7) There is insufficient follow-up to evaluate the cardiac risks associated with ustekinumab; (8) As maintenance therapy, ustekinumab is administered as one subcutaneous injection every 12 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785"}, {"offsetInBeginSection": 0, "offsetInEndSection": 197, "text": "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18486739"}, {"offsetInBeginSection": 125, "offsetInEndSection": 255, "text": "Findings suggest that interleukins 12 and 23 might affect clinical symptoms and pathological joint changes of psoriatic arthritis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19217154"}, {"offsetInBeginSection": 256, "offsetInEndSection": 349, "text": "Ustekinumab is a human monoclonal antibody that inhibits receptor-binding of these cytokines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19217154"}]}, {"id": "5a8863948cb19eca6b000002", "body": "How can network assortativity be applied in the three-dimensional analysis of the genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27391817", "http://www.ncbi.nlm.nih.gov/pubmed/23536826", "http://www.ncbi.nlm.nih.gov/pubmed/25121490", "http://www.ncbi.nlm.nih.gov/pubmed/26816262", "http://www.ncbi.nlm.nih.gov/pubmed/26172652", "http://www.ncbi.nlm.nih.gov/pubmed/25981854", "http://www.ncbi.nlm.nih.gov/pubmed/27967190", "http://www.ncbi.nlm.nih.gov/pubmed/25894574", "http://www.ncbi.nlm.nih.gov/pubmed/24505274", "http://www.ncbi.nlm.nih.gov/pubmed/15697429"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Integrating epigenomic data and 3D genomic structure with a new measure of chromatin assortativity.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391817"}, {"offsetInBeginSection": 207, "offsetInEndSection": 446, "text": "We propose a new approach, using chromatin assortativity, to integrate the epigenomic landscape of a specific cell type with its chromatin interaction network and thus investigate which proteins or chromatin marks mediate genomic contacts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391817"}, {"offsetInBeginSection": 932, "offsetInEndSection": 1073, "text": "Polycomb group proteins and associated histone marks are the features with the highest chromatin assortativity in promoter-centered networks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391817"}, {"offsetInBeginSection": 1665, "offsetInEndSection": 1836, "text": "Our approach facilitates the study of multiple genome-wide epigenomic profiles, considering network topology and allowing the comparison of chromatin interaction networks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391817"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "The properties of genome conformation and spatial gene interaction and regulation networks of normal and malignant human cell types.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "The spatial conformation of a genome plays an important role in the long-range regulation of genome-wide gene expression and methylation, but has not been extensively studied due to lack of genome conformation data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826"}, {"offsetInBeginSection": 610, "offsetInEndSection": 823, "text": "In this work, we conducted a comprehensive, large-scale computational analysis of this new stream of genome conformation data generated for three different human leukemia cells or cell lines by the Hi-C technique.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826"}, {"offsetInBeginSection": 1091, "offsetInEndSection": 1370, "text": "Our analysis demonstrates that Hi-C data can be effectively applied to study tissue-specific genome conformation, chromosome-chromosome interaction, chromosomal translocations, and spatial gene-gene interaction and regulation in a three-dimensional genome of primary tumor cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826"}, {"offsetInBeginSection": 1371, "offsetInEndSection": 1612, "text": "Particularly, for the first time, we constructed genome-scale spatial gene-gene interaction network, transcription factor binding site (TFBS) - TFBS interaction network, and TFBS-gene interaction network from chromosomal contact information.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826"}, {"offsetInBeginSection": 851, "offsetInEndSection": 972, "text": "In directed networks, assortativity comprises four distinct components that collectively form an assortativity signature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25121490"}]}, {"id": "5a6fabfeb750ff4455000062", "body": "Are there mammalian promoters with distal enhancer functions?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28581502"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Genome-wide characterization of mammalian promoters with distal enhancer functions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Gene expression in mammals is precisely regulated by the combination of promoters and gene-distal regulatory regions, known as enhancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 138, "offsetInEndSection": 219, "text": "Several studies have suggested that some promoters might have enhancer functions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 220, "offsetInEndSection": 366, "text": "However, the extent of this type of promoters and whether they actually function to regulate the expression of distal genes have remained elusive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 367, "offsetInEndSection": 499, "text": "Here, by exploiting a high-throughput enhancer reporter assay, we unravel a set of mammalian promoters displaying enhancer activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 500, "offsetInEndSection": 612, "text": "These promoters have distinct genomic and epigenomic features and frequently interact with other gene promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 613, "offsetInEndSection": 778, "text": "Extensive CRISPR-Cas9 genomic manipulation demonstrated the involvement of these promoters in the cis regulation of expression of distal genes in their natural loci.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 779, "offsetInEndSection": 902, "text": "Our results have important implications for the understanding of complex gene regulation in normal development and disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}]}, {"id": "5a774431faa1ab7d2e000004", "body": "Why is the Fyn kinase considered a promising therapeutic target for Alzheimer's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25874001", "http://www.ncbi.nlm.nih.gov/pubmed/28709498", "http://www.ncbi.nlm.nih.gov/pubmed/24495408"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "INTRODUCTION: Despite significant progress, a disease-modifying therapy for Alzheimer's disease (AD) has not yet been developed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 249, "offsetInEndSection": 448, "text": "We recently described a signaling cascade whereby oligomeric amyloid beta binds to cellular prion protein on the neuronal cell surface, activating intracellular Fyn kinase to mediate synaptotoxicity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 449, "offsetInEndSection": 598, "text": "Fyn kinase has been implicated in AD pathophysiology both in in vitro models and in human subjects, and is a promising new therapeutic target for AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 599, "offsetInEndSection": 801, "text": "Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1714, "text": "Secondary endpoints included changes in clinical efficacy measures (Alzheimer's Disease Assessment Scale - cognitive subscale, MMSE, Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory, Neuropsychiatric Inventory, and Clinical Dementia Rating Scale - Sum of Boxes) and regional cerebral glucose metabolism measured by fluorodeoxyglucose positron emission tomography.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 2480, "offsetInEndSection": 2662, "text": "Targeting Fyn kinase may be a promising therapeutic approach in AD, and a larger Phase IIa clinical trial of AZD0530 for the treatment of patients with AD has recently launched.TRIAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 0, "offsetInEndSection": 44, "text": "Targeting Fyn Kinase in Alzheimer's Disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "The past decade has brought tremendous progress in unraveling the pathophysiology of Alzheimer's disease (AD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498"}, {"offsetInBeginSection": 661, "offsetInEndSection": 878, "text": "In this review, I highlight the discovery of cellular prion protein as a high-affinity receptor for A\u03b2 oligomers, and the downstream signaling pathway elucidated to date, converging on nonreceptor tyrosine kinase Fyn.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498"}]}, {"id": "5a6f7138b750ff445500004f", "body": "How does parathyroid hormone affect circulating levels of periostin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23918682", "http://www.ncbi.nlm.nih.gov/pubmed/26721738", "http://www.ncbi.nlm.nih.gov/pubmed/22927401", "http://www.ncbi.nlm.nih.gov/pubmed/20654714"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 128, "offsetInEndSection": 284, "text": "Reduced periostin expression may affect osteoblast differentiation and collagen type I synthesis and predispose to osteoporosis and increased fracture risk.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 285, "offsetInEndSection": 497, "text": "We aimed to evaluate circulating periostin levels in postmenopausal women with low bone mass, their possible correlations with clinical and laboratory parameters, as well as the 3-month effect of zoledronic acid.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 498, "offsetInEndSection": 863, "text": "Serum samples for periostin, 25-hydroxyvitamin D, parathyroid hormone (PTH), C-terminal telopeptide of type I collagen (CTx), and total alkaline phosphatase (tALP) were obtained from 46 postmenopausal women with low bone mass at baseline and 3 months after zoledronic acid infusion and from 30 age-matched, postmenopausal controls with normal bone mass at baseline.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 864, "offsetInEndSection": 1001, "text": "There was no difference in periostin levels between women with normal and low bone mass (250\u00b115 vs. 272\u00b114\u2009ng/ml, respectively; p=0.279).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 1099, "offsetInEndSection": 1243, "text": "Serum periostin levels at baseline were not affected by previous bisphosphonate treatment, and were correlated only to tALP (rs=0.351; p=0.018).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 1244, "offsetInEndSection": 1646, "text": "In multiple linear regression analysis, tALP (B=3.17; 95% CI=0.59-5.79; p=0.018) was associated with serum periostin levels at baseline, independently from previous anti-osteoporotic treatment, age, body mass index, and 25-hydroxyvitamin D. In conclusion, serum periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 1647, "offsetInEndSection": 1713, "text": "Women with higher tALP have independently higher periostin levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 418, "offsetInEndSection": 630, "text": "The development of periostin null mice has allowed to elucidate the crucial role of periostin on dentinogenesis and osteogenesis, as well as on the skeletal response to mechanical loading and parathyroid hormone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26721738"}, {"offsetInBeginSection": 631, "offsetInEndSection": 753, "text": "The use of circulating periostin as a potential clinical biomarker has been explored in different non skeletal conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26721738"}]}, {"id": "5a7247182dc08e987e000010", "body": "Describe mechanism of action of Ozanimod.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28783871", "http://www.ncbi.nlm.nih.gov/pubmed/29125718", "http://www.ncbi.nlm.nih.gov/pubmed/27144850", "http://www.ncbi.nlm.nih.gov/pubmed/28398597", "http://www.ncbi.nlm.nih.gov/pubmed/26239599", "http://www.ncbi.nlm.nih.gov/pubmed/26879276", "http://www.ncbi.nlm.nih.gov/pubmed/26702336", "http://www.ncbi.nlm.nih.gov/pubmed/28812220"], "snippets": [{"offsetInBeginSection": 160, "offsetInEndSection": 349, "text": "This randomized, double-blind, placebo-controlled, positive-controlled, parallel-group thorough QT study characterized the effects of ozanimod on cardiac repolarization in healthy subjects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 563, "offsetInEndSection": 663, "text": "The primary end point was the time-matched, placebo-corrected, baseline-adjusted mean QTcF (\u0394\u0394QTcF).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 721, "offsetInEndSection": 869, "text": "The upper limits of the 2-sided 90% confidence intervals for \u0394\u0394QTcF for both ozanimod 1 and 2\u00a0mg were below the 10-millisecond regulatory threshold.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 957, "offsetInEndSection": 1079, "text": "There was no evidence of a positive relationship between concentrations of ozanimod and its active metabolites and \u0394\u0394QTcF.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 1223, "offsetInEndSection": 1400, "text": "Results demonstrate that ozanimod does not prolong the QTc interval or cause clinically significant bradycardia, supporting ozanimod's evolving favorable cardiac safety profile.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718"}, {"offsetInBeginSection": 199, "offsetInEndSection": 388, "text": "The effects of high-fat and low-fat meals on the pharmacokinetics (PK) of a single oral dose of ozanimod were evaluated in 24 healthy volunteers in a randomized, open-label crossover trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718"}, {"offsetInBeginSection": 389, "offsetInEndSection": 531, "text": "Each subject received a 1-mg dose of ozanimod hydrochloride under 3 meal conditions (fasted, high-fat, and low-fat), each separated by 7 days.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718"}, {"offsetInBeginSection": 532, "offsetInEndSection": 685, "text": "Mean plasma concentration-time profiles for ozanimod and its active metabolites (RP101988 [major], RP101075 [minor]) were similar under all 3 conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718"}, {"offsetInBeginSection": 686, "offsetInEndSection": 792, "text": "Moreover, all PK parameters for ozanimod, RP101988, and RP101075 were similar under the 3 meal conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718"}]}, {"id": "5a895f51fcd1d6a10c000004", "body": "What is the preferred orientation of CTCF binding sites for chromatin looping?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26527277", "http://www.ncbi.nlm.nih.gov/pubmed/28536180", "http://www.ncbi.nlm.nih.gov/pubmed/25135475", "http://www.ncbi.nlm.nih.gov/pubmed/26276636", "http://www.ncbi.nlm.nih.gov/pubmed/27569350", "http://www.ncbi.nlm.nih.gov/pubmed/28137913", "http://www.ncbi.nlm.nih.gov/pubmed/24990380", "http://www.ncbi.nlm.nih.gov/pubmed/29076501", "http://www.ncbi.nlm.nih.gov/pubmed/21282187", "http://www.ncbi.nlm.nih.gov/pubmed/23650640"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "CTCF Binding Polarity Determines Chromatin Looping.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "CCCTC-binding factor (CTCF) is an architectural protein involved in the three-dimensional (3D) organization of chromatin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 122, "offsetInEndSection": 248, "text": "In this study, we assayed the 3D genomic contact profiles of a large number of CTCF binding sites with high-resolution 4C-seq.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 249, "offsetInEndSection": 393, "text": "As recently reported, our data also suggest that chromatin loops preferentially form between CTCF binding sites oriented in a convergent manner.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 394, "offsetInEndSection": 552, "text": "To directly test this, we used CRISPR/Cas9 genome editing to delete core CTCF binding sites in three loci, including the CTCF site in the Sox2 super-enhancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 553, "offsetInEndSection": 697, "text": "In all instances, CTCF and cohesin recruitment were lost, and chromatin loops with distal, convergent CTCF sites were disrupted or destabilized.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 698, "offsetInEndSection": 841, "text": "Re-insertion of oppositely oriented CTCF recognition sequences restored CTCF and cohesin recruitment, but did not re-establish chromatin loops.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 842, "offsetInEndSection": 958, "text": "We conclude that CTCF binding polarity plays a functional role in the formation of higher-order chromatin structure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "YY1 and CTCF orchestrate a 3D chromatin looping switch during early neural lineage commitment.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28536180"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "CTCF is an architectural protein with a critical role in connecting higher-order chromatin folding in pluripotent stem cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28536180"}]}, {"id": "5a761ac7aacfb9cd4c000003", "body": "What is the ReliableGenome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27605105"], "snippets": [{"offsetInBeginSection": 468, "offsetInEndSection": 636, "text": "RESULTS: Here, we describe our method ReliableGenome (RG) for partitioning genomes into high and low concordance regions with respect to a set of surveyed VC pipelines.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105"}, {"offsetInBeginSection": 1834, "offsetInEndSection": 1987, "text": "IMPLEMENTATION: RG was implemented in Java, source code and binaries are freely available for non-commercial use at https://github.com/popitsch/wtchg-rg/", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105"}, {"offsetInBeginSection": 1988, "offsetInEndSection": 2101, "text": "CONTACT: niko@wtchg.ox.ac.ukSupplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "ReliableGenome: annotation of genomic regions with high/low variant calling concordance.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105"}, {"offsetInBeginSection": 155, "offsetInEndSection": 468, "text": "The observed discordance between state-of-the-art VC pipelines, however, indicates that the current practice still suffers from non-negligible numbers of false positive and negative SNV and INDEL calls that were shown to be enriched among discordant calls but also in genomic regions with low sequence complexity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105"}, {"offsetInBeginSection": 1398, "offsetInEndSection": 1452, "text": "RG allows focusing resource-intensive algorithms (e.g.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105"}, {"offsetInBeginSection": 1453, "offsetInEndSection": 1605, "text": "consensus calling methods) on the smaller, discordant share of the genome (20-30%) which might result in increased overall accuracy at reasonable costs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "MOTIVATION: The increasing adoption of clinical whole-genome resequencing (WGS) demands for highly accurate and reproducible variant calling (VC) methods.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105"}, {"offsetInBeginSection": 1606, "offsetInEndSection": 1833, "text": "Our method and analysis of discordant calls may further be useful for development, benchmarking and optimization of VC algorithms and for the relative comparison of call sets between different studies/pipelines.AVAILABILITY AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105"}, {"offsetInBeginSection": 637, "offsetInEndSection": 803, "text": "Our method combines call sets derived by multiple pipelines from arbitrary numbers of datasets and interpolates expected concordance for genomic regions without data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105"}]}, {"id": "5a774585faa1ab7d2e000005", "body": "What is masitinib an inhibitor of?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25961655", "http://www.ncbi.nlm.nih.gov/pubmed/19789626", "http://www.ncbi.nlm.nih.gov/pubmed/18823406", "http://www.ncbi.nlm.nih.gov/pubmed/25122671", "http://www.ncbi.nlm.nih.gov/pubmed/19614621", "http://www.ncbi.nlm.nih.gov/pubmed/19541476", "http://www.ncbi.nlm.nih.gov/pubmed/26978025", "http://www.ncbi.nlm.nih.gov/pubmed/20033487", "http://www.ncbi.nlm.nih.gov/pubmed/27400786", "http://www.ncbi.nlm.nih.gov/pubmed/21504563"], "snippets": [{"offsetInBeginSection": 717, "offsetInEndSection": 852, "text": "Dual actions of masitinib as an inhibitor of mast cell-glia axis and a Fyn kinase blocker are discussed in the context of AD pathology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961655"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626"}, {"offsetInBeginSection": 130, "offsetInEndSection": 306, "text": "Here, we characterise the in vitro and in vivo profiles of masitinib (AB1010), a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets KIT.METHODOLOGY/PRINCIPAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626"}, {"offsetInBeginSection": 824, "offsetInEndSection": 975, "text": "In contrast, masitinib demonstrated weak inhibition of ABL and c-Fms and was inactive against a variety of other tyrosine and serine/threonine kinases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626"}, {"offsetInBeginSection": 976, "offsetInEndSection": 1208, "text": "This highly selective nature of masitinib suggests that it will exhibit a better safety profile than other tyrosine kinase inhibitors; indeed, masitinib-induced cardiotoxicity or genotoxicity has not been observed in animal studies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626"}, {"offsetInBeginSection": 1209, "offsetInEndSection": 1425, "text": "Molecular modelling and kinetic analysis suggest a different mode of binding than imatinib, and masitinib more strongly inhibited degranulation, cytokine production, and bone marrow mast cell migration than imatinib.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626"}, {"offsetInBeginSection": 1671, "offsetInEndSection": 1826, "text": "CONCLUSIONS: Masitinib is a potent and selective tyrosine kinase inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626"}, {"offsetInBeginSection": 138, "offsetInEndSection": 260, "text": "OBJECTIVE: To evaluate the efficacy of masitinib, a potent and selective inhibitor of KIT, in the treatment of canine MCT.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823406"}, {"offsetInBeginSection": 1165, "offsetInEndSection": 1324, "text": "IMPORTANCE: Masitinib is safe and effective at delaying tumor progression in dogs presenting with recurrent or nonresectable grade II or III nonmetastatic MCT.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823406"}, {"offsetInBeginSection": 0, "offsetInEndSection": 160, "text": "BACKGROUND: Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25122671"}]}, {"id": "5a6f7245b750ff4455000050", "body": "What is the mode of action of teriparatide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24870841", "http://www.ncbi.nlm.nih.gov/pubmed/20872215", "http://www.ncbi.nlm.nih.gov/pubmed/15262455", "http://www.ncbi.nlm.nih.gov/pubmed/16234962", "http://www.ncbi.nlm.nih.gov/pubmed/17538470", "http://www.ncbi.nlm.nih.gov/pubmed/15940379", "http://www.ncbi.nlm.nih.gov/pubmed/22451221", "http://www.ncbi.nlm.nih.gov/pubmed/19281056", "http://www.ncbi.nlm.nih.gov/pubmed/26104116", "http://www.ncbi.nlm.nih.gov/pubmed/24086927"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Teriparatide is an only available bone anabolic drug in practice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841"}, {"offsetInBeginSection": 125, "offsetInEndSection": 250, "text": "Mode of actions of teriparatide is pharmacological but not physiological as it is administered to patients with osteoporosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841"}, {"offsetInBeginSection": 251, "offsetInEndSection": 362, "text": "Physicians need to understand the fact that treatment with teriparatide is not just like a hormone replacement.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841"}, {"offsetInBeginSection": 363, "offsetInEndSection": 559, "text": "They also should administer teriparatide to their patients after rigorous evaluation of its clinical superiority to other anti-osteoprosis drugs, because it is not classified as a first-line drug.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215"}, {"offsetInBeginSection": 0, "offsetInEndSection": 249, "text": "The objective of this systematic review was to examine the influence of treatments for postmenopausal osteoporosis (parathyroid hormone [PTH], bisphosphonates, strontium ranelate, and denosumab) on bone quality and discuss the clinical implications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215"}, {"offsetInBeginSection": 250, "offsetInEndSection": 302, "text": "Most bone-quality data for PTH is from teriparatide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215"}, {"offsetInBeginSection": 303, "offsetInEndSection": 499, "text": "Teriparatide results in a rapid increase in bone-formation markers, followed by increases in bone-resorption markers, opening an \"anabolic window,\" a period of time when PTH is maximally anabolic.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215"}, {"offsetInBeginSection": 500, "offsetInEndSection": 611, "text": "Teriparatide reverses the structural damage seen in osteoporosis and restores the structure of trabecular bone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215"}, {"offsetInBeginSection": 897, "offsetInEndSection": 1074, "text": "Concerns have been raised that the prolonged antiresorptive action of bisphosphonates may lead to failure to repair microdamage, resulting in microcracks and atypical fragility.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215"}]}, {"id": "5a7340962dc08e987e000017", "body": "Is Apremilast effective for Behcet\u2019s syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25875256", "http://www.ncbi.nlm.nih.gov/pubmed/26676621", "http://www.ncbi.nlm.nih.gov/pubmed/24882690", "http://www.ncbi.nlm.nih.gov/pubmed/24797159", "http://www.ncbi.nlm.nih.gov/pubmed/28823583", "http://www.ncbi.nlm.nih.gov/pubmed/27747762", "http://www.ncbi.nlm.nih.gov/pubmed/28213862", "http://www.ncbi.nlm.nih.gov/pubmed/26555450", "http://www.ncbi.nlm.nih.gov/pubmed/27486641", "http://www.ncbi.nlm.nih.gov/pubmed/26089047"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Apremilast for Beh\u00e7et's syndrome--a phase 2, placebo-controlled study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "BACKGROUND: Oral ulcers, the hallmark of Beh\u00e7et's syndrome, can be resistant to conventional treatment; therefore, alternative agents are needed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 243, "offsetInEndSection": 481, "text": "METHODS: We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Beh\u00e7et's syndrome who had two or more oral ulcers were randomly assigned to receive 30 mg of apremilast twice daily or placebo for 12 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 1183, "offsetInEndSection": 1305, "text": "PCONCLUSIONS: Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 1306, "offsetInEndSection": 1504, "text": "This preliminary study was neither large enough nor long enough to assess long-term efficacy, the effect on other manifestations of Beh\u00e7et's syndrome, or the risk of uncommon serious adverse events.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 0, "offsetInEndSection": 95, "text": "Apremilast in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Pilot Study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26676621"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "OBJECTIVE: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a disease with an uncertain cause and limited effective treatments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26676621"}, {"offsetInBeginSection": 0, "offsetInEndSection": 214, "text": "Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in psoriasis, psoriatic arthropathies, and Beh\u00e7et's syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24882690"}, {"offsetInBeginSection": 786, "offsetInEndSection": 967, "text": "While both apremilast and thalidomide share a phthalimide ring structure, apremilast lacks the glutarimide ring and thus fails to bind to cereblon, the target of thalidomide action.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24882690"}, {"offsetInBeginSection": 0, "offsetInEndSection": 298, "text": "Apremilast (Otezla(\u00ae)), an oral small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4), is under development with Celgene Corporation for the treatment of psoriatic arthritis, psoriasis, ankylosing spondylitis, Beh\u00e7et's syndrome, atopic dermatitis, and rheumatoid arthritis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24797159"}]}, {"id": "5a857bfffaa1ab7d2e000030", "body": "Can the yeast protein Abf1 act as insulator?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7663308", "http://www.ncbi.nlm.nih.gov/pubmed/10601031", "http://www.ncbi.nlm.nih.gov/pubmed/7608180", "http://www.ncbi.nlm.nih.gov/pubmed/9430660", "http://www.ncbi.nlm.nih.gov/pubmed/18996839", "http://www.ncbi.nlm.nih.gov/pubmed/8536307", "http://www.ncbi.nlm.nih.gov/pubmed/1545789", "http://www.ncbi.nlm.nih.gov/pubmed/25748434", "http://www.ncbi.nlm.nih.gov/pubmed/15456886", "http://www.ncbi.nlm.nih.gov/pubmed/2511628"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Autonomously replicating sequence (ARS)-binding factor 1 (ABF1) is a multifunctional protein involved in transcriptional activation and repression, as well as DNA replication, in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7663308"}, {"offsetInBeginSection": 317, "offsetInEndSection": 422, "text": "To examine the effect of ABF1 on expression of the ADH1 gene, we constructed an ADH1-lacZ fusion plasmid.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7663308"}, {"offsetInBeginSection": 572, "offsetInEndSection": 762, "text": "The ABF1 binding sites also acted in an orientation-independent manner when a synthetic ABF1 binding site was inserted into the yeast CYC1 gene lacking its transcriptional activation region.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7663308"}, {"offsetInBeginSection": 763, "offsetInEndSection": 884, "text": "A gel mobility shift assay showed that ABF1 bound in vitro to both ABF1 binding sites in the promoter and coding regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7663308"}, {"offsetInBeginSection": 976, "offsetInEndSection": 1056, "text": "The expression of ADH1 was activated synergistically by both ABF1 binding sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7663308"}, {"offsetInBeginSection": 110, "offsetInEndSection": 199, "text": "Recently, we identified a stable subcomplex containing the yeast Rad7 and Rad16 proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10601031"}, {"offsetInBeginSection": 345, "offsetInEndSection": 473, "text": "Yeast ABF1 protein is encoded by an essential gene required for DNA replication, transcriptional regulation, and gene silencing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10601031"}, {"offsetInBeginSection": 825, "offsetInEndSection": 911, "text": "These studies define a novel and unexpected role for ABF1 protein during NER in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10601031"}, {"offsetInBeginSection": 160, "offsetInEndSection": 306, "text": "We isolated a protein kinase from extracts of Saccharomyces cerevisiae on the basis of its ability to specifically phosphorylate the ABF1 protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7608180"}, {"offsetInBeginSection": 504, "offsetInEndSection": 640, "text": "Furthermore, when incubated with ABF1 and anti-ABF1 antibodies, the kinase forms an immunocomplex active in the phosphorylation of ABF1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7608180"}]}, {"id": "5a8053effaa1ab7d2e00001e", "body": "Describe the Manta algorithm for detection of structural variants", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26647377"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "UNLABELLED: : We describe Manta, a method to discover structural variants and indels from next generation sequencing data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 123, "offsetInEndSection": 472, "text": "Manta is optimized for rapid germline and somatic analysis, calling structural variants, medium-sized indels and large insertions on standard compute hardware in less than a tenth of the time that comparable methods require to identify only subsets of these variant types: for example NA12878 at 50\u00d7 genomic coverage is analyzed in less than 20\u2009min.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 1036, "offsetInEndSection": 1203, "text": "We provide Manta as a community resource to facilitate practical and routine structural variant analysis in clinical and research sequencing scenarios.AVAILABILITY AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 689, "offsetInEndSection": 867, "text": "Call quality is similar to or better than comparable methods, as determined by pedigree consistency of germline calls and comparison of somatic calls to COSMIC database variants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 1275, "offsetInEndSection": 1374, "text": "Source code, documentation and Linux binaries are available from https://github.com/Illumina/manta.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 1204, "offsetInEndSection": 1274, "text": "IMPLEMENTATION: Manta is released under the open-source GPLv3 license.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 473, "offsetInEndSection": 688, "text": "Manta can discover and score variants based on supporting paired and split-read evidence, with scoring models optimized for germline analysis of diploid individuals and somatic analysis of tumor-normal sample pairs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 868, "offsetInEndSection": 1035, "text": "Manta consistently assembles a higher fraction of its calls to base-pair resolution, allowing for improved downstream annotation and analysis of clinical significance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 1419, "offsetInEndSection": 1490, "text": "INFORMATION: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}]}, {"id": "5a7d4e9afaa1ab7d2e000013", "body": "How many amino acids does davunetide consist of?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21902667", "http://www.ncbi.nlm.nih.gov/pubmed/24210139", "http://www.ncbi.nlm.nih.gov/pubmed/24533805", "http://www.ncbi.nlm.nih.gov/pubmed/22956189"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24210139"}, {"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 583, "offsetInEndSection": 707, "text": "NAP (davunetide), an eight amino acid peptide derived from ADNP partly ameliorated deficits associated with ADNP deficiency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 305, "offsetInEndSection": 417, "text": "ADNP haploinsufficiency in mice results in tauopathy and cognitive deficits ameliorated by davunetide treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22956189"}, {"offsetInBeginSection": 77, "offsetInEndSection": 265, "text": "Davunetide is an eight-amino-acid peptide fragment derived by structure-activity studies from activity-dependent neuroprotective protein, activity-dependent neuroprotective protein (ADNP).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22956189"}, {"offsetInBeginSection": 667, "offsetInEndSection": 757, "text": "Clinical trials with NAP (davunetide) are reviewed paving the path to future developments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24210139"}, {"offsetInBeginSection": 0, "offsetInEndSection": 223, "text": "This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in our laboratory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24210139"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in the laboratory of Prof. Illana Gozes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24533805"}, {"offsetInBeginSection": 418, "offsetInEndSection": 560, "text": "This article summarizes in brief recent reviews about NAP protection against tauopathy including the all D-amino acid analogue-D-NAP (AL-408).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22956189"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "This review focuses on the discovery of activity-dependent neuroprotective protein (ADNP) and the ensuing discovery of NAP (davunetide) toward clinical development with emphasis on microtubule protection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}]}, {"id": "5a6f77d7b750ff4455000051", "body": "Is autosomal dominant inheritanced form of Osteogenesis imperfecta caused by mutations in the genes associated with collagen production?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2886666", "http://www.ncbi.nlm.nih.gov/pubmed/17192541", "http://www.ncbi.nlm.nih.gov/pubmed/23771926", "http://www.ncbi.nlm.nih.gov/pubmed/18566967", "http://www.ncbi.nlm.nih.gov/pubmed/19533842", "http://www.ncbi.nlm.nih.gov/pubmed/20839288", "http://www.ncbi.nlm.nih.gov/pubmed/27312322", "http://www.ncbi.nlm.nih.gov/pubmed/25656619", "http://www.ncbi.nlm.nih.gov/pubmed/8100856", "http://www.ncbi.nlm.nih.gov/pubmed/25007323"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Prenatal prediction of osteogenesis imperfecta (OI type IV): exclusion of inheritance using a collagen gene probe.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2886666"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Autosomal dominant osteogenesis imperfecta is caused by mutations in the COL1A2 and COL1A1 genes of type I collagen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2886666"}, {"offsetInBeginSection": 404, "offsetInEndSection": 512, "text": "Linkage analysis can thus be used in the prenatal diagnosis of dominantly inherited osteogenesis imperfecta.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2886666"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Classic osteogenesis imperfecta, an autosomal dominant disorder associated with osteoporosis and bone fragility, is caused by mutations in the genes for type I collagen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 228, "offsetInEndSection": 491, "text": "Since the loss of cartilage-associated protein (CRTAP), which is required for post-translational prolyl 3-hydroxylation of collagen, causes severe osteoporosis in mice, we investigated whether CRTAP deficiency is associated with recessive osteogenesis imperfecta.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 492, "offsetInEndSection": 825, "text": "Three of 10 children with lethal or severe osteogenesis imperfecta, who did not have a primary collagen defect yet had excess post-translational modification of collagen, were found to have a recessive condition resulting in CRTAP deficiency, suggesting that prolyl 3-hydroxylation of type I collagen is important for bone formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "New genes in bone development: what's new in osteogenesis imperfecta.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771926"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by bone fragility and deformity and growth deficiency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771926"}, {"offsetInBeginSection": 128, "offsetInEndSection": 256, "text": "Most cases of OI (classical types) have autosomal dominant inheritance and are caused by mutations in the type I collagen genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771926"}]}, {"id": "5a7346662dc08e987e00001a", "body": "What causes \"Puffy hand syndrome\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19216010", "http://www.ncbi.nlm.nih.gov/pubmed/16911735", "http://www.ncbi.nlm.nih.gov/pubmed/15529083", "http://www.ncbi.nlm.nih.gov/pubmed/17072191", "http://www.ncbi.nlm.nih.gov/pubmed/27269656", "http://www.ncbi.nlm.nih.gov/pubmed/24198977", "http://www.ncbi.nlm.nih.gov/pubmed/23856549"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 22, "text": "[Puffy hand syndrome].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010"}, {"offsetInBeginSection": 304, "offsetInEndSection": 508, "text": "Physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies, infectious complications and direct toxicity of injected drugs and their adulterants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010"}, {"offsetInBeginSection": 509, "offsetInEndSection": 634, "text": "Low-stretch bandage and elastic garment, usually used in lymphedema treatment, are proposed to treat the puffy hand syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Puffy hand syndrome due to drug addiction: a case-control study of the pathogenesis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16911735"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "AIM: We studied the pathogenesis of puffy hand syndrome of intravenous drug use.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16911735"}, {"offsetInBeginSection": 1013, "offsetInEndSection": 1212, "text": "In 69.7% of the cases and 59.4% of the controls, respectively, there was a high-dose sublingual buprenorphine misuse, although it appeared not to be a significant risk factor for puffy hand syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16911735"}, {"offsetInBeginSection": 1212, "offsetInEndSection": 1366, "text": "CONCLUSIONS: Injection practices are likely to cause puffy hands syndrome, but buprenorphine misuse should not be considered as a significant risk factor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16911735"}, {"offsetInBeginSection": 162, "offsetInEndSection": 245, "text": "The puffy hand sign is a more uncommon complication of hard-core injection addicts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15529083"}, {"offsetInBeginSection": 246, "offsetInEndSection": 359, "text": "Three long-term intravenous drug users, two males, one female, mean age 30.6 years (26-37) presented puffy hands.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15529083"}]}, {"id": "5a86e66dfaa1ab7d2e000035", "body": "Does the association of PARP1 and CTCF follow a circadian rhythm?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26321255"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "PARP1- and CTCF-Mediated Interactions between Active and Repressed Chromatin at the Lamina Promote Oscillating Transcription.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 153, "offsetInEndSection": 306, "text": "However, here we uncovered an inter-chromosomal network connecting active loci enriched in circadian genes to repressed lamina-associated domains (LADs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 307, "offsetInEndSection": 368, "text": "The interactome is regulated by PARP1 and its co-factor CTCF.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 369, "offsetInEndSection": 486, "text": "They not only mediate chromatin fiber interactions but also promote the recruitment of circadian genes to the lamina.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 487, "offsetInEndSection": 760, "text": "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 761, "offsetInEndSection": 958, "text": "Furthermore, depletion of H3K9me2/3, inhibition of PARP activity by olaparib, or downregulation of PARP1 or CTCF expression counteracts both recruitment to the envelope and circadian transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 959, "offsetInEndSection": 1127, "text": "PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Transcriptionally active and inactive chromatin domains tend to segregate into separate sub-nuclear compartments to maintain stable expression patterns.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}]}, {"id": "5a805974faa1ab7d2e000020", "body": "What is the Strelka workflow?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22581179"], "snippets": [{"offsetInBeginSection": 329, "offsetInEndSection": 463, "text": "RESULTS: We describe Strelka, a method for somatic SNV and small indel detection from sequencing data of matched tumor-normal samples.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 1175, "offsetInEndSection": 1270, "text": "AVAILABILITY: The Strelka workflow source code is available at ftp://strelka@ftp.illumina.com/.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 1270, "offsetInEndSection": 1301, "text": "CONTACT: csaunders@illumina.com", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 464, "offsetInEndSection": 651, "text": "The method uses a novel Bayesian approach which represents continuous allele frequencies for both tumor and normal samples, while leveraging the expected genotype structure of the normal.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "MOTIVATION: Whole genome and exome sequencing of matched tumor-normal sample pairs is becoming routine in cancer research.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 842, "offsetInEndSection": 983, "text": "A natural consequence of the model structure is that sensitivity can be maintained at high tumor impurity without requiring purity estimates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 652, "offsetInEndSection": 841, "text": "This is achieved by representing the normal sample as a mixture of germline variation with noise, and representing the tumor sample as a mixture of the normal sample with somatic variation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 984, "offsetInEndSection": 1175, "text": "We demonstrate that the method has superior accuracy and sensitivity on impure samples compared with approaches based on either diploid genotype likelihoods or general allele-frequency tests.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 123, "offsetInEndSection": 329, "text": "The consequent increased demand for somatic variant analysis of paired samples requires methods specialized to model this problem so as to sensitively call variants at any practical level of tumor impurity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}]}, {"id": "5a7d535ffaa1ab7d2e000018", "body": "What does the human IVIG treatment for Alzheimer's disease contain?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24760109", "http://www.ncbi.nlm.nih.gov/pubmed/28381506", "http://www.ncbi.nlm.nih.gov/pubmed/24760112", "http://www.ncbi.nlm.nih.gov/pubmed/23861639", "http://www.ncbi.nlm.nih.gov/pubmed/18294736", "http://www.ncbi.nlm.nih.gov/pubmed/20329802", "http://www.ncbi.nlm.nih.gov/pubmed/25115546", "http://www.ncbi.nlm.nih.gov/pubmed/18956886", "http://www.ncbi.nlm.nih.gov/pubmed/21138577", "http://www.ncbi.nlm.nih.gov/pubmed/23735288"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760109"}, {"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760109"}, {"offsetInBeginSection": 272, "offsetInEndSection": 472, "text": "Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760109"}, {"offsetInBeginSection": 473, "offsetInEndSection": 747, "text": "Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760109"}, {"offsetInBeginSection": 748, "offsetInEndSection": 896, "text": "We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760109"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "A phase 3 trial of IV immunoglobulin for Alzheimer disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "OBJECTIVE: We tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment for mild to moderate Alzheimer disease (AD) dementia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}, {"offsetInBeginSection": 435, "offsetInEndSection": 715, "text": "The primary cognitive outcome was change from baseline to 18 months on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale; the primary functional outcome was 18-month change on the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}, {"offsetInBeginSection": 856, "offsetInEndSection": 966, "text": "RESULTS: No beneficial effects were observed in the dual primary outcome measures for the 2 IVIg doses tested.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}, {"offsetInBeginSection": 967, "offsetInEndSection": 1069, "text": "Significant decreases in plasma A\u03b242 (but not A\u03b240) levels were observed in IVIg-treated participants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}]}, {"id": "5a70ce4ab750ff4455000064", "body": "List the 6 genes associated with the autosomal recessive form of Osteogenesis imperfecta", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12110407", "http://www.ncbi.nlm.nih.gov/pubmed/17192541", "http://www.ncbi.nlm.nih.gov/pubmed/25565926", "http://www.ncbi.nlm.nih.gov/pubmed/25656619", "http://www.ncbi.nlm.nih.gov/pubmed/8100856", "http://www.ncbi.nlm.nih.gov/pubmed/23613367", "http://www.ncbi.nlm.nih.gov/pubmed/23054245", "http://www.ncbi.nlm.nih.gov/pubmed/12110406", "http://www.ncbi.nlm.nih.gov/pubmed/23301918", "http://www.ncbi.nlm.nih.gov/pubmed/21670757"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "We have identified a novel form of autosomal recessive osteogenesis imperfecta (OI) in a small First Nations community from northern Quebec.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12110407"}, {"offsetInBeginSection": 276, "offsetInEndSection": 398, "text": "By linkage analysis, we mapped this unique autosomal recessive variant of osteogenesis imperfecta to chromosome 3p22-24.1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12110407"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Classic osteogenesis imperfecta, an autosomal dominant disorder associated with osteoporosis and bone fragility, is caused by mutations in the genes for type I collagen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 228, "offsetInEndSection": 491, "text": "Since the loss of cartilage-associated protein (CRTAP), which is required for post-translational prolyl 3-hydroxylation of collagen, causes severe osteoporosis in mice, we investigated whether CRTAP deficiency is associated with recessive osteogenesis imperfecta.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 492, "offsetInEndSection": 825, "text": "Three of 10 children with lethal or severe osteogenesis imperfecta, who did not have a primary collagen defect yet had excess post-translational modification of collagen, were found to have a recessive condition resulting in CRTAP deficiency, suggesting that prolyl 3-hydroxylation of type I collagen is important for bone formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Novel Deletion of SERPINF1 Causes Autosomal Recessive Osteogenesis Imperfecta Type VI in Two Brazilian Families.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25565926"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "Autosomal recessive osteogenesis imperfecta (OI) accounts for 10% of all OI cases, and, currently, mutations in 10 genes (CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, SERPINF1, SP7, BMP1, TMEM38B, and WNT1) are known to be responsible for this form of the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25565926"}, {"offsetInBeginSection": 0, "offsetInEndSection": 171, "text": "Defective Proteolytic Processing of Fibrillar Procollagens and Prodecorin Due to Biallelic BMP1 Mutations Results in a Severe, Progressive Form of Osteogenesis Imperfecta.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25656619"}, {"offsetInBeginSection": 0, "offsetInEndSection": 311, "text": "Whereas the vast majority of osteogenesis imperfecta (OI) is caused by autosomal dominant defects in the genes encoding type I procollagen, mutations in a myriad of genes affecting type I procollagen biosynthesis or bone formation and homeostasis have now been associated with rare autosomal recessive OI forms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25656619"}]}, {"id": "5a737e233b9d13c70800000d", "body": "Does Enzastaurin improve survival of glioblastoma patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20124186", "http://www.ncbi.nlm.nih.gov/pubmed/23911595", "http://www.ncbi.nlm.nih.gov/pubmed/28259301", "http://www.ncbi.nlm.nih.gov/pubmed/26643807", "http://www.ncbi.nlm.nih.gov/pubmed/20150385", "http://www.ncbi.nlm.nih.gov/pubmed/25398844", "http://www.ncbi.nlm.nih.gov/pubmed/19098118", "http://www.ncbi.nlm.nih.gov/pubmed/21896554", "http://www.ncbi.nlm.nih.gov/pubmed/22917813"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "PURPOSE: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4).PATIENTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 340, "offsetInEndSection": 516, "text": "Assuming a 45% improvement in progression-free survival (PFS), 397 patients were required to provide 80% power to achieve statistical significance at a one-sided level of .025.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 1220, "offsetInEndSection": 1312, "text": "Four patients discontinued enzastaurin because of drug-related serious adverse events (AEs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 1313, "offsetInEndSection": 1412, "text": "Eleven patients treated with enzastaurin died on study (four because of AEs; one was drug-related).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 1622, "offsetInEndSection": 1810, "text": "CONCLUSION: Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 0, "offsetInEndSection": 189, "text": "Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23911595"}, {"offsetInBeginSection": 0, "offsetInEndSection": 377, "text": "BACKGROUND: This study's primary objective was evaluation of the progression-free survival rate at 6 months (PFS-6) in patients with newly diagnosed glioblastoma without O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter hypermethylation postsurgically treated with enzastaurin before and concomitantly with radiation therapy, followed by enzastaurin maintenance therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23911595"}, {"offsetInBeginSection": 487, "offsetInEndSection": 690, "text": "METHODS: Adult patients with a life expectancy of at least 12 weeks who were newly diagnosed with a histologically proven supratentorial glioblastoma without MGMT promoter hypermethylation were eligible.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23911595"}, {"offsetInBeginSection": 691, "offsetInEndSection": 806, "text": "Patients were treated with enzastaurin prior to, concomitantly with, and after standard partial brain radiotherapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23911595"}]}, {"id": "5a8965f6fcd1d6a10c000005", "body": "Are splicing speckles associated with transcription?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16467386", "http://www.ncbi.nlm.nih.gov/pubmed/10444064", "http://www.ncbi.nlm.nih.gov/pubmed/26496460", "http://www.ncbi.nlm.nih.gov/pubmed/10366587", "http://www.ncbi.nlm.nih.gov/pubmed/21984414", "http://www.ncbi.nlm.nih.gov/pubmed/15093744", "http://www.ncbi.nlm.nih.gov/pubmed/26441864", "http://www.ncbi.nlm.nih.gov/pubmed/9135155", "http://www.ncbi.nlm.nih.gov/pubmed/22871813", "http://www.ncbi.nlm.nih.gov/pubmed/12473687"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Splicing speckles are not reservoirs of RNA polymerase II, but contain an inactive form, phosphorylated on serine2 residues of the C-terminal domain.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "\"Splicing speckles\" are major nuclear domains rich in components of the splicing machinery and polyA(+) RNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386"}, {"offsetInBeginSection": 109, "offsetInEndSection": 320, "text": "Although speckles contain little detectable transcriptional activity, they are found preferentially associated with specific mRNA-coding genes and gene-rich R bands, and they accumulate some unspliced pre-mRNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386"}, {"offsetInBeginSection": 321, "offsetInEndSection": 476, "text": "RNA polymerase II transcribes mRNAs and is required for splicing, with some reports suggesting that the inactive complexes are stored in splicing speckles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386"}, {"offsetInBeginSection": 477, "offsetInEndSection": 655, "text": "Using ultrathin cryosections to improve optical resolution and preserve nuclear structure, we find that all forms of polymerase II are present, but not enriched, within speckles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386"}, {"offsetInBeginSection": 1022, "offsetInEndSection": 1184, "text": "Paraspeckle domains lie adjacent to speckles, but little is known about their protein content or putative roles in the expression of the speckle-associated genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386"}, {"offsetInBeginSection": 1185, "offsetInEndSection": 1399, "text": "We find that paraspeckles are transcriptionally inactive but contain polymerase II, which remains stably associated upon transcriptional inhibition, when paraspeckles reorganize around nucleoli in the form of caps.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Three-dimensional visualization of transcription sites and their association with splicing factor-rich nuclear speckles.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10444064"}, {"offsetInBeginSection": 163, "offsetInEndSection": 384, "text": "Inhibition and enzyme digestion studies confirm that the labeled sites are from RNA transcripts and that RNA polymerase I (RP I) and II (RP II) are responsible for nucleolar and extranucleolar transcription, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10444064"}, {"offsetInBeginSection": 562, "offsetInEndSection": 683, "text": "The number of transcription sites, their three-dimensional organization and arrangement into functional zones (Wei et al.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10444064"}]}, {"id": "5a80a63ffaa1ab7d2e000023", "body": "What is the HPG pore?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26921234", "http://www.ncbi.nlm.nih.gov/pubmed/26148840"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "HPG pore: an efficient and scalable framework for nanopore sequencing data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234"}, {"offsetInBeginSection": 769, "offsetInEndSection": 1006, "text": "HPG Pore can run on both individual computers and in the Hadoop distributed computing framework, which allows easy scale-up to manage the large amounts of data expected to result from extensive use of nanopore technologies in the future.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234"}, {"offsetInBeginSection": 1006, "offsetInEndSection": 1156, "text": "CONCLUSIONS: HPG Pore allows for virtually unlimited sequencing data scalability, thus guaranteeing its continued management in near future scenarios.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234"}, {"offsetInBeginSection": 1157, "offsetInEndSection": 1226, "text": "HPG Pore is available in GitHub at http://github.com/opencb/hpg-pore.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "A microporous hydrogel scaffold was developed from hyperbranched poly(glycidol) (HPG) and poly(ethylene oxide) (PEO) using electron beam (e-beam) induced cross-linking for tissue engineering applications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840"}, {"offsetInBeginSection": 205, "offsetInEndSection": 386, "text": "In this study, HPG was synthesized from glycidol using trimethylol propane as a core initiator and cross-linked hydrogels were made using 0, 10, 20, and 30% HPG with respect to PEO.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840"}, {"offsetInBeginSection": 387, "offsetInEndSection": 568, "text": "The effects of %-HPG on the swelling ratio, cross-linking density, mechanical properties, morphology, degradation, and cytotoxicity of the hydrogel scaffolds were then investigated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840"}, {"offsetInBeginSection": 569, "offsetInEndSection": 733, "text": "Increasing the HPG content increased the pore size of the hydrogel scaffold, as well as the porosity, elongation at break, degree of degradation and swelling ratio.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840"}, {"offsetInBeginSection": 734, "offsetInEndSection": 819, "text": "In contrast, the presence of HPG decreased the cross-linking density of the hydrogel.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840"}, {"offsetInBeginSection": 921, "offsetInEndSection": 1037, "text": "The pore size of hydrogel scaffolds could be easily tailored by controlling the content of HPG in the polymer blend.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840"}]}, {"id": "5a70ce82b750ff4455000065", "body": "What is the mode of action of the drug Prolia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25052047", "http://www.ncbi.nlm.nih.gov/pubmed/19836866", "http://www.ncbi.nlm.nih.gov/pubmed/25509894", "http://www.ncbi.nlm.nih.gov/pubmed/22023901"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Development and evaluation of an algorithm to identify users of Prolia(\u00ae) during the early postmarketing period using health insurance claims data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047"}, {"offsetInBeginSection": 713, "offsetInEndSection": 1037, "text": "Requiring claims for a bone or cartilage disorder or osteoporotic fracture after excluding claims for cancer prior to a denosumab-specific administration code gave the highest PPV (95.8%), followed by requiring a Prolia National Drug Code on the same claim as a denosumab-specific or nonspecific administration code (88.2%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1368, "text": "CONCLUSIONS: Prolia users are most accurately identified with administration code claims in conjunction with claims for Prolia National Drug Code and bone disorder treatment and diagnosis codes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047"}, {"offsetInBeginSection": 231, "offsetInEndSection": 465, "text": "Recently anti-RANKL agents (receptor activator of nuclear factor-kappaB ligand) such as denosumab (Prolia, Amgen Inc., California, USA) that have a similar mode of action to bisphosphonates have been introduced to treat such diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19836866"}, {"offsetInBeginSection": 265, "offsetInEndSection": 395, "text": "METHODS: Patients aged 50 years or older with postmenopausal OP, who were treated with Prolia in clinical practice, were examined.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25509894"}, {"offsetInBeginSection": 789, "offsetInEndSection": 986, "text": "CONCLUSION: The preliminary results of the open-label study of Prolia in postmenopausal OP suggest that the significantly lower BR activity determines the efficacy of this drug and its high safety.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25509894"}, {"offsetInBeginSection": 0, "offsetInEndSection": 206, "text": "Denosumab (Prolia) is a fully human monoclonal antibody directed against receptor activator of nuclear factor-\u03baB ligand (RANKL), which interferes with the formation, activation, and survival of osteoclasts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023901"}, {"offsetInBeginSection": 207, "offsetInEndSection": 366, "text": "It was approved by the Food and Drug Administration in June 2010 as a new treatment for postmenopausal osteoporosis in women who are at high risk for fracture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023901"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "AIM: To evaluate the efficacy and safety of Denosumab (Prolia), a first-line osteoporosis (OP) medication that is a fully human monoclonal antibody to the receptor activator of nuclear factor xB ligand (RANKL), within an open-label observational study.SUBJECTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25509894"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "PURPOSE: The goal of this study is to develop and validate an algorithm to identify Prolia(\u00ae) users within a health insurance claims database.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047"}]}, {"id": "5a75df9483b0d9ea66000001", "body": "What is the mechanism of action of Tisagenlecleucel?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28887358", "http://www.ncbi.nlm.nih.gov/pubmed/28751490"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 209, "text": "An expert panel recommended approval of Novartis's experimental chimeric antigen T-cell therapy, tisagenlecleucel, for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751490"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received FDA approval for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia who haven't responded to standard therapy or who have relapsed at least twice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887358"}, {"offsetInBeginSection": 210, "offsetInEndSection": 352, "text": "The therapy would be the first of its kind approved for cancer and has the potential to transform standard of care for advanced blood cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751490"}, {"offsetInBeginSection": 0, "offsetInEndSection": 46, "text": "First-Ever CAR T-cell Therapy Approved in U.S.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887358"}, {"offsetInBeginSection": 0, "offsetInEndSection": 37, "text": "Panel OKs CAR T Therapy for Leukemia.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751490"}]}, {"id": "5a74e6eb0384be9551000009", "body": "What is Morgellons disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16489838", "http://www.ncbi.nlm.nih.gov/pubmed/21390982", "http://www.ncbi.nlm.nih.gov/pubmed/23326202", "http://www.ncbi.nlm.nih.gov/pubmed/19681520", "http://www.ncbi.nlm.nih.gov/pubmed/20489569", "http://www.ncbi.nlm.nih.gov/pubmed/21437061", "http://www.ncbi.nlm.nih.gov/pubmed/21110523", "http://www.ncbi.nlm.nih.gov/pubmed/19830222", "http://www.ncbi.nlm.nih.gov/pubmed/25192328", "http://www.ncbi.nlm.nih.gov/pubmed/21749875"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "The mystery of Morgellons disease: infection or delusion?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Morgellons disease is a mysterious skin disorder that was first described more than 300 years ago.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838"}, {"offsetInBeginSection": 99, "offsetInEndSection": 245, "text": "The disease is characterized by fiber-like strands extruding from the skin in conjunction with various dermatologic and neuropsychiatric symptoms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838"}, {"offsetInBeginSection": 246, "offsetInEndSection": 340, "text": "In this respect, Morgellons disease resembles and may be confused with delusional parasitosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838"}, {"offsetInBeginSection": 341, "offsetInEndSection": 507, "text": "The association with Lyme disease and the apparent response to antibacterial therapy suggest that Morgellons disease may be linked to an undefined infectious process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838"}, {"offsetInBeginSection": 508, "offsetInEndSection": 602, "text": "Further clinical and molecular research is needed to unlock the mystery of Morgellons disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Hypnosis in the treatment of Morgellons disease: a case study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "Morgellons Disease is a condition involving painful skin lesions, fibrous growths protruding from the skin, and subcutaneous stinging and burning sensations, along with symptoms of anxiety, depression, fatigue, and memory and attention deficits.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982"}, {"offsetInBeginSection": 378, "offsetInEndSection": 447, "text": "There are currently no established treatments for Morgellons Disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982"}, {"offsetInBeginSection": 448, "offsetInEndSection": 547, "text": "The following case example depicts treatment of a woman with Morgellons Disease using hypnotherapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982"}]}]}